<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>1900</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="1900"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=1900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=1800&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=2000&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925857842"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925857842?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925857842&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925857842&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925857842</prism:url><dc:identifier>SCOPUS_ID:84925857842</dc:identifier><eid>2-s2.0-84925857842</eid><dc:title>MiR-210 links hypoxia with cell proliferation regulation in human laryngocarcinoma cancer</dc:title><dc:creator>Zuo J.</dc:creator><prism:publicationName>Journal of Cellular Biochemistry</prism:publicationName><prism:issn>07302312</prism:issn><prism:eIssn>10974644</prism:eIssn><prism:volume>116</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1039-1049</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1002/jcb.25059</prism:doi><dc:description>© 2015 Wiley Periodicals, Inc. The microRNA hsa-miR-210 (miR-210) is associated with hypoxia; however its function has not fully identified. In the present study, we aim to detect its role concerning proliferation in Laryngocarcinoma. We found that miR-210 was highly expressed in hypoxia, which inhibited proliferation by inducing cell cycle arrest in G1/G0 as well as apoptosis. We further identified that miR-210 targeted fibroblast growth factor receptor-like 1 (FGFRL1). Down regulation of FGFRL1 decreased cell proliferation by promoting proportion of cells in G1/G0 phase and decreasing in S and G2/M phases. Moreover, overexpression of FGFRL1 effectively released the miR-210-induced suppression of SCC10A cell proliferation. Expression of miR-210 repressed tumor xenograft growth in vivo as well. Together, our findings reveal a new mechanism of adaptation to hypoxia that miR-210 inhibits the proliferation via inducing cell cycle arrest and apoptosis by the targeting of FGFRL1. J. Cell. Biochem. 116: 1039-1049, 2015.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000937</affiliation-url><afid>60000937</afid><affilname>Shenzhen University</affilname><name-variant>Shenzhen University</name-variant><affiliation-city>Qingshuihe, Shenzhen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088268</affiliation-url><afid>60088268</afid><affilname>University of South China</affilname><name-variant>University of South China</name-variant><affiliation-city>Hengyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088268</affiliation-url><afid>60088268</afid><affilname>University of South China</affilname><name-variant>University of South China</name-variant><affiliation-city>Hengyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112820001</affiliation-url><afid>112820001</afid><affilname>Zhangjiajie City Hospital</affilname><name-variant>Zhangjiajie City Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000937</affiliation-url><afid>60000937</afid><affilname>Shenzhen University</affilname><name-variant>Shenzhen University</name-variant><affiliation-city>Qingshuihe, Shenzhen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36656813200</author-url><authid>36656813200</authid><authname>Zuo J.</authname><surname>Zuo</surname><given-name>Jianhong</given-name><initials>J.</initials><afid>60000937</afid><afid>60088268</afid><afid>60088268</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36656813200</author-url><authid>36656813200</authid><authname>Zuo J.</authname><surname>Zuo</surname><given-name>Jianhong</given-name><initials>J.</initials><afid>60000937</afid><afid>60088268</afid><afid>60088268</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36656813200</author-url><authid>36656813200</authid><authname>Zuo J.</authname><surname>Zuo</surname><given-name>Jianhong</given-name><initials>J.</initials><afid>60000937</afid><afid>60088268</afid><afid>60088268</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55611654200</author-url><authid>55611654200</authid><authname>Wen M.</authname><surname>Wen</surname><given-name>Meiling</given-name><initials>M.</initials><afid>60088268</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56120465600</author-url><authid>56120465600</authid><authname>Lei M.</authname><surname>Lei</surname><given-name>Mingsheng</given-name><initials>M.</initials><afid>112820001</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7401594259</author-url><authid>7401594259</authid><authname>Peng X.</authname><surname>Peng</surname><given-name>Xiang</given-name><initials>X.</initials><afid>60000937</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7408600779</author-url><authid>7408600779</authid><authname>Yang X.</authname><surname>Yang</surname><given-name>Xuefeng</given-name><initials>X.</initials><afid>60088268</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35744851800</author-url><authid>35744851800</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhigang</given-name><initials>Z.</initials><afid>60000937</afid></author><authkeywords>CELL PROLIFERATION | FGFRL1 | HYPOXIA | LARYNGOCARCINOMA CANCER | MiR-210</authkeywords><intid>1035372839</intid><source-id>17598</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924229907"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924229907?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924229907&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924229907&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167487015000264"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924229907</prism:url><dc:identifier>SCOPUS_ID:84924229907</dc:identifier><eid>2-s2.0-84924229907</eid><dc:title>The shadow of the past: Financial risk taking and negative life events</dc:title><dc:creator>Bucciol A.</dc:creator><prism:publicationName>Journal of Economic Psychology</prism:publicationName><prism:issn>01674870</prism:issn><prism:volume>48</prism:volume><prism:pageRange>1-16</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.joep.2015.02.006</prism:doi><pii>S0167487015000264</pii><dc:description>© 2015 Elsevier B.V. Based on data from the four 2004-2010 waves of the US Health and Retirement Study (HRS), we show that financial risk taking is significantly related to life-history negative events out of an individual's control. Using observed portfolio decisions to proxy for risk taking, we find correlation with two of such individual-specific events: having been victim of a physical attack and (especially) the loss of a child are associated with lower and less frequent investments in risky assets, with an intensity similar to that of the beginning, in 2008, of a collectively experienced event such as the recent financial crisis. We also find evidence that the correlation of risk taking with a child loss is long-lasting, as opposed to the correlation with a physical attack that disappears after few years. Our analysis is more in favor of a preference-based - rather than a belief-based - explanation of the observed change in risk taking. Overall our findings indicate that the past, especially through the loss of a child, casts a long shadow that extends over individuals' current decisions also within unrelated domains.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032256</affiliation-url><afid>60032256</afid><affilname>Universita degli Studi di Verona</affilname><name-variant>University of Verona</name-variant><affiliation-city>Verona</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Netspar</affilname><affiliation-city>LE Tilburg</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36247183300</author-url><authid>36247183300</authid><authname>Bucciol A.</authname><surname>Bucciol</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60032256</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36247183300</author-url><authid>36247183300</authid><authname>Bucciol A.</authname><surname>Bucciol</surname><given-name>Alessandro</given-name><initials>A.</initials><afid>60032256</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36938893600</author-url><authid>36938893600</authid><authname>Zarri L.</authname><surname>Zarri</surname><given-name>Luca</given-name><initials>L.</initials><afid>60032256</afid></author><authkeywords>Behavioral finance | Financial asset ownership | Negative life events | Risk taking</authkeywords><intid>1785104592</intid><source-id>22915</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923604300"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923604300?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923604300&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923604300&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0161589015000528"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923604300</prism:url><dc:identifier>SCOPUS_ID:84923604300</dc:identifier><eid>2-s2.0-84923604300</eid><dc:title>IQGAP1: Insights into the function of a molecular puppeteer</dc:title><dc:creator>Abel A.</dc:creator><prism:publicationName>Molecular Immunology</prism:publicationName><prism:issn>01615890</prism:issn><prism:eIssn>18729142</prism:eIssn><prism:volume>65</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>336-349</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.molimm.2015.02.012</prism:doi><pii>S0161589015000528</pii><dc:description>© 2015 Elsevier Ltd. The intracellular spatiotemporal organization of signaling events is critical for normal cellular function. In response to environmental stimuli, cells utilize highly organized signaling pathways that are subject to multiple layers of regulation. However, the molecular mechanisms that coordinate these complex processes remain an enigma. Scaffolding proteins (scaffolins) have emerged as critical regulators of signaling pathways, many of which have well-described functions in immune cells. IQGAP1, a highly conserved cytoplasmic scaffold protein, is able to curb, compartmentalize, and coordinate multiple signaling pathways in a variety of cell types. IQGAP1 plays a central role in cell-cell interaction, cell adherence, and movement via actin/tubulin-based cytoskeletal reorganization. Evidence also implicates IQGAP1 as an essential regulator of the MAPK and Wnt/β-catenin signaling pathways. Here, we summarize the recent advances on the cellular and molecular biology of IQGAP1. We also describe how this pleiotropic scaffolin acts as a true molecular puppeteer, and highlight the significance of future research regarding the role of IQGAP1 in immune cells.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012553</affiliation-url><afid>60012553</afid><affilname>Medical College of Wisconsin</affilname><name-variant>Medical College of Wisconsin</name-variant><affiliation-city>Milwaukee</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><pubmed-id>25733387</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56529146500</author-url><authid>56529146500</authid><authname>Abel A.</authname><surname>Abel</surname><given-name>Alex M.</given-name><initials>A.M.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56529146500</author-url><authid>56529146500</authid><authname>Abel A.</authname><surname>Abel</surname><given-name>Alex M.</given-name><initials>A.M.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55028124000</author-url><authid>55028124000</authid><authname>Schuldt K.</authname><surname>Schuldt</surname><given-name>Kristina M.</given-name><initials>K.M.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55028124000</author-url><authid>55028124000</authid><authname>Schuldt K.</authname><surname>Schuldt</surname><given-name>Kristina M.</given-name><initials>K.M.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36768803400</author-url><authid>36768803400</authid><authname>Rajasekaran K.</authname><surname>Rajasekaran</surname><given-name>Kamalakannan</given-name><initials>K.</initials><afid>60012553</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56528845900</author-url><authid>56528845900</authid><authname>Hwang D.</authname><surname>Hwang</surname><given-name>David</given-name><initials>D.</initials><afid>60012553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005446580</author-url><authid>7005446580</authid><authname>Riese M.</authname><surname>Riese</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005446580</author-url><authid>7005446580</authid><authname>Riese M.</authname><surname>Riese</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56522118600</author-url><authid>56522118600</authid><authname>Rao S.</authname><surname>Rao</surname><given-name>Sridhar</given-name><initials>S.</initials><afid>60012553</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:51665971300</author-url><authid>51665971300</authid><authname>Thakar M.</authname><surname>Thakar</surname><given-name>Monica S.</given-name><initials>M.S.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:51665971300</author-url><authid>51665971300</authid><authname>Thakar M.</authname><surname>Thakar</surname><given-name>Monica S.</given-name><initials>M.S.</initials><afid>60012553</afid><afid>60012553</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:13806162400</author-url><authid>13806162400</authid><authname>Malarkannan S.</authname><surname>Malarkannan</surname><given-name>Subramaniam</given-name><initials>S.</initials><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:13806162400</author-url><authid>13806162400</authid><authname>Malarkannan S.</authname><surname>Malarkannan</surname><given-name>Subramaniam</given-name><initials>S.</initials><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:13806162400</author-url><authid>13806162400</authid><authname>Malarkannan S.</authname><surname>Malarkannan</surname><given-name>Subramaniam</given-name><initials>S.</initials><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:13806162400</author-url><authid>13806162400</authid><authname>Malarkannan S.</authname><surname>Malarkannan</surname><given-name>Subramaniam</given-name><initials>S.</initials><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid><afid>60012553</afid></author><authkeywords>IQGAP1 | Lymphocytes | Scaffold proteins | Signaling</authkeywords><intid>535004381</intid><source-id>14156</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930178903"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930178903?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930178903&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930178903&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1878540915000092"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930178903</prism:url><dc:identifier>SCOPUS_ID:84930178903</dc:identifier><eid>2-s2.0-84930178903</eid><dc:title>A five-year follow-up of a patient with fulminant myocarditis who underwent a stepwise and goal-oriented individualized comprehensive cardiac rehabilitation program</dc:title><dc:creator>Sasanuma N.</dc:creator><prism:publicationName>Journal of Cardiology Cases</prism:publicationName><prism:issn>18785409</prism:issn><prism:eIssn>18785409</prism:eIssn><prism:volume>11</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>160-163</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jccase.2015.02.001</prism:doi><pii>S1878540915000092</pii><dc:description>© 2015 Japanese College of Cardiology. A 39-year-old man developed fulminant myocarditis and was transferred on mechanical ventilation and a ventricular-assist device to our hospital. On Hospital Day 10, he was weaned from all medical engineering devices, and bedside rehabilitation was initiated. Although a multidisciplinary cardiac rehabilitation team had intervened since Hospital Day 3, he could not be encouraged to begin ambulation because of hypotension and tachycardia. Moreover, he complained of loss of self-confidence and anxiety regarding physical strength, and expansion of activities was difficult. Exercises reflecting his immediate desires and daily activities were used as activity goals, and we developed an individualized exercise program with stepwise increase in load to motivate him to perform rehabilitation. At the time of discharge, his cardiac function recovered to nearly normal levels; however, muscle strength and respiratory function had not recovered. While the intervention was continued at the cardiac rehabilitation outpatient unit, improvement was observed in physical health and mental health-related scale scores. The patient returned to work 4 months after onset of his myocarditis. Moreover, the cardiac rehabilitation team provided support to him for his long-term overseas assignment in the fifth year after myocarditis onset. Long-term comprehensive support by the cardiac rehabilitation team was feasible and useful.&lt;. Learning objective: Comprehensive intervention by a cardiac rehabilitation team from the acute phase may be helpful for motivating patients not only to participate in rehabilitation during hospitalization, but also to continue it on an outpatient basis after discharge. Moreover, continuous outpatient intervention can lead to recovery of physical/mental function in patients that is not achievable with only inpatient intervention, and support can be provided to patients for setting new life goals.&gt;.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030873</affiliation-url><afid>60030873</afid><affilname>Hyogo College of Medicine</affilname><name-variant>Hyogo College of Medicine</name-variant><affiliation-city>Nishinomiya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030873</affiliation-url><afid>60030873</afid><affilname>Hyogo College of Medicine</affilname><name-variant>Hyogo College of Medicine</name-variant><affiliation-city>Nishinomiya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030873</affiliation-url><afid>60030873</afid><affilname>Hyogo College of Medicine</affilname><name-variant>Hyogo College of Medicine</name-variant><affiliation-city>Nishinomiya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030873</affiliation-url><afid>60030873</afid><affilname>Hyogo College of Medicine</affilname><name-variant>Hyogo College of Medicine</name-variant><affiliation-city>Nishinomiya</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56485958400</author-url><authid>56485958400</authid><authname>Sasanuma N.</authname><surname>Sasanuma</surname><given-name>Naoki</given-name><initials>N.</initials><afid>60030873</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56544836600</author-url><authid>56544836600</authid><authname>Takahashi K.</authname><surname>Takahashi</surname><given-name>Keiko</given-name><initials>K.</initials><afid>60030873</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55260105400</author-url><authid>55260105400</authid><authname>Yamauchi S.</authname><surname>Yamauchi</surname><given-name>Shinya</given-name><initials>S.</initials><afid>60030873</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56485502700</author-url><authid>56485502700</authid><authname>Itani Y.</authname><surname>Itani</surname><given-name>Yusuke</given-name><initials>Y.</initials><afid>60030873</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55628538541</author-url><authid>55628538541</authid><authname>Tanaka T.</authname><surname>Tanaka</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60030873</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56545343900</author-url><authid>56545343900</authid><authname>Mabuchi S.</authname><surname>Mabuchi</surname><given-name>Satoshi</given-name><initials>S.</initials><afid>60030873</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:37072596200</author-url><authid>37072596200</authid><authname>Kodama N.</authname><surname>Kodama</surname><given-name>Norihiko</given-name><initials>N.</initials><afid>60030873</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56485364800</author-url><authid>56485364800</authid><authname>Masuyama T.</authname><surname>Masuyama</surname><given-name>Tohru</given-name><initials>T.</initials><afid>60030873</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7101848315</author-url><authid>7101848315</authid><authname>Domen K.</authname><surname>Domen</surname><given-name>Kazuhisa</given-name><initials>K.</initials><afid>60030873</afid></author><authkeywords>Cardiac rehabilitation | Fulminant myocarditis | Goal-oriented program</authkeywords><intid>1036074434</intid><source-id>19600156852</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929521282"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929521282?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929521282&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929521282&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929521282</prism:url><dc:identifier>SCOPUS_ID:84929521282</dc:identifier><eid>2-s2.0-84929521282</eid><dc:title>Adoption of Software as a Service (SaaS) Enterprise Resource Planning (ERP) Systems in Small and Medium Sized Enterprises (SMEs)</dc:title><dc:creator>Seethamraju R.</dc:creator><prism:publicationName>Information Systems Frontiers</prism:publicationName><prism:issn>13873326</prism:issn><prism:volume>17</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>475-492</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10796-014-9506-5</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Enterprise Resource Planning (ERP) systems are now offered on the cloud under the Software as a Service (SaaS) model. For small and medium sized enterprises (SMEs), this is considered the best opportunity to take advantage of the capabilities of an ERP system without the investment and management costs associated with the on-premise model. Using a cross-sectional field study conducted across four case study organizations, this study investigated the determinants and challenges in the adoption of SaaS ERP systems by SMEs. The study found that the determining factors in deciding to adopt SaaS ERP are software vendor’s reputation in the market, software fit to the business, the potential willingness of the vendor to support the customer throughout the product life cycle, the vendor’s participation in co-creation of value for customers and the generic benefits of implementing an integrated ERP system. With switching considered a costly option, accounting shift of capital costs to operating expenses is considered advantageous by firms. Competitive pressures faced by the enterprise, external factors, concerns about data security and system performance have no influence on adoption decision, according to this study. Change management and increasing the effectiveness of use are challenges, but the willingness of the software vendor to work with organizations’ requests for changes and improvements and the continuous co-creation of value through improved product offerings is reassuring to the firms in the post-implementation phase.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24779044100</author-url><authid>24779044100</authid><authname>Seethamraju R.</authname><surname>Seethamraju</surname><given-name>Ravi</given-name><initials>R.</initials><afid>60025709</afid></author><authkeywords>Adoption | ERP | SaaS | SMEs</authkeywords><intid>535969853</intid><source-id>15572</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929091920"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929091920?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929091920&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929091920&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929091920</prism:url><dc:identifier>SCOPUS_ID:84929091920</dc:identifier><eid>2-s2.0-84929091920</eid><dc:title>Development and validation of a liquid chromatography–mass spectrometry method for simultaneous determination of metoprolol and telmisartan in rat plasma and its application to pharmacokinetic study</dc:title><dc:creator>Nandi U.</dc:creator><prism:publicationName>Journal of Pharmaceutical Investigation</prism:publicationName><prism:issn>20935552</prism:issn><prism:eIssn>20936214</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>329-340</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s40005-015-0180-5</prism:doi><dc:description>© 2015, The Korean Society of Pharmaceutical Sciences and Technology. A simple, rapid and sensitive high-performance liquid chromatography–tandem mass spectrometry method has been developed and validated according to the Food and Drug Administration (FDA) guidelines for simultaneous determination of metoprolol and telmisartan in rat plasma using atorvastatin as an internal standard. The analytes were separated on a Gemini C&lt;inf&gt;18&lt;/inf&gt; column (50 mm × 4.6 mm, 5 µm) with an isocratic mobile phase of methanol–water containing 0.5 % formic acid (9:1, v/v) at a flow rate of 0.5 mL/min. The estimation was carried out by triple quadrupole mass spectrometry using electrospray ionization technique, operating in multiple reaction monitoring and positive ion modes. Simple liquid–liquid extraction was used for sample preparation. Linearity was achieved over the concentration range of 1–500 ng/mL for both the analytes in rat plasma. Results of validation parameters of the method were with the acceptance criteria of the FDA guidelines. The method was found suitable to quantitatively assess the pharmacokinetics of metoprolol and telmisartan in rat following administration of a single oral dose 2.5 and 2 mg/kg body weight, respectively in Wistar albino rat.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60042202</affiliation-url><afid>60042202</afid><affilname>Ministry of Health and Family Welfare</affilname><name-variant>Ministry of Health and Family Welfare</name-variant><affiliation-city>New Delhi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020825</affiliation-url><afid>60020825</afid><affilname>Jadavpur University</affilname><name-variant>Jadavpur University</name-variant><affiliation-city>Kolkata</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004631336</author-url><authid>7004631336</authid><authname>Nandi U.</authname><surname>Nandi</surname><given-name>Utpal</given-name><initials>U.</initials><afid>60042202</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55804454400</author-url><authid>55804454400</authid><authname>Dan S.</authname><surname>Dan</surname><given-name>Shubhasis</given-name><initials>S.</initials><afid>60020825</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:21735907600</author-url><authid>21735907600</authid><authname>Pal T.</authname><surname>Pal</surname><given-name>Tapan Kumar</given-name><initials>T.K.</initials><afid>60020825</afid></author><authkeywords>Liquid chromatography–tandem mass spectrometry | Metoprolol | Pharmacokinetics | Telmisartan | Validation</authkeywords><intid>35902300</intid><source-id>21100220486</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199472"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199472?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199472&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199472&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199472</prism:url><dc:identifier>SCOPUS_ID:84930199472</dc:identifier><eid>2-s2.0-84930199472</eid><dc:title>Tolled multi-class traffic equilibria and toll sensitivities</dc:title><dc:creator>Lindberg P.</dc:creator><prism:publicationName>EURO Journal on Transportation and Logistics</prism:publicationName><prism:issn>21924376</prism:issn><prism:eIssn>21924384</prism:eIssn><prism:volume>4</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>197-222</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s13676-014-0058-0</prism:doi><dc:description>© 2015, Springer-Verlag Berlin Heidelberg and EURO - The Association of European Operational Research Societies. We review properties of tolled equilibria in road networks, with users differing in their time values, and study corresponding sensitivities of equilibrium link flows w.r.t. tolls. Possible applications include modeling of individual travellers that have different trip purposes (e.g. work, business, leisure, etc.) and therefore perceive the relation between travel time and monetary cost in dissimilar ways. The typical objective is to reduce the total value of travel time (TVT) over all users. For first best congestion pricing, where all links in the network can be tolled, the solution can be internalized through marginal social cost (MSC) pricing. The MSC equilibrium typically has to be implemented through fixed tolls. The MSC as well as the fixed-toll equilibrium problems can be stated as optimization problems, which in general are convex in the fixed-toll case and non-convex in the MSC case. Thus, there may be several MSC equilibria. Second-best congestion pricing, where one only tolls a subset of the links, is much more complex, and equilibrium flows, times and TVT are not in general differentiable w.r.t. tolls in sub-routes used by several classes. For generic tolls, where the sets of shortest paths are stable, we show how to compute Jacobians (w.r.t positive tolls) of link flows and times as well as of the TVT. This can be used in descent schemes to find tolls that minimize the TVT at least locally. We further show that a condition of independent equilibrium cycles, together with a natural extension of the single class regularity condition of strict complementarity, leads to genericity, and hence existence of said Jacobians.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002014</affiliation-url><afid>60002014</afid><affilname>The Royal Institute of Technology (KTH)</affilname><name-variant>Royal Institute of Technology</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002014</affiliation-url><afid>60002014</afid><affilname>The Royal Institute of Technology (KTH)</affilname><name-variant>Royal Institute of Technology</name-variant><affiliation-city>Stockholm</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24312021400</author-url><authid>24312021400</authid><authname>Lindberg P.</authname><surname>Lindberg</surname><given-name>P. O.</given-name><initials>P.O.</initials><afid>60002014</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24491457800</author-url><authid>24491457800</authid><authname>Engelson L.</authname><surname>Engelson</surname><given-name>Leonid</given-name><initials>L.</initials><afid>60002014</afid></author><authkeywords>Congestion pricing | Marginal social cost | Multi-class traffic assignment | Second-Best road pricing | Sensitivity</authkeywords><intid>2036082748</intid><source-id>21100394099</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930000487"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930000487?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930000487&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930000487&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930000487</prism:url><dc:identifier>SCOPUS_ID:84930000487</dc:identifier><eid>2-s2.0-84930000487</eid><dc:title>Blood pressure-lowering effects of propofol or sevoflurane anaesthesia are not due to enhanced nitric oxide formation or bioavailability</dc:title><dc:creator>Tsikas D.</dc:creator><prism:publicationName>British Journal of Clinical Pharmacology</prism:publicationName><prism:issn>03065251</prism:issn><prism:eIssn>13652125</prism:eIssn><prism:volume>79</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1030-1033</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1111/bcp.12568</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024052</affiliation-url><afid>60024052</afid><affilname>Medizinische Hochschule Hannover (MHH)</affilname><name-variant>Hannover Medical School</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7005822024</author-url><authid>7005822024</authid><authname>Tsikas D.</authname><surname>Tsikas</surname><given-name>Dimitrios</given-name><initials>D.</initials><afid>60024052</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55516933800</author-url><authid>55516933800</authid><authname>Jordan J.</authname><surname>Jordan</surname><given-name>Jens</given-name><initials>J.</initials><afid>60024052</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56589674600</author-url><authid>56589674600</authid><authname>Engeli S.</authname><surname>Engeli</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60024052</afid></author><intid>1036044802</intid><source-id>20082</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926285589"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926285589?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926285589&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926285589&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0959437X15000234"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926285589</prism:url><dc:identifier>SCOPUS_ID:84926285589</dc:identifier><eid>2-s2.0-84926285589</eid><dc:title>The lure of zebrafish in liver research: Regulation of hepatic growth in development and regeneration</dc:title><dc:creator>Cox A.</dc:creator><prism:publicationName>Current Opinion in Genetics and Development</prism:publicationName><prism:issn>0959437X</prism:issn><prism:eIssn>18790380</prism:eIssn><prism:volume>32</prism:volume><prism:pageRange>153-161</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.gde.2015.03.002</prism:doi><pii>S0959437X15000234</pii><dc:description>© 2015 Elsevier Ltd. The liver is an essential organ that plays a pivotal role in metabolism, digestion and nutrient storage. Major efforts have been made to develop zebrafish (. Danio rerio) as a model system to study the pathways regulating hepatic growth during liver development and regeneration. Zebrafish offer unique advantages over other vertebrates including in vivo imaging at cellular resolution and the capacity for large-scale chemical and genetic screens. Here, we review the cellular and molecular mechanisms that regulate hepatic growth during liver development in zebrafish. We also highlight emerging evidence that developmental pathways are reactivated following liver injury to facilitate regeneration. Finally, we discuss how zebrafish have transformed drug discovery efforts and enabled the identification of drugs that stimulate hepatic growth and provide hepatoprotection in pre-clinical models of liver injury, with the ultimate goal of identifying novel therapeutic approaches to treat liver disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016782</affiliation-url><afid>60016782</afid><affilname>Brigham and Women's Hospital</affilname><name-variant>Brigham and Women's Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014334</affiliation-url><afid>60014334</afid><affilname>Dana-Farber Cancer Institute</affilname><name-variant>Dana Farber Cancer Institute</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027452</affiliation-url><afid>60027452</afid><affilname>Harvard Stem Cell Institute</affilname><name-variant>Harvard University</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001001</affiliation-url><afid>60001001</afid><affilname>Broad Institute</affilname><name-variant>Broad Institute</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:22633887200</author-url><authid>22633887200</authid><authname>Cox A.</authname><surname>Cox</surname><given-name>Andrew G.</given-name><initials>A.G.</initials><afid>60016782</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603646962</author-url><authid>6603646962</authid><authname>Goessling W.</authname><surname>Goessling</surname><given-name>Wolfram</given-name><initials>W.</initials><afid>60016782</afid><afid>60014334</afid><afid>60027452</afid><afid>60001001</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603646962</author-url><authid>6603646962</authid><authname>Goessling W.</authname><surname>Goessling</surname><given-name>Wolfram</given-name><initials>W.</initials><afid>60016782</afid><afid>60014334</afid><afid>60027452</afid><afid>60001001</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603646962</author-url><authid>6603646962</authid><authname>Goessling W.</authname><surname>Goessling</surname><given-name>Wolfram</given-name><initials>W.</initials><afid>60016782</afid><afid>60014334</afid><afid>60027452</afid><afid>60001001</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603646962</author-url><authid>6603646962</authid><authname>Goessling W.</authname><surname>Goessling</surname><given-name>Wolfram</given-name><initials>W.</initials><afid>60016782</afid><afid>60014334</afid><afid>60027452</afid><afid>60001001</afid></author><intid>1785431608</intid><source-id>22080</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925398087"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925398087?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925398087&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925398087&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0141813015001233"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925398087</prism:url><dc:identifier>SCOPUS_ID:84925398087</dc:identifier><eid>2-s2.0-84925398087</eid><dc:title>Molecular mechanism on cadmium-induced activity changes of catalase and superoxide dismutase</dc:title><dc:creator>Wang J.</dc:creator><prism:publicationName>International Journal of Biological Macromolecules</prism:publicationName><prism:issn>01418130</prism:issn><prism:eIssn>18790003</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>59-67</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijbiomac.2015.02.037</prism:doi><pii>S0141813015001233</pii><dc:description>© 2015 Elsevier B.V. Cadmium contributes to adverse effects of organisms probably because of its ability to induce oxidative stress via alterations in activities of antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD), but their molecular mechanisms remain unclear. We investigated the molecular mechanism of CAT and SOD response under Cd-induced oxidative stress in the liver of zebrafish. The enzyme activity changes observed in vitro were consistent with those seen in vivo, indicating the direct interaction of CAT and SOD with Cd contributes to their activity change in vivo. Further experiments utilizing multiple spectroscopic methods, isothermal titration calorimetry and a molecular docking study were performed to explore the mechanism of molecular interaction of CAT and SOD with Cd. Different interaction patterns were found that resulted in misfolding and changed the enzyme activities. Taken together, we suggest the misfolding of CAT and SOD contributes to their activity change under Cd-induced oxidative stress in vivo.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005500</affiliation-url><afid>60005500</afid><affilname>China Pharmaceutical University</affilname><name-variant>China Pharmaceutical University</name-variant><affiliation-city>Nanjing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56040380900</author-url><authid>56040380900</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jing</given-name><initials>J.</initials><afid>60031031</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56038022900</author-url><authid>56038022900</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Hao</given-name><initials>H.</initials><afid>60031031</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56431613700</author-url><authid>56431613700</authid><authname>Zhang T.</authname><surname>Zhang</surname><given-name>Tong</given-name><initials>T.</initials><afid>60031031</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56328093700</author-url><authid>56328093700</authid><authname>Zhang R.</authname><surname>Zhang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60031031</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7404552214</author-url><authid>7404552214</authid><authname>Liu R.</authname><surname>Liu</surname><given-name>Rutao</given-name><initials>R.</initials><afid>60031031</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56169019100</author-url><authid>56169019100</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yadong</given-name><initials>Y.</initials><afid>60005500</afid></author><authkeywords>Cadmium | Catalase and superoxide dismutase | Oxidative stress</authkeywords><intid>1785298706</intid><source-id>17544</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924252470"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924252470?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924252470&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924252470&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S8756328215000125"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924252470</prism:url><dc:identifier>SCOPUS_ID:84924252470</dc:identifier><eid>2-s2.0-84924252470</eid><dc:title>Dkk1 haploinsufficiency requires expression of Bmp2 for bone anabolic activity</dc:title><dc:creator>Intini G.</dc:creator><prism:publicationName>Bone</prism:publicationName><prism:issn>87563282</prism:issn><prism:volume>75</prism:volume><prism:pageRange>151-160</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bone.2015.01.008</prism:doi><pii>S8756328215000125</pii><dc:description>© 2015 Elsevier Inc. Bone fractures remain a serious health burden and prevention and enhanced healing of fractures have been obtained by augmenting either BMP or Wnt signaling. However, whether BMP and Wnt signaling are both required or are self-sufficient for anabolic and fracture healing activities has never been fully elucidated. Mice haploinsufficient for Dkk1 (Dkk1+/-) exhibit a high bone mass phenotype due to an up-regulation of canonical Wnt signaling while mice lacking Bmp2 expression in the limbs (Bmp2c/c;Prx1::cre) succumb to spontaneous fracture and are unable to initiate fracture healing; combined, these mice offer an opportunity to examine the requirement for activated BMP signaling on the anabolic and fracture healing activity of Wnts. When Dkk1+/- mice were crossed with Bmp2c/c;Prx1::cre mice, the offspring bearing both genetic alterations were unable to increase bone mass and heal fractures, indicating that increased canonical Wnt signaling is unable to exploit its activity in absence of Bmp2. Thus, our data suggest that BMP signaling is required for Wnt-mediated anabolic activity and that therapies aimed at preventing fractures and fostering fracture repair may need to target both pathways for maximal efficacy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005856</affiliation-url><afid>60005856</afid><affilname>Harvard School of Dental Medicine</affilname><name-variant>Harvard Sch. Dent. Med.</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027452</affiliation-url><afid>60027452</afid><affilname>Harvard Stem Cell Institute</affilname><name-variant>Harvard University</name-variant><affiliation-city>Cambridge</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030769</affiliation-url><afid>60030769</afid><affilname>Vanderbilt University Medical Center</affilname><name-variant>Vanderbilt University Medical Center</name-variant><affiliation-city>Nashville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023695</affiliation-url><afid>60023695</afid><affilname>Department of Veterans Affairs</affilname><name-variant>Department of Veterans Affairs</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507161496</author-url><authid>6507161496</authid><authname>Intini G.</authname><surname>Intini</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60005856</afid><afid>60027452</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507161496</author-url><authid>6507161496</authid><authname>Intini G.</authname><surname>Intini</surname><given-name>Giuseppe</given-name><initials>G.</initials><afid>60005856</afid><afid>60027452</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006598811</author-url><authid>7006598811</authid><authname>Nyman J.</authname><surname>Nyman</surname><given-name>Jeffry S.</given-name><initials>J.S.</initials><afid>60030769</afid><afid>60023695</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006598811</author-url><authid>7006598811</authid><authname>Nyman J.</authname><surname>Nyman</surname><given-name>Jeffry S.</given-name><initials>J.S.</initials><afid>60030769</afid><afid>60023695</afid></author><authkeywords>BMP signaling | Bmp2 | Bone homeostasis | Dkk1 | Fracture healing | Wnt signaling</authkeywords><intid>1535100835</intid><source-id>29551</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927602807"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927602807?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927602807&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927602807&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0891584915000945"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927602807</prism:url><dc:identifier>SCOPUS_ID:84927602807</dc:identifier><eid>2-s2.0-84927602807</eid><dc:title>Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimers disease</dc:title><dc:creator>Lloret A.</dc:creator><prism:publicationName>Free Radical Biology and Medicine</prism:publicationName><prism:issn>08915849</prism:issn><prism:eIssn>18734596</prism:eIssn><prism:volume>83</prism:volume><prism:pageRange>186-191</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.freeradbiomed.2015.02.028</prism:doi><pii>S0891584915000945</pii><dc:description>© 2015 Elsevier Inc. Neurofibrillary tangles (aggregates of cytoskeletal Tau protein) and senile plaques (aggregates mainly formed by amyloid β peptide) are two landmark lesions in Alzheimers disease. Some researchers have proposed tangles, whereas others have proposed plaques, as primary lesions. For a long time, these were thought of as independent mechanisms. However, experimental evidence suggests that both lesions are intimately related. We review here some molecular pathways linking amyloid β and Tau toxicities involving, among others, glycogen synthase kinase 3β, p38, Pin1, cyclin-dependent kinase 5, and regulator of calcineurin 1. Understanding amyloid β and Tau toxicities as part of a common pathophysiological mechanism may help to find molecular targets to prevent or even treat the disease.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002644</affiliation-url><afid>60002644</afid><affilname>Universitat de ValEncia</affilname><name-variant>Universitat de València</name-variant><affiliation-city>Valencia</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003514309</author-url><authid>7003514309</authid><authname>Lloret A.</authname><surname>Lloret</surname><given-name>A.</given-name><initials>A.</initials><afid>60002644</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7801650299</author-url><authid>7801650299</authid><authname>Fuchsberger T.</authname><surname>Fuchsberger</surname><given-name>T.</given-name><initials>T.</initials><afid>60002644</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23993494000</author-url><authid>23993494000</authid><authname>Giraldo E.</authname><surname>Giraldo</surname><given-name>E.</given-name><initials>E.</initials><afid>60002644</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35244114900</author-url><authid>35244114900</authid><authname>Viña J.</authname><surname>Viña</surname><given-name>J.</given-name><initials>J.</initials><afid>60002644</afid></author><authkeywords>Alzheimers disease | Amyloid β | Dementia p-Tau | Free radicals | Neurodegeneration</authkeywords><intid>1785649250</intid><source-id>15095</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926168799"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926168799?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926168799&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926168799&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0939641115001514"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926168799</prism:url><dc:identifier>SCOPUS_ID:84926168799</dc:identifier><eid>2-s2.0-84926168799</eid><dc:title>Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy</dc:title><dc:creator>Pérez-Herrero E.</dc:creator><prism:publicationName>European Journal of Pharmaceutics and Biopharmaceutics</prism:publicationName><prism:issn>09396411</prism:issn><prism:eIssn>18733441</prism:eIssn><prism:volume>93</prism:volume><prism:pageRange>52-79</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejpb.2015.03.018</prism:doi><pii>S0939641115001514</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Cancer is the second worldwide cause of death, exceeded only by cardiovascular diseases. It is characterized by uncontrolled cell proliferation and an absence of cell death that, except for hematological cancers, generates an abnormal cell mass or tumor. This primary tumor grows thanks to new vascularization and, in time, acquires metastatic potential and spreads to other body sites, which causes metastasis and finally death. Cancer is caused by damage or mutations in the genetic material of the cells due to environmental or inherited factors. While surgery and radiotherapy are the primary treatment used for local and non-metastatic cancers, anti-cancer drugs (chemotherapy, hormone and biological therapies) are the choice currently used in metastatic cancers. Chemotherapy is based on the inhibition of the division of rapidly growing cells, which is a characteristic of the cancerous cells, but unfortunately, it also affects normal cells with fast proliferation rates, such as the hair follicles, bone marrow and gastrointestinal tract cells, generating the characteristic side effects of chemotherapy. The indiscriminate destruction of normal cells, the toxicity of conventional chemotherapeutic drugs, as well as the development of multidrug resistance, support the need to find new effective targeted treatments based on the changes in the molecular biology of the tumor cells. These novel targeted therapies, of increasing interest as evidenced by FDA-approved targeted cancer drugs in recent years, block biologic transduction pathways and/or specific cancer proteins to induce the death of cancer cells by means of apoptosis and stimulation of the immune system, or specifically deliver chemotherapeutic agents to cancer cells, minimizing the undesirable side effects. Although targeted therapies can be achieved directly by altering specific cell signaling by means of monoclonal antibodies or small molecules inhibitors, this review focuses on indirect targeted approaches that mainly deliver chemotherapeutic agents to molecular targets overexpressed on the surface of tumor cells. In particular, we offer a detailed description of different cytotoxic drug carriers, such as liposomes, carbon nanotubes, dendrimers, polymeric micelles, polymeric conjugates and polymeric nanoparticles, in passive and active targeted cancer therapy, by enhancing the permeability and retention or by the functionalization of the surface of the carriers, respectively, emphasizing those that have received FDA approval or are part of the most important clinical studies up to date. These drug carriers not only transport the chemotherapeutic agents to tumors, avoiding normal tissues and reducing toxicity in the rest of the body, but also protect cytotoxic drugs from degradation, increase the half-life, payload and solubility of cytotoxic agents and reduce renal clearance. Despite the many advantages of all the anticancer drug carriers analyzed, only a few of them have reached the FDA approval, in particular, two polymer-protein conjugates, five liposomal formulations and one polymeric nanoparticle are available in the market, in contrast to the sixteen FDA approval of monoclonal antibodies. However, there are numerous clinical trials in progress of polymer-protein and polymer-drug conjugates, liposomal formulations, including immunoliposomes, polymeric micelles and polymeric nanoparticles. Regarding carbon nanotubes or dendrimers, there are no FDA approvals or clinical trials in process up to date due to their unresolved toxicity. Moreover, we analyze in detail the more promising and advanced preclinical studies of the particular case of polymeric nanoparticles as carriers of different cytotoxic agents to active and passive tumor targeting published in the last 5 years, since they have a huge potential in cancer therapy, being one of the most widely studied nano-platforms in this field in the last years. The interest that these formulations have recently achieved is stressed by the fact that 90% of the papers based on cancer therapeutics with polymeric nanoparticles have been published in the last 6 years (PubMed search).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025028</affiliation-url><afid>60025028</afid><affilname>Universidad de Salamanca</affilname><name-variant>Universidad de Salamanca</name-variant><affiliation-city>Salamanca</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103760</affiliation-url><afid>60103760</afid><affilname>CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC)</affilname><name-variant>Instituto de Biología Molecular Y Celular del Cáncer</name-variant><affiliation-city>Salamanca</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56580311600</author-url><authid>56580311600</authid><authname>Pérez-Herrero E.</authname><surname>Pérez-Herrero</surname><given-name>Edgar</given-name><initials>E.</initials><afid>60025028</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506390195</author-url><authid>6506390195</authid><authname>Fernández-Medarde A.</authname><surname>Fernández-Medarde</surname><given-name>Alberto</given-name><initials>A.</initials><afid>60103760</afid></author><authkeywords>Active targeting | Cancer | Chemotherapy | Clinical status | Nanocarriers | Passive targeting | Polymeric nanoparticles | Targeted therapy</authkeywords><intid>1035401403</intid><source-id>21332</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925881180"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925881180?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925881180&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925881180&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0005273615000735"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925881180</prism:url><dc:identifier>SCOPUS_ID:84925881180</dc:identifier><eid>2-s2.0-84925881180</eid><dc:title>Phosphorylation, nitrosation and plasminogen K3 modulation make VDAC-1 lucid as part of the extrinsic apoptotic pathway - Resulting thesis: Native VDAC-1 indispensible for finalisation of its 3D structure</dc:title><dc:creator>Thinnes F.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Biomembranes</prism:publicationName><prism:issn>00052736</prism:issn><prism:eIssn>18792642</prism:eIssn><prism:volume>1848</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1410-1416</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbamem.2015.02.031</prism:doi><pii>S0005273615000735</pii><dc:description>© 2015 Elsevier B.V. Native and recombinant VDAC preparations differ in their acetylation, phosphorylation and nitrosation state; additionally, proteineous modulators are missing in the latter. They thus vary in channel characteristics, as can be taken from comparative black lipid bilayer experiments. Furthermore, the multi-compartment expression makes expect even differing native VDAC-1 molecules. Recent structural work on mammalian VDAC-1 has only used recombinant material, refolded from Escherichia coli inclusion bodies. While this approach established the basic three-dimensional structure of VDAC-1, a ß-barrel set up by nineteen ß-pleated sheets, dissent is on positioning and movements of its free N-terminal helical peptide stretch preceding ß-pleated sheet-1. A synopsis of data concerning posttranslational modifications, cyto-topology and physiology of native VDAC-1, from my point of view, suggests that the finalisation of its three-dimensional structure will need native channel preparations to be studied. Concerning relevance, recent evidence on the regulation of cell membrane-integrated VDAC-1 by posttranslational modifications and proteineous modulators, taken together with experimental demonstrations that VDAC-1 is involved in cell volume regulation, it thus may be part of the extrinsic apoptotic pathway can hopefully help to understand some relevant medical syndromes, e.g. cystic fibrosis, Alzheimer's disease, autism and malaria.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115111214</affiliation-url><afid>115111214</afid><affilname>Baumschulenweg 5</affilname><name-variant>Baumschulenweg 5</name-variant><affiliation-city>Gottingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004822885</author-url><authid>7004822885</authid><authname>Thinnes F.</authname><surname>Thinnes</surname><given-name>Friedrich P.</given-name><initials>F.P.</initials><afid>115111214</afid></author><authkeywords>Alzheimers disease | Autism | Cystic fibrosis | Malaria | Porin | VRAC</authkeywords><intid>2035365573</intid><source-id>18406</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84919822103"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84919822103?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84919822103&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84919822103&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814614019268"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84919822103</prism:url><dc:identifier>SCOPUS_ID:84919822103</dc:identifier><eid>2-s2.0-84919822103</eid><dc:title>Changes in the contents and profiles of selected phenolics, soyasapogenols, tocopherols, and amino acids during soybean-rice mixture cooking: Electric rice cooker vs electric pressure rice cooker</dc:title><dc:creator>Kim S.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>176</prism:volume><prism:pageRange>45-53</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2014.12.024</prism:doi><pii>S0308814614019268</pii><dc:description>©2014 Elsevier Ltd. All rights reserved. This study investigated the changes in the contents and profiles of 35 phenolics (including 12 isoflavones), four tocopherols, two soyasapogenols and 20 amino acids when soybean and rice were cooked together (soybean-rice mixture) using either an electric rice cooker (ERC) or an electric pressure rice cooker (EPRC). The contents of the 35 selected phenolics in soybean decreased by 12% and 8% upon cooking by ERC and EPRC, respectively, and their profiles were different from that prior to cooking (P &lt; 0.05). Total tocopherol content of soybeans decreased by 7% after cooking in an ERC, but increased by 3% in soybeans cooked by EPRC. Total soyasapogenol content in soybeans cooked by ERC and EPRC decreased by 15% and 6%, respectively. Lastly, the total amino acid content of soybeans increased by 41% and 10% after cooking by ERC and EPRC, respectively. This study extends our knowledge about the effects of heat and pressure on the contents and profiles of bioactive compounds during soybean-rice mixture cooking. These results may be useful for improving the quality of bioactive compounds in soybean and rice depending on cooking conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000142</affiliation-url><afid>60000142</afid><affilname>Konkuk University</affilname><name-variant>Konkuk University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56460464600</author-url><authid>56460464600</authid><authname>Kim S.</authname><surname>Kim</surname><given-name>Seung Hyun</given-name><initials>S.H.</initials><afid>60000142</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55963885000</author-url><authid>55963885000</authid><authname>Yu B.</authname><surname>Yu</surname><given-name>Bo Ra</given-name><initials>B.R.</initials><afid>60000142</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56067884300</author-url><authid>56067884300</authid><authname>Chung I.</authname><surname>Chung</surname><given-name>Ill Min</given-name><initials>I.M.</initials><afid>60000142</afid></author><authkeywords>Amino acids | Cooking conditions | Phenolics | Soyasapogenols | Soybean-rice mixture | Tocopherols</authkeywords><intid>1534362486</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928170536"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928170536?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928170536&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928170536&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0041008X15001210"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928170536</prism:url><dc:identifier>SCOPUS_ID:84928170536</dc:identifier><eid>2-s2.0-84928170536</eid><dc:title>The proteasome inhibitor bortezomib induces testicular toxicity by upregulation of oxidative stress, AMP-activated protein kinase (AMPK) activation and deregulation of germ cell development in adult murine testis</dc:title><dc:creator>Li W.</dc:creator><prism:publicationName>Toxicology and Applied Pharmacology</prism:publicationName><prism:issn>0041008X</prism:issn><prism:eIssn>10960333</prism:eIssn><prism:volume>285</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>98-109</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.taap.2015.04.001</prism:doi><pii>S0041008X15001210</pii><dc:description>© 2015 Elsevier Inc. Understanding how chemotherapeutic agents mediate testicular toxicity is crucial in light of compelling evidence that male infertility, one of the severe late side effects of intensive cancer treatment, occurs more often than they are expected to. Previous study demonstrated that bortezomib (BTZ), a 26S proteasome inhibitor used to treat refractory multiple myeloma (MM), exerts deleterious impacts on spermatogenesis in pubertal mice via unknown mechanisms. Here, we showed that intermittent treatment with BTZ resulted in fertility impairment in adult mice, evidenced by testicular atrophy, desquamation of immature germ cells and reduced caudal sperm storage. These deleterious effects may originate from the elevated apoptosis in distinct germ cells during the acute phase and the subsequent disruption of Sertoli-germ cell anchoring junctions (AJs) during the late recovery. Mechanistically, balance between AMP-activated protein kinase (AMPK) activation and Akt/ERK pathway appeared to be indispensable for AJ integrity during the late testicular recovery. Of particular interest, the upregulated testicular apoptosis and the following disturbance of Sertoli-germ cell interaction may both stem from the excessive oxidative stress elicited by BTZ exposure. We also provided the in vitro evidence that AMPK-dependent mechanisms counteract follicle-stimulating hormone (FSH) proliferative effects in BTZ-exposed Sertoli cells. Collectively, BTZ appeared to efficiently prevent germ cells from normal development via multiple mechanisms in adult mice. Employment of antioxidants and/or AMPK inhibitor may represent an attractive strategy of fertility preservation in male MM patients exposed to conventional BTZ therapy and warrants further investigation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088187</affiliation-url><afid>60088187</afid><affilname>The Fourth Military Medical University</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069708</affiliation-url><afid>60069708</afid><affilname>Xijing Hospital</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088188</affiliation-url><afid>60088188</afid><affilname>Tangdu Hospital, Fourth Military Medical University</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088188</affiliation-url><afid>60088188</afid><affilname>Tangdu Hospital, Fourth Military Medical University</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069708</affiliation-url><afid>60069708</afid><affilname>Xijing Hospital</affilname><name-variant>Fourth Military Medical University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56599399000</author-url><authid>56599399000</authid><authname>Li W.</authname><surname>Li</surname><given-name>Wei</given-name><initials>W.</initials><afid>60088187</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56599515400</author-url><authid>56599515400</authid><authname>Fu J.</authname><surname>Fu</surname><given-name>Jianfang</given-name><initials>J.</initials><afid>60069708</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54783778700</author-url><authid>54783778700</authid><authname>Zhang S.</authname><surname>Zhang</surname><given-name>Shun</given-name><initials>S.</initials><afid>60088188</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56176662800</author-url><authid>56176662800</authid><authname>Zhao J.</authname><surname>Zhao</surname><given-name>Jie</given-name><initials>J.</initials><afid>60088187</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56599931600</author-url><authid>56599931600</authid><authname>Xie N.</authname><surname>Xie</surname><given-name>Nianlin</given-name><initials>N.</initials><afid>60088188</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56599745000</author-url><authid>56599745000</authid><authname>Cai G.</authname><surname>Cai</surname><given-name>Guoqing</given-name><initials>G.</initials><afid>60069708</afid></author><authkeywords>AMP-activated protein kinase | Anchoring junction | Apoptosis | Bortezomib | Oxidative stress | Testis</authkeywords><intid>1535733438</intid><source-id>25222</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928744898"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928744898?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928744898&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928744898&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928744898</prism:url><dc:identifier>SCOPUS_ID:84928744898</dc:identifier><eid>2-s2.0-84928744898</eid><dc:title>Characterization of chicken waste fat for application in food technology</dc:title><dc:creator>Farmani J.</dc:creator><prism:publicationName>Journal of Food Measurement and Characterization</prism:publicationName><prism:issn>21934126</prism:issn><prism:eIssn>21934134</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>143-150</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11694-014-9219-y</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. Chicken waste which mainly contains skin and depot fat can be used for extraction of edible fat. In this study physicochemical properties of chicken waste and its fat was determined. The content of fat, moisture, protein and ash in chicken waste was 38.92, 50.78, 8.93 and 1.28 %, respectively. Chicken waste fat (CWF) contained palmitic acid as the main saturated fatty acid and oleic and linoleic acid as the main unsaturated fatty acids. It contained considerably lower saturated fatty acids than beef tallow, lard and palm oil. The fatty acid composition of CWF was very similar to that of rice bran oil. CWF contained lower level of cholesterol (780 ppm) than tallow and lard. Phosphorus level of CWF was much lower than vegetable oils and it may be refined without degumming. The iron content of the CWF, however, was much higher than that reported for vegetable oils, which necessitates a careful bleaching of the fat. Iodine value and refractive index of CWF were lower than tallow, lard and palm oil but higher than that of cottonseed and rice bran oil. Free fatty acid content (0.62 %) and peroxide value (1.84 meq/kg) were found to be at acceptable levels. Melting point and solid fat content (SFC) of CWF at 10–35 °C were lower than those reported for tallow, lard and palm oil. CWF can be used for production of soft tub margarine and vanaspati.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60077840</affiliation-url><afid>60077840</afid><affilname>University of Mazandaran Faculty of Natural Resources</affilname><name-variant>Sari Agricultural Sciences and Natural Resources University</name-variant><affiliation-city>Sari</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031777</affiliation-url><afid>60031777</afid><affilname>Daneshgahe Azad Eslami</affilname><name-variant>Islamic Azad University</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14424128500</author-url><authid>14424128500</authid><authname>Farmani J.</authname><surname>Farmani</surname><given-name>Jamshid</given-name><initials>J.</initials><afid>60077840</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56532531400</author-url><authid>56532531400</authid><authname>Rostammiri L.</authname><surname>Rostammiri</surname><given-name>Leila</given-name><initials>L.</initials><afid>60031777</afid></author><authkeywords>Characterization | Chicken waste fat | Fatty acid composition</authkeywords><intid>1535839308</intid><source-id>21100224010</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922386567"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922386567?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922386567&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922386567&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S095279151500014X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922386567</prism:url><dc:identifier>SCOPUS_ID:84922386567</dc:identifier><eid>2-s2.0-84922386567</eid><dc:title>Discovering protective CD8 T cell epitopes-no single immunologic property predicts it!</dc:title><dc:creator>Gilchuk P.</dc:creator><prism:publicationName>Current Opinion in Immunology</prism:publicationName><prism:issn>09527915</prism:issn><prism:eIssn>18790372</prism:eIssn><prism:volume>34</prism:volume><prism:pageRange>43-51</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.coi.2015.01.013</prism:doi><pii>S095279151500014X</pii><dc:description>© 2015. Once a burgeoning field of study, over the past decade or so, T cell epitope discovery has lost some luster. The contributory factors perchance are the general notion that any newly discovered epitope will reveal very little about an immune response and that knowledge of epitopes are less critical for vaccine design. Despite these notions, the breadth and depth of T cell epitopes derived from clinically important microbial agents of human diseases largely remain ill defined. We review here a flurry of recent reports that have rebirthed the field. These reports reveal that epitope discovery is an essential step toward rational vaccine design and critical for monitoring vaccination efficacy. The new findings also indicate that neither immunogenicity nor immunodominance predict protective immunity. Hence, an immunogenic epitope is but a peptide unless proven protective against disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003915</affiliation-url><afid>60003915</afid><affilname>Vanderbilt University</affilname><name-variant>Vanderbilt University</name-variant><affiliation-city>Nashville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003915</affiliation-url><afid>60003915</afid><affilname>Vanderbilt University</affilname><name-variant>Vanderbilt University</name-variant><affiliation-city>Nashville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003915</affiliation-url><afid>60003915</afid><affilname>Vanderbilt University</affilname><name-variant>Vanderbilt University</name-variant><affiliation-city>Nashville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56333544100</author-url><authid>56333544100</authid><authname>Gilchuk P.</authname><surname>Gilchuk</surname><given-name>Pavlo</given-name><initials>P.</initials><afid>60003915</afid><afid>60003915</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56333544100</author-url><authid>56333544100</authid><authname>Gilchuk P.</authname><surname>Gilchuk</surname><given-name>Pavlo</given-name><initials>P.</initials><afid>60003915</afid><afid>60003915</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56506348300</author-url><authid>56506348300</authid><authname>Hill T.</authname><surname>Hill</surname><given-name>Timothy M.</given-name><initials>T.M.</initials><afid>60003915</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56505846200</author-url><authid>56505846200</authid><authname>Wilson J.</authname><surname>Wilson</surname><given-name>John T.</given-name><initials>J.T.</initials><afid>60003915</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007076880</author-url><authid>7007076880</authid><authname>Joyce S.</authname><surname>Joyce</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60003915</afid><afid>60003915</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007076880</author-url><authid>7007076880</authid><authname>Joyce S.</authname><surname>Joyce</surname><given-name>Sebastian</given-name><initials>S.</initials><afid>60003915</afid><afid>60003915</afid></author><intid>34795956</intid><source-id>18797</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225147"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225147?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225147&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225147&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225147</prism:url><dc:identifier>SCOPUS_ID:84930225147</dc:identifier><eid>2-s2.0-84930225147</eid><dc:title>Iron oxide-based multifunctional nanoparticulate systems for biomedical applications: A patent review (2008-present)</dc:title><dc:creator>El-Hammadi M.</dc:creator><prism:publicationName>Expert Opinion on Therapeutic Patents</prism:publicationName><prism:issn>13543776</prism:issn><prism:eIssn>17447674</prism:eIssn><prism:volume>25</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>691-709</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1517/13543776.2015.1028358</prism:doi><dc:description>© 2015 Informa UK, Ltd. Iron oxide nanoparticles (IO NPs) exhibit remarkable properties, including inherent magnetism, biocompatibility, high surface to volume ratio, and versatility of engineering, making them ideal candidates for a variety of clinical applications.Areas covered: The review provides an in-depth discussion on recent patents and developments related to IO NPs in Biomedicine from the last 7 years. It covers innovations in the chemical synthesis, surface coating and functionalization, and biomedical applications, including MRI and multimodal imaging, molecular imaging, cell labeling, drug delivery, hyperthermia, hyperphosphatemia, and antibacterial activity. A brief outline of the important properties of IO NPs is also presented.Expert opinion: The main focus of current research is the development of new approaches to generate high-quality IO NPs with optimal properties in terms of particle geometry, crystal structure, surface functionalities, stability, and magnetization. Among chemical synthesis methods, thermal decomposition and hydrothermal synthetics processes allow fine control of the particle properties. Plenty of coating materials have been successfully used as shells for these NPs to provide colloidal stability, even enabling the formulation of nanotheranostics for simultaneous disease diagnosis and therapy. However, long-term toxicity and pharmacokinetic studies are necessary before magnetic nanosystems can be approved for clinical use.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027844</affiliation-url><afid>60027844</afid><affilname>Universidad de Granada</affilname><name-variant>Universidad de Granada</name-variant><affiliation-city>Granada</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072760</affiliation-url><afid>60072760</afid><affilname>Damascus University</affilname><name-variant>University of Damascus</name-variant><affiliation-city>Damascus</affiliation-city><affiliation-country>Syrian Arab Republic</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507531985</author-url><authid>6507531985</authid><authname>El-Hammadi M.</authname><surname>El-Hammadi</surname><given-name>Mazen M.</given-name><initials>M.M.</initials><afid>60027844</afid><afid>60072760</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507531985</author-url><authid>6507531985</authid><authname>El-Hammadi M.</authname><surname>El-Hammadi</surname><given-name>Mazen M.</given-name><initials>M.M.</initials><afid>60027844</afid><afid>60072760</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35247693900</author-url><authid>35247693900</authid><authname>Arias J.</authname><surname>Arias</surname><given-name>José L.</given-name><initials>J.L.</initials><afid>60027844</afid></author><authkeywords>Drug delivery | Hyperthermia | Iron oxide nanoparticles | Magnetic properties | MRI | Multifunctional nanoparticles | Multimodal imaging | Surface coating | Theranosis</authkeywords><intid>536087812</intid><source-id>21353</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930091848"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930091848?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930091848&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930091848&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930091848</prism:url><dc:identifier>SCOPUS_ID:84930091848</dc:identifier><eid>2-s2.0-84930091848</eid><dc:title>Bilateral meandering pulmonary veins</dc:title><dc:creator>Thupili C.</dc:creator><prism:publicationName>Pediatric Radiology</prism:publicationName><prism:issn>03010449</prism:issn><prism:eIssn>14321998</prism:eIssn><prism:volume>45</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>924-926</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s00247-014-3200-0</prism:doi><dc:description>© 2014, Springer-Verlag Berlin Heidelberg. Meandering pulmonary veins is a rare clinical entity that can be mistaken for more complex congenital syndromes such as hypogenetic lung syndrome. We report imaging findings in a rare incidentally detected case of bilateral meandering pulmonary veins. We briefly discuss the role of imaging in diagnosing this condition, with particular emphasis on contrast-enhanced CT.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113955639</affiliation-url><afid>113955639</afid><affilname>Imaging Institute Cleveland Clinic</affilname><name-variant>Imaging Institute Cleveland Clinic</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113955639</affiliation-url><afid>113955639</afid><affilname>Imaging Institute Cleveland Clinic</affilname><name-variant>Imaging Institute Cleveland Clinic</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55391193100</author-url><authid>55391193100</authid><authname>Thupili C.</authname><surname>Thupili</surname><given-name>Chakradhar R.</given-name><initials>C.R.</initials><afid>113955639</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15833281400</author-url><authid>15833281400</authid><authname>Udayasankar U.</authname><surname>Udayasankar</surname><given-name>Unni</given-name><initials>U.</initials><afid>113955639</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:34168256300</author-url><authid>34168256300</authid><authname>Renapurkar R.</authname><surname>Renapurkar</surname><given-name>Rahul</given-name><initials>R.</initials><afid>113955639</afid></author><authkeywords>Child | Computed tomography | Meandering pulmonary veins</authkeywords><intid>536064061</intid><source-id>15753</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923328226"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923328226?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923328226&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923328226&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378437115001065"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923328226</prism:url><dc:identifier>SCOPUS_ID:84923328226</dc:identifier><eid>2-s2.0-84923328226</eid><dc:title>Statistical persistence of air pollutants (O3,SO2,NO2 and PM10) in Mexico City</dc:title><dc:creator>Meraz M.</dc:creator><prism:publicationName>Physica A: Statistical Mechanics and its Applications</prism:publicationName><prism:issn>03784371</prism:issn><prism:volume>427</prism:volume><prism:pageRange>202-217</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.physa.2015.02.009</prism:doi><pii>S0378437115001065</pii><dc:description>© 2015 Elsevier B.V. 2015 Elsevier B.V. All rights reserved. The rescaled range (R/S) analysis was used for analyzing the statistical persistence of air pollutants in Mexico City. The air-pollution time series consisted of hourly observations of ozone, nitrogen dioxide, sulfur dioxide and particulate matter obtained at the Mexico City downtown monitoring station during 1999-2014. The results showed that long-range persistence is not a uniform property over a wide range of time scales, from days to months. In fact, although the air pollutant concentrations exhibit an average persistent behavior, environmental (e.g., daily and yearly) and socio-economic (e.g., daily and weekly) cycles are reflected in the dependence of the persistence strength as quantified in terms of the Hurst exponent. It was also found that the Hurst exponent exhibits time variations, with the ozone and nitrate oxide concentrations presenting some regularity, such as annual cycles. The persistence dynamics of the pollutant concentrations increased during the rainy season and decreased during the dry season. The time and scale dependences of the persistence properties provide some insights in the mechanisms involved in the internal dynamics of the Mexico City atmosphere for accumulating and dissipating dangerous air pollutants. While in the short-term individual pollutants dynamics seems to be governed by specific mechanisms, in the long-term (for monthly and higher scales) meteorological and seasonal mechanisms involved in atmospheric recirculation seem to dominate the dynamics of all air pollutant concentrations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028381</affiliation-url><afid>60028381</afid><affilname>Universidad Autonoma Metropolitana - Iztapalapa</affilname><name-variant>Universidad Autónoma Metropolitana-Iztapalapa</name-variant><affiliation-city>Iztapalapa</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028381</affiliation-url><afid>60028381</afid><affilname>Universidad Autonoma Metropolitana - Iztapalapa</affilname><name-variant>Universidad Autónoma Metropolitana-Iztapalapa</name-variant><affiliation-city>Iztapalapa</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112713057</affiliation-url><afid>112713057</afid><affilname>División de Matemáticas Aplicadas</affilname><name-variant>División de Matemáticas Aplicadas</name-variant><affiliation-city>San Luis Potosi</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028381</affiliation-url><afid>60028381</afid><affilname>Universidad Autonoma Metropolitana - Iztapalapa</affilname><name-variant>Universidad Autónoma Metropolitana-Iztapalapa</name-variant><affiliation-city>Iztapalapa</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028381</affiliation-url><afid>60028381</afid><affilname>Universidad Autonoma Metropolitana - Iztapalapa</affilname><name-variant>Universidad Autónoma Metropolitana-Iztapalapa</name-variant><affiliation-city>Iztapalapa</affiliation-city><affiliation-country>Mexico</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6601910796</author-url><authid>6601910796</authid><authname>Meraz M.</authname><surname>Meraz</surname><given-name>M.</given-name><initials>M.</initials><afid>60028381</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56351414800</author-url><authid>56351414800</authid><authname>Rodriguez E.</authname><surname>Rodriguez</surname><given-name>E.</given-name><initials>E.</initials><afid>60028381</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003737384</author-url><authid>7003737384</authid><authname>Femat R.</authname><surname>Femat</surname><given-name>R.</given-name><initials>R.</initials><afid>112713057</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7007145337</author-url><authid>7007145337</authid><authname>Echeverria J.</authname><surname>Echeverria</surname><given-name>J. C.</given-name><initials>J.C.</initials><afid>60028381</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55399527300</author-url><authid>55399527300</authid><authname>Alvarez-Ramirez J.</authname><surname>Alvarez-Ramirez</surname><given-name>J.</given-name><initials>J.</initials><afid>112713057</afid><afid>60028381</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55399527300</author-url><authid>55399527300</authid><authname>Alvarez-Ramirez J.</authname><surname>Alvarez-Ramirez</surname><given-name>J.</given-name><initials>J.</initials><afid>112713057</afid><afid>60028381</afid></author><authkeywords>Air pollutants | Mexico City downtown | Persistence | Rescaled range analysis</authkeywords><intid>1784961530</intid><source-id>29115</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925430611"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925430611?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925430611&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925430611&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0267726115000573"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925430611</prism:url><dc:identifier>SCOPUS_ID:84925430611</dc:identifier><eid>2-s2.0-84925430611</eid><dc:title>Numerical simulation of earthquake excited dam-reservoirs with irregular geometries using an immersed boundary method</dc:title><dc:creator>Demirel E.</dc:creator><prism:publicationName>Soil Dynamics and Earthquake Engineering</prism:publicationName><prism:issn>02677261</prism:issn><prism:volume>73</prism:volume><prism:pageRange>80-90</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.soildyn.2015.03.003</prism:doi><pii>S0267726115000573</pii><dc:description>© 2015 Elsevier Ltd. In this work, a ghost-cell immersed boundary method is proposed for the hydrodynamic response of earthquake excited dam-reservoirs. The numerical method employs a second order accurate two-step projection algorithm including compressibility effects in pressure field due to earthquake. The effects of reservoir bottom absorption are treated by introducing damping terms into the momentum equations. Hydrodynamic response of earthquake excited dam with a sloping face is simulated to demonstrate the accuracy of the present numerical method. Numerical results compared with previous numerical and analytical solutions show that the present immersed boundary method can accurately compute the hydrodynamic forces on inclined and curved dam faces including the effects of water compressibility and reservoir bottom absorption for the possibility of resonance. The proposed numerical method was shown to have significant advantages in computational time and memory usage for the hydrodynamic simulation of large dam-reservoirs with arbitrary geometries. Hydrodynamic forces on a double curvature arch dam subjected to real earthquake induced ground motion are also simulated to demonstrate the capability of the method.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029016</affiliation-url><afid>60029016</afid><affilname>Eskisehir Osmangazi Universitesi</affilname><name-variant>Osmangazi University</name-variant><affiliation-city>Eskisehir</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56103568000</author-url><authid>56103568000</authid><authname>Demirel E.</authname><surname>Demirel</surname><given-name>Ender</given-name><initials>E.</initials><afid>60029016</afid></author><authkeywords>Arch dam | Compressibility | Dam-reservoir | Earthquake | Hydrodynamic pressure | Immersed boundary | Reservoir bottom absorption</authkeywords><intid>1785298148</intid><source-id>28960</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929083944"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929083944?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929083944&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929083944&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0176161715000930"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929083944</prism:url><dc:identifier>SCOPUS_ID:84929083944</dc:identifier><eid>2-s2.0-84929083944</eid><dc:title>Hydrogen sulfide alleviates toxic effects of arsenate in pea seedlings through up-regulation of the ascorbate-glutathione cycle: Possible involvement of nitric oxide</dc:title><dc:creator>Singh V.</dc:creator><prism:publicationName>Journal of Plant Physiology</prism:publicationName><prism:issn>01761617</prism:issn><prism:volume>181</prism:volume><prism:pageRange>20-29</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jplph.2015.03.015</prism:doi><pii>S0176161715000930</pii><dc:description>© 2015 Elsevier GmbH. In plants, hydrogen sulfide (H&lt;inf&gt;2&lt;/inf&gt;S) is an emerging novel signaling molecule that is involved in growth regulation and abiotic stress responses. However, little is known about its role in the regulation of arsenate (As&lt;sup&gt;V&lt;/sup&gt;) toxicity. Therefore, hydroponic experiments were conducted to investigate whether sodium hydrosulfide (NaHS; a source of H&lt;inf&gt;2&lt;/inf&gt;S) is involved in the regulation of As&lt;sup&gt;V&lt;/sup&gt; toxicity in pea seedlings. Results showed that As&lt;sup&gt;V&lt;/sup&gt; caused decreases in growth, photosynthesis (measured as chlorophyll fluorescence) and nitrogen content, which was accompanied by the accumulation of As. As&lt;sup&gt;V&lt;/sup&gt; treatment also reduced the activities of cysteine desulfhydrase and nitrate reductase, and contents of H&lt;inf&gt;2&lt;/inf&gt;S and nitric oxide (NO). However, addition of NaHS ameliorated As&lt;sup&gt;V&lt;/sup&gt; toxicity in pea seedlings, which coincided with the increased contents of H&lt;inf&gt;2&lt;/inf&gt;S and NO. The cysteine level was higher under As&lt;sup&gt;V&lt;/sup&gt; treatment in comparison to all other treatments (As-free; NaHS; As&lt;sup&gt;V&lt;/sup&gt;+NaHS). The content of reactive oxygen species (ROS) and damage to lipids, proteins and membranes increased by As&lt;sup&gt;V&lt;/sup&gt; while NaHS alleviated these effects. Enzymes of the ascorbate-glutathione cycle (AsA-GSH cycle) showed inhibition of their activities following As&lt;sup&gt;V&lt;/sup&gt; treatment while their activities were increased by application of NaHS. The redox status of ascorbate and glutathione was disturbed by As&lt;sup&gt;V&lt;/sup&gt; as indicated by a steep decline in their reduced/oxidized ratios. However, simultaneous NaHS application restored the redox status of the ascorbate and glutathione pools. The results of this study demonstrated that H&lt;inf&gt;2&lt;/inf&gt;S and NO might both be involved in reducing the accumulation of As and triggering up-regulation of the AsA-GSH cycle to counterbalance ROS-mediated damage to macromolecules. Furthermore, the results suggest a crucial role of H&lt;inf&gt;2&lt;/inf&gt;S in plant priming, and in particular for pea seedlings in mitigating As&lt;sup&gt;V&lt;/sup&gt; stress.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114741834</affiliation-url><afid>114741834</afid><affilname>Govt. Ramanuj Pratap Singhdev Post Graduate College</affilname><name-variant>Govt Ramanuj Pratap Singhdev Post Graduate College</name-variant><affiliation-city/><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018476</affiliation-url><afid>60018476</afid><affilname>University of Allahabad</affilname><name-variant>University of Allahabad</name-variant><affiliation-city>Allahabad</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56497996900</author-url><authid>56497996900</authid><authname>Singh V.</authname><surname>Singh</surname><given-name>Vijay Pratap</given-name><initials>V.P.</initials><afid>114741834</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56416706300</author-url><authid>56416706300</authid><authname>Singh S.</authname><surname>Singh</surname><given-name>Samiksha</given-name><initials>S.</initials><afid>60018476</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56423135000</author-url><authid>56423135000</authid><authname>Kumar J.</authname><surname>Kumar</surname><given-name>Jitendra</given-name><initials>J.</initials><afid>60018476</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7403003271</author-url><authid>7403003271</authid><authname>Prasad S.</authname><surname>Prasad</surname><given-name>Sheo Mohan</given-name><initials>S.M.</initials><afid>60018476</afid></author><authkeywords>Arsenate toxicity | Ascorbate-glutathione cycle | Hydrogen sulfide | Nitric oxide | Reactive oxygen species</authkeywords><intid>1035896741</intid><source-id>19257</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927145475"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927145475?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927145475&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927145475&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0005272815000572"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927145475</prism:url><dc:identifier>SCOPUS_ID:84927145475</dc:identifier><eid>2-s2.0-84927145475</eid><dc:title>Cardiolipin is a key determinant for mtDNA stability and segregation during mitochondrial stress</dc:title><dc:creator>Luévano-Martínez L.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Bioenergetics</prism:publicationName><prism:issn>00052728</prism:issn><prism:eIssn>18792650</prism:eIssn><prism:volume>1847</prism:volume><prism:issueIdentifier>6-7</prism:issueIdentifier><prism:pageRange>587-598</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbabio.2015.03.007</prism:doi><pii>S0005272815000572</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Mitochondria play a key role in adaptation during stressing situations. Cardiolipin, the main anionic phospholipid in mitochondrial membranes, is expected to be a determinant in this adaptive mechanism since it modulates the activity of most membrane proteins. Here, we used Saccharomyces cerevisiae subjected to conditions that affect mitochondrial metabolism as a model to determine the possible role of cardiolipin in stress adaptation. Interestingly, we found that thermal stress promotes a 30% increase in the cardiolipin content and modifies the physical state of mitochondrial membranes. These changes have effects on mtDNA stability, adapting cells to thermal stress. Conversely, this effect is cardiolipin-dependent since a cardiolipin synthase-null mutant strain is unable to adapt to thermal stress as observed by a 60% increase of cells lacking mtDNA (ρ&lt;sup&gt;0&lt;/sup&gt;). Interestingly, we found that the loss of cardiolipin specifically affects the segregation of mtDNA to daughter cells, leading to a respiratory deficient phenotype after replication. We also provide evidence that mtDNA physically interacts with cardiolipin both in S. cerevisiae and in mammalian mitochondria. Overall, our results demonstrate that the mitochondrial lipid cardiolipin is a key determinant in the maintenance of mtDNA stability and segregation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35218173000</author-url><authid>35218173000</authid><authname>Luévano-Martínez L.</authname><surname>Luévano-Martínez</surname><given-name>Luis Alberto</given-name><initials>L.A.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25225301100</author-url><authid>25225301100</authid><authname>Forni M.</authname><surname>Forni</surname><given-name>Maria Fernanda</given-name><initials>M.F.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56587541500</author-url><authid>56587541500</authid><authname>Dos Santos V.</authname><surname>Dos Santos</surname><given-name>Valquiria Tiago</given-name><initials>V.T.</initials><afid>60008088</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55908169600</author-url><authid>55908169600</authid><authname>Souza-Pinto N.</authname><surname>Souza-Pinto</surname><given-name>Nadja C.</given-name><initials>N.C.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7004476272</author-url><authid>7004476272</authid><authname>Kowaltowski A.</authname><surname>Kowaltowski</surname><given-name>Alicia J.</given-name><initials>A.J.</initials><afid>60008088</afid></author><authkeywords>Membrane plasticity | Mitochondrial DNA | Mitochondrion | Phospholipid</authkeywords><intid>2035564730</intid><source-id>16791</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926372228"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926372228?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926372228&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926372228&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167488914003735"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926372228</prism:url><dc:identifier>SCOPUS_ID:84926372228</dc:identifier><eid>2-s2.0-84926372228</eid><dc:title>Structure-function analysis of NEET proteins uncovers their role as key regulators of iron and ROS homeostasis in health and disease</dc:title><dc:creator>Tamir S.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Molecular Cell Research</prism:publicationName><prism:issn>01674889</prism:issn><prism:eIssn>18792596</prism:eIssn><prism:volume>1853</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:pageRange>1294-1315</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbamcr.2014.10.014</prism:doi><pii>S0167488914003735</pii><dc:description>© 2013 Elsevier B.V. A novel family of 2Fe-2S proteins, the NEET family, was discovered during the last decade in numerous organisms, including archea, bacteria, algae, plant and human; suggesting an evolutionary-conserved function, potentially mediated by their CDGSH Iron-Sulfur Domain. In human, three NEET members encoded by the CISD1-3 genes were identified. The structures of CISD1 (mitoNEET, mNT), CISD2 (NAF-1), and the plant At-NEET uncovered a homodimer with a unique "NEET fold", as well as two distinct domains: a beta-cap and a 2Fe-2S cluster-binding domain. The 2Fe-2S clusters of NEET proteins were found to be coordinated by a novel 3Cys:1His structure that is relatively labile compared to other 2Fe-2S proteins and is the reason of the NEETs' clusters could be transferred to apo-acceptor protein(s) or mitochondria. Positioned at the protein surface, the NEET's 2Fe-2S's coordinating His is exposed to protonation upon changes in its environment, potentially suggesting a sensing function for this residue. Studies in different model systems demonstrated a role for NAF-1 and mNT in the regulation of cellular iron, calcium and ROS homeostasis, and uncovered a key role for NEET proteins in critical processes, such as cancer cell proliferation and tumor growth, lipid and glucose homeostasis in obesity and diabetes, control of autophagy, longevity in mice, and senescence in plants. Abnormal regulation of NEET proteins was consequently found to result in multiple health conditions, and aberrant splicing of NAF-1 was found to be a causative of the neurological genetic disorder Wolfram Syndrome 2. Here we review the discovery of NEET proteins, their structural, biochemical and biophysical characterization, and their most recent structure-function analyses. We additionally highlight future avenues of research focused on NEET proteins and propose an essential role for NEETs in health and disease. This article is part of a Special Issue entitled: Fe/S proteins: Analysis, structure, function, biogenesis and diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007903</affiliation-url><afid>60007903</afid><affilname>Hebrew University of Jerusalem</affilname><name-variant>Hebrew University of Jerusalem</name-variant><affiliation-city>Jerusalem</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024438</affiliation-url><afid>60024438</afid><affilname>University of North Texas</affilname><name-variant>University of North Texas</name-variant><affiliation-city>Denton</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005286</affiliation-url><afid>60005286</afid><affilname>Rice University</affilname><name-variant>Rice University</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:42862383600</author-url><authid>42862383600</authid><authname>Tamir S.</authname><surname>Tamir</surname><given-name>Sagi</given-name><initials>S.</initials><afid>60007903</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003782650</author-url><authid>7003782650</authid><authname>Paddock M.</authname><surname>Paddock</surname><given-name>Mark L.</given-name><initials>M.L.</initials><afid>60030612</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56582538100</author-url><authid>56582538100</authid><authname>Darash-Yahana-Baram M.</authname><surname>Darash-Yahana-Baram</surname><given-name>Merav</given-name><initials>M.</initials><afid>60007903</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35758604100</author-url><authid>35758604100</authid><authname>Holt S.</authname><surname>Holt</surname><given-name>Sarah H.</given-name><initials>S.H.</initials><afid>60024438</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23490464600</author-url><authid>23490464600</authid><authname>Sohn Y.</authname><surname>Sohn</surname><given-name>Yang Sung</given-name><initials>Y.S.</initials><afid>60007903</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:24075394600</author-url><authid>24075394600</authid><authname>Agranat L.</authname><surname>Agranat</surname><given-name>Lily</given-name><initials>L.</initials><afid>60007903</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7005165859</author-url><authid>7005165859</authid><authname>Michaeli D.</authname><surname>Michaeli</surname><given-name>Dorit</given-name><initials>D.</initials><afid>60007903</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55943906300</author-url><authid>55943906300</authid><authname>Stofleth J.</authname><surname>Stofleth</surname><given-name>Jason T.</given-name><initials>J.T.</initials><afid>60030612</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55743745200</author-url><authid>55743745200</authid><authname>Lipper C.</authname><surname>Lipper</surname><given-name>Colin H.</given-name><initials>C.H.</initials><afid>60030612</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16031594600</author-url><authid>16031594600</authid><authname>Morcos F.</authname><surname>Morcos</surname><given-name>Faruck</given-name><initials>F.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16031594600</author-url><authid>16031594600</authid><authname>Morcos F.</authname><surname>Morcos</surname><given-name>Faruck</given-name><initials>F.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16031594600</author-url><authid>16031594600</authid><authname>Morcos F.</authname><surname>Morcos</surname><given-name>Faruck</given-name><initials>F.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:16031594600</author-url><authid>16031594600</authid><authname>Morcos F.</authname><surname>Morcos</surname><given-name>Faruck</given-name><initials>F.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6603395620</author-url><authid>6603395620</authid><authname>Cabantchik I.</authname><surname>Cabantchik</surname><given-name>Ioav Z.</given-name><initials>I.Z.</initials><afid>60007903</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35602445700</author-url><authid>35602445700</authid><authname>Onuchic J.</authname><surname>Onuchic</surname><given-name>Jose' N.</given-name><initials>J.N.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35602445700</author-url><authid>35602445700</authid><authname>Onuchic J.</authname><surname>Onuchic</surname><given-name>Jose' N.</given-name><initials>J.N.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35602445700</author-url><authid>35602445700</authid><authname>Onuchic J.</authname><surname>Onuchic</surname><given-name>Jose' N.</given-name><initials>J.N.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35602445700</author-url><authid>35602445700</authid><authname>Onuchic J.</authname><surname>Onuchic</surname><given-name>Jose' N.</given-name><initials>J.N.</initials><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid><afid>60005286</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:7202926101</author-url><authid>7202926101</authid><authname>Jennings P.</authname><surname>Jennings</surname><given-name>Patricia A.</given-name><initials>P.A.</initials><afid>60030612</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7005364724</author-url><authid>7005364724</authid><authname>Mittler R.</authname><surname>Mittler</surname><given-name>Ron</given-name><initials>R.</initials><afid>60024438</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7004464888</author-url><authid>7004464888</authid><authname>Nechushtai R.</authname><surname>Nechushtai</surname><given-name>Rachel</given-name><initials>R.</initials><afid>60007903</afid></author><authkeywords>2Fe-2S cluster | Cancer | Cluster donor/acceptor protein | Homeostasis | Mitochondria | Obesity and diabetes | Wolfram Syndrome 2</authkeywords><intid>1535428645</intid><source-id>18408</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927642383"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927642383?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927642383&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927642383&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S009130571500101X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927642383</prism:url><dc:identifier>SCOPUS_ID:84927642383</dc:identifier><eid>2-s2.0-84927642383</eid><dc:title>Alcohol use across the lifespan: An analysis of adolescent and aged rodents and humans</dc:title><dc:creator>Novier A.</dc:creator><prism:publicationName>Pharmacology Biochemistry and Behavior</prism:publicationName><prism:issn>00913057</prism:issn><prism:eIssn>18735177</prism:eIssn><prism:volume>133</prism:volume><prism:pageRange>65-82</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pbb.2015.03.015</prism:doi><pii>S009130571500101X</pii><dc:description>© 2015 Elsevier Inc. Adolescence and old age are unique periods of the lifespan characterized by differential sensitivity to the effects of alcohol. Adolescents and the elderly appear to be more vulnerable to many of alcohol's physiological and behavioral effects compared to adults. The current review explores the differential effects of acute alcohol, predominantly in terms of motor function and cognition, in adolescent and aged humans and rodents. Adolescents are less sensitive to the sedative-hypnotic, anxiolytic, and motor-impairing effects of acute alcohol, but research results are less consistent as it relates to alcohol's effects on cognition. Specifically, previous research has shown adolescents to be more, less, and similarly sensitive to alcohol-induced cognitive deficits compared to adults. These equivocal findings suggest that learning acquisition may be differentially affected by ethanol compared to memory, or that ethanol-induced cognitive deficits are task-dependent. Older rodents appear to be particularly vulnerable to the motor- and cognitive-impairing effects of acute alcohol relative to younger adults. Given that alcohol consumption and abuse is prevalent throughout the lifespan, it is important to recognize age-related differences in response to acute and long-term alcohol. Unfortunately, diagnostic measures and treatment options for alcohol dependence are rarely dedicated to adolescent and aging populations. As discussed, although much scientific advancement has been made regarding the differential effects of alcohol between adolescents and adults, research with the aged is underrepresented. Future researchers should be aware that adolescents and the aged are uniquely affected by alcohol and should continue to investigate alcohol's effects at different stages of maturation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011278</affiliation-url><afid>60011278</afid><affilname>Baylor University</affilname><name-variant>Baylor University</name-variant><affiliation-city>Waco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006020</affiliation-url><afid>60006020</afid><affilname>University of Wisconsin Eau Claire</affilname><name-variant>University of Wisconsin-Eau Claire</name-variant><affiliation-city>Eau Claire</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55012838800</author-url><authid>55012838800</authid><authname>Novier A.</authname><surname>Novier</surname><given-name>Adelle</given-name><initials>A.</initials><afid>60011278</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603308668</author-url><authid>6603308668</authid><authname>Diaz-Granados J.</authname><surname>Diaz-Granados</surname><given-name>Jaime L.</given-name><initials>J.L.</initials><afid>60011278</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56346575100</author-url><authid>56346575100</authid><authname>Matthews D.</authname><surname>Matthews</surname><given-name>Douglas B.</given-name><initials>D.B.</initials><afid>60011278</afid><afid>60006020</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56346575100</author-url><authid>56346575100</authid><authname>Matthews D.</authname><surname>Matthews</surname><given-name>Douglas B.</given-name><initials>D.B.</initials><afid>60011278</afid><afid>60006020</afid></author><authkeywords>Adolescent | Aged | Alcohol | Cognition | Motor</authkeywords><intid>35645436</intid><source-id>21197</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928608467"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928608467?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928608467&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928608467&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014483515001311"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928608467</prism:url><dc:identifier>SCOPUS_ID:84928608467</dc:identifier><eid>2-s2.0-84928608467</eid><dc:title>Neuroprotective effect of memantine on the retinal ganglion cells of APPswe/PS1δE9 mice and its immunomodulatory mechanisms</dc:title><dc:creator>Gao L.</dc:creator><prism:publicationName>Experimental Eye Research</prism:publicationName><prism:issn>00144835</prism:issn><prism:eIssn>10960007</prism:eIssn><prism:volume>135</prism:volume><prism:pageRange>47-58</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.exer.2015.04.013</prism:doi><pii>S0014483515001311</pii><dc:description>© 2015 Elsevier Ltd. Besides the cognitive impairment and degeneration in the brain, vision dysfunction and retina damage are always prevalent in patients with Alzheimer's disease (AD). The uncompetitive antagonist of the N-methyl- d-aspartate receptor, memantine (MEM), has been proven to improve the cognition of patients with AD. However, limited information exists regarding the mechanism of neurodegeneration and the possible neuroprotective mechanisms of MEM on the retinas of patients with AD. In the present study, by using APPswe/PS1δE. 9 double transgenic (dtg) mice, we found that MEM rescued the loss of retinal ganglion cells (RGCs), as well as improved visual impairments, including improving the P50 component in pattern electroretinograms and the latency delay of the P2 component in flash visual evoked potentials of APPswe/PS1δE. 9 dtg mice. The activated microglia in the retinas of APPswe/PS1δE. 9 dtg mice were also inhibited by MEM. Additionally, the level of glutamine synthetase expressed by Müller cells within the RGC layer was upregulated in APPswe/PS1δE. 9 dtg mice, which was inhibited by MEM. Simultaneously, MEM also reduced the apoptosis of choline acetyl transferase-immunoreactive cholinergic amacrine cells within the RGC layer of AD mice. Moreover, the phosphorylation level of extracellular regulated protein kinases 1 and 2 was increased in APPswe/PS1δE. 9 dtg mice, which was blocked by MEM treatment. These findings suggest that MEM protects RGCs in the retinas of APPswe/PS1δE. 9 dtg mice by modulating the immune response of microglia and the adapted response of Müller cells, making MEM a potential ophthalmic treatment alternative in patients with AD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112976413</affiliation-url><afid>112976413</afid><affilname>Key Lab of Visual Damage and Regeneration and Restoration of Chongqing</affilname><name-variant>Key Lab of Visual Damage and Regeneration and Restoration of Chongqing</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018038</affiliation-url><afid>60018038</afid><affilname>Nankai University</affilname><name-variant>Nankai University</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107935039</affiliation-url><afid>107935039</afid><affilname>Chinese People's Liberation Army General Hospital</affilname><name-variant>Chinese People's Liberation Army General Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56575798400</author-url><authid>56575798400</authid><authname>Gao L.</authname><surname>Gao</surname><given-name>Lixiong</given-name><initials>L.</initials><afid>60023797</afid><afid>112976413</afid><afid>60023797</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56575798400</author-url><authid>56575798400</authid><authname>Gao L.</authname><surname>Gao</surname><given-name>Lixiong</given-name><initials>L.</initials><afid>60023797</afid><afid>112976413</afid><afid>60023797</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56575798400</author-url><authid>56575798400</authid><authname>Gao L.</authname><surname>Gao</surname><given-name>Lixiong</given-name><initials>L.</initials><afid>60023797</afid><afid>112976413</afid><afid>60023797</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56259407200</author-url><authid>56259407200</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xi</given-name><initials>X.</initials><afid>60023797</afid><afid>112976413</afid><afid>60018038</afid><afid>107935039</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56259407200</author-url><authid>56259407200</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xi</given-name><initials>X.</initials><afid>60023797</afid><afid>112976413</afid><afid>60018038</afid><afid>107935039</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56259407200</author-url><authid>56259407200</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xi</given-name><initials>X.</initials><afid>60023797</afid><afid>112976413</afid><afid>60018038</afid><afid>107935039</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56259407200</author-url><authid>56259407200</authid><authname>Chen X.</authname><surname>Chen</surname><given-name>Xi</given-name><initials>X.</initials><afid>60023797</afid><afid>112976413</afid><afid>60018038</afid><afid>107935039</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55660458100</author-url><authid>55660458100</authid><authname>Tang Y.</authname><surname>Tang</surname><given-name>Yongping</given-name><initials>Y.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55660458100</author-url><authid>55660458100</authid><authname>Tang Y.</authname><surname>Tang</surname><given-name>Yongping</given-name><initials>Y.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56575702300</author-url><authid>56575702300</authid><authname>Zhao J.</authname><surname>Zhao</surname><given-name>Jinghui</given-name><initials>J.</initials><afid>60023797</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56404768100</author-url><authid>56404768100</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qiyou</given-name><initials>Q.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56404768100</author-url><authid>56404768100</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qiyou</given-name><initials>Q.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403394067</author-url><authid>7403394067</authid><authname>Fan X.</authname><surname>Fan</surname><given-name>Xiaotang</given-name><initials>X.</initials><afid>60023797</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7407450997</author-url><authid>7407450997</authid><authname>Xu H.</authname><surname>Xu</surname><given-name>Haiwei</given-name><initials>H.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7407450997</author-url><authid>7407450997</authid><authname>Xu H.</authname><surname>Xu</surname><given-name>Haiwei</given-name><initials>H.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7401499977</author-url><authid>7401499977</authid><authname>Yin Z.</authname><surname>Yin</surname><given-name>Zheng Qin</given-name><initials>Z.Q.</initials><afid>60023797</afid><afid>112976413</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7401499977</author-url><authid>7401499977</authid><authname>Yin Z.</authname><surname>Yin</surname><given-name>Zheng Qin</given-name><initials>Z.Q.</initials><afid>60023797</afid><afid>112976413</afid></author><authkeywords>Alzheimer's disease | Memantine | Microglia | Müller cell | Retinal ganglion cell</authkeywords><intid>535815509</intid><source-id>13866</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928978805"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928978805?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928978805&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928978805&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928978805</prism:url><dc:identifier>SCOPUS_ID:84928978805</dc:identifier><eid>2-s2.0-84928978805</eid><dc:title>Recent Advances in the Genetics of Autism Spectrum Disorder</dc:title><dc:creator>De Rubeis S.</dc:creator><prism:publicationName>Current Neurology and Neuroscience Reports</prism:publicationName><prism:issn>15284042</prism:issn><prism:eIssn>15346293</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>6</prism:issueIdentifier><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s11910-015-0553-1</prism:doi><dc:description>© 2015, Springer Science+Business Media New York. Autism spectrum disorder (ASD) is a devastating neurodevelopmental disorder with high prevalence in the population and a pronounced male preponderance. ASD has a strong genetic basis, but until recently, a large fraction of the genetic factors contributing to liability was still unknown. Over the past 3 years, high-throughput next-generation sequencing on large cohorts has exposed a heterogeneous and complex genetic landscape and has revealed novel risk genes. Here, we provide an overview of the recent advances on the ASD genetic architecture, with an emphasis on the estimates of heritability, the contribution of common variants, and the role of inherited and de novo rare variation. We also examine the genetic components of the reported gender bias. Finally, we discuss the emerging findings from sequencing studies and how they illuminate crucial aspects of ASD pathophysiology.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012981</affiliation-url><afid>60012981</afid><affilname>Icahn School of Medicine at Mount Sinai</affilname><name-variant>Mount Sinai School of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16240868200</author-url><authid>16240868200</authid><authname>De Rubeis S.</authname><surname>De Rubeis</surname><given-name>Silvia</given-name><initials>S.</initials><afid>60012981</afid><afid>60012981</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16240868200</author-url><authid>16240868200</authid><authname>De Rubeis S.</authname><surname>De Rubeis</surname><given-name>Silvia</given-name><initials>S.</initials><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26643309400</author-url><authid>26643309400</authid><authname>Buxbaum J.</authname><surname>Buxbaum</surname><given-name>Joseph D.</given-name><initials>J.D.</initials><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid><afid>60012981</afid></author><authkeywords>Autism risk genes | Autism spectrum disorder | Copy number variation | De novo variation | Exome sequencing | Heritability</authkeywords><intid>35876240</intid><source-id>14989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922360754"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922360754?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922360754&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922360754&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S019566631500029X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922360754</prism:url><dc:identifier>SCOPUS_ID:84922360754</dc:identifier><eid>2-s2.0-84922360754</eid><dc:title>Relationships between bullying victimization psychological distress and breakfast skipping among boys and girls</dc:title><dc:creator>Sampasa-Kanyinga H.</dc:creator><prism:publicationName>Appetite</prism:publicationName><prism:issn>01956663</prism:issn><prism:eIssn>10958304</prism:eIssn><prism:volume>89</prism:volume><prism:pageRange>41-46</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.appet.2015.01.020</prism:doi><pii>S019566631500029X</pii><dc:description>© 2015 Elsevier Ltd. The purpose of this study was to further explore the association between bullying victimization and breakfast skipping in children and adolescents. Compared to the previous study, we have used a larger and representative sample of middle and high school students, examined the effect of gender, different forms (physical, verbal, theft/vandalism and cyber) and severity of bullying on breakfast eating behaviour. Data from students (2286 boys and 2859 girls) aged 11 to 19 years (mean±SD age: 14.6±1.9 years) from the 2013 Ontario Student Drug Use and Health Survey (OSDUHS) were analysed using self-reports of being bullied, diet, psychological distress, demographics, socio-economic status, weight status, and substance use. Results revealed greater odds of breakfast skipping in girl victims of physical, verbal, and cyber bullying, and in boy victims of verbal and cyber bullying. There was a dose-response relationship between experience of both school and cyber bullying victimization and breakfast skipping behaviour for both genders. Mediation analysis indicated that psychological distress fully mediated the relationship between both verbal and physical bullying victimization and breakfast skipping in girls, and partially mediated the relationship between verbal bullying victimization and breakfast skipping in boys. Psychological distress also partially mediated the link between cyber bullying victimization and breakfast skipping in both boys and girls. These results corroborate previous findings on the association between bullying victimization and breakfast skipping in children and adolescents. The strong and consistent associations with different forms of bullying victimization, the dose-response relationship, and the mediating role of psychological distress suggest a causal relationship.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112600623</affiliation-url><afid>112600623</afid><affilname>Ottawa Public Health</affilname><name-variant>Ottawa Public Health</name-variant><affiliation-city>Ottawa</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55249935900</author-url><authid>55249935900</authid><authname>Sampasa-Kanyinga H.</authname><surname>Sampasa-Kanyinga</surname><given-name>Hugues</given-name><initials>H.</initials><afid>112600623</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54780965500</author-url><authid>54780965500</authid><authname>Willmore J.</authname><surname>Willmore</surname><given-name>Jacqueline</given-name><initials>J.</initials><afid>112600623</afid></author><authkeywords>Adolescents | Breakfast skipping | Bullying | Nutrition | Psychological distress</authkeywords><intid>1784796146</intid><source-id>29994</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925144185"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925144185?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925144185&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925144185&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0166432815001539"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925144185</prism:url><dc:identifier>SCOPUS_ID:84925144185</dc:identifier><eid>2-s2.0-84925144185</eid><dc:title>Neural representation of swallowing is retained with age. A functional neuroimaging study validated by classical and Bayesian inference</dc:title><dc:creator>Windel A.</dc:creator><prism:publicationName>Behavioural Brain Research</prism:publicationName><prism:issn>01664328</prism:issn><prism:eIssn>18727549</prism:eIssn><prism:volume>286</prism:volume><prism:pageRange>308-317</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbr.2015.03.009</prism:doi><pii>S0166432815001539</pii><dc:description>© 2015 Elsevier B.V. We investigated the neural representation of swallowing in two age groups for a total of 51 healthy participants (seniors: average age 64 years; young adults: average age 24 years) using high spatial resolution functional magnetic resonance imaging (fMRI). Two statistical comparisons (classical and Bayesian inference) revealed no significant differences between subject groups, apart from higher cortical activation for the seniors in the frontal pole 1 of Brodmann's Area 10 using Bayesian inference. Seniors vs. young participants showed longer reaction times and higher skin conductance response (SCR) during swallowing. We found a positive association of SCR and fMRI-activation only among seniors in areas processing sensorimotor performance, arousal and emotional perception. The results indicate that the highly automated swallowing network retains its functionality with age. However, seniors with higher SCR during swallowing appear to also engage areas involved in attention control and emotional regulation, possibly suggesting increased attention and emotional demands during task performance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021311</affiliation-url><afid>60021311</afid><affilname>Ernst-Moritz-Arndt-Universitat Greifswald</affilname><name-variant>University of Greifswald</name-variant><affiliation-city>Greifswald</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56560268000</author-url><authid>56560268000</authid><authname>Windel A.</authname><surname>Windel</surname><given-name>Anne Sophie</given-name><initials>A.S.</initials><afid>60021311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55757169900</author-url><authid>55757169900</authid><authname>Mihai P.</authname><surname>Mihai</surname><given-name>Paul Glad</given-name><initials>P.G.</initials><afid>60021311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7101871947</author-url><authid>7101871947</authid><authname>Lotze M.</authname><surname>Lotze</surname><given-name>Martin</given-name><initials>M.</initials><afid>60021311</afid></author><authkeywords>Age | BA 10 | Bayes | FMRI | SCR | Swallowing</authkeywords><intid>2035260984</intid><source-id>14285</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928891705"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928891705?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928891705&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928891705&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928891705</prism:url><dc:identifier>SCOPUS_ID:84928891705</dc:identifier><eid>2-s2.0-84928891705</eid><dc:title>Measuring income inequality using survey data: the case of China</dc:title><dc:creator>Chen Y.</dc:creator><prism:publicationName>Journal of Economic Inequality</prism:publicationName><prism:issn>15691721</prism:issn><prism:eIssn>15738701</prism:eIssn><prism:volume>13</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>299-307</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>1 June 2015</prism:coverDisplayDate><prism:doi>10.1007/s10888-014-9283-x</prism:doi><dc:description>© 2014, Springer Science+Business Media New York. The purpose of this paper is to raise awareness of missing data when we evaluate income inequality using survey data. If the income data are not missing completely at random, the calculated income inequalities are more likely to be biased, which may lead to inappropriate conclusions and policy recommendations. To handle the missing data on income, a multiple imputation approach is utilized. In particular, we propose an extended approach to correct the possible sample selection bias in the imputation process. A case study using China’s household survey suggests that extended imputation corrects for biases effectively in the calculation of Gini coefficients and results in gains in efficiency as well.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Zhongnan University of Economics and Law</affilname><name-variant>School of Statistics and Mathematics</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Central University of Finance and Economics</affilname><name-variant>School of International Trade and Economics</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56127271600</author-url><authid>56127271600</authid><authname>Chen Y.</authname><surname>Chen</surname><given-name>Yongwei</given-name><initials>Y.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55286706900</author-url><authid>55286706900</authid><authname>Fu D.</authname><surname>Fu</surname><given-name>Dahai</given-name><initials>D.</initials><afid/></author><authkeywords>China | Income inequality | Missing data | Multiple imputation</authkeywords><intid>1035857977</intid><source-id>22751</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926442141"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926442141?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926442141&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926442141&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0304380015001210"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926442141</prism:url><dc:identifier>SCOPUS_ID:84926442141</dc:identifier><eid>2-s2.0-84926442141</eid><dc:title>Simple movement rules result in ideal free distribution of mobile pastoralists</dc:title><dc:creator>Moritz M.</dc:creator><prism:publicationName>Ecological Modelling</prism:publicationName><prism:issn>03043800</prism:issn><prism:volume>305</prism:volume><prism:pageRange>54-63</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ecolmodel.2015.03.010</prism:doi><pii>S0304380015001210</pii><dc:description>© 2015 Elsevier B.V. While open access to common-pool resources has been equated with a tragedy of the commons, we have found that mobile pastoralists in the Logone Floodplain in Cameroon are sustain ably managing open access to common-pool grazing resources. We have described this pastoral system as a self-organizing complex adaptive system (CAS) in which mobile pastoralists distribute themselves over common-pool grazing resources without central or collective decision-making. We have found evidence of management of open access in the form of an ideal free distribution (IFD). Here we discuss the results of an agent-based model (ABM) simulation and show how pastoralists are able to achieve an IFD with relatively simple movement rules. We describe this system as an Emergent Commons (EC).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018251</affiliation-url><afid>60018251</afid><affilname>Netherlands Institute for Advanced Study in the Humanities and Social Sciences NIAS - KNAW</affilname><name-variant>Netherlands Institute for Advanced Study</name-variant><affiliation-city>Wassenaar</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003500</affiliation-url><afid>60003500</afid><affilname>Ohio State University</affilname><name-variant>The Ohio State University</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115141625</affiliation-url><afid>115141625</afid><affilname>German Technical Development Organization GIZ</affilname><name-variant>German Technical Development Organization GIZ</name-variant><affiliation-city>Yaounde</affiliation-city><affiliation-country>Cameroon</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115131576</affiliation-url><afid>115131576</afid><affilname>Research for Undergraduates: Adventures in Mathematical Biology and Its Applications (RUMBA)</affilname><name-variant>Research for Undergraduates: Adventures in Mathematical Biology and Its Applications (RUMBA)</name-variant><affiliation-city>Columbus</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36054645200</author-url><authid>36054645200</authid><authname>Moritz M.</authname><surname>Moritz</surname><given-name>Mark</given-name><initials>M.</initials><afid>60003500</afid><afid>60018251</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36054645200</author-url><authid>36054645200</authid><authname>Moritz M.</authname><surname>Moritz</surname><given-name>Mark</given-name><initials>M.</initials><afid>60003500</afid><afid>60018251</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7101859333</author-url><authid>7101859333</authid><authname>Hamilton I.</authname><surname>Hamilton</surname><given-name>Ian M.</given-name><initials>I.M.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7101859333</author-url><authid>7101859333</authid><authname>Hamilton I.</authname><surname>Hamilton</surname><given-name>Ian M.</given-name><initials>I.M.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55918143400</author-url><authid>55918143400</authid><authname>Yoak A.</authname><surname>Yoak</surname><given-name>Andrew J.</given-name><initials>A.J.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55918143400</author-url><authid>55918143400</authid><authname>Yoak A.</authname><surname>Yoak</surname><given-name>Andrew J.</given-name><initials>A.J.</initials><afid>60003500</afid><afid>60003500</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003277623</author-url><authid>7003277623</authid><authname>Scholte P.</authname><surname>Scholte</surname><given-name>Paul</given-name><initials>P.</initials><afid>115141625</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56584454200</author-url><authid>56584454200</authid><authname>Cronley J.</authname><surname>Cronley</surname><given-name>Jeff</given-name><initials>J.</initials><afid>115131576</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56584318300</author-url><authid>56584318300</authid><authname>Maddock P.</authname><surname>Maddock</surname><given-name>Paul</given-name><initials>P.</initials><afid>60003500</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56583800600</author-url><authid>56583800600</authid><authname>Pi H.</authname><surname>Pi</surname><given-name>Hongyang</given-name><initials>H.</initials><afid>115131576</afid></author><authkeywords>Agent-based model | Common-pool resources | Complex adaptive systems | Emergent Commons | Ideal free distribution | Pastoralism</authkeywords><intid>1035451211</intid><source-id>23274</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923607748"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923607748?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923607748&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923607748&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0001879115000160"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923607748</prism:url><dc:identifier>SCOPUS_ID:84923607748</dc:identifier><eid>2-s2.0-84923607748</eid><dc:title>The effects of intrinsic and extrinsic sources of motivation on well-being depend on time of day: The moderating effects of workday accumulation</dc:title><dc:creator>Benedetti A.</dc:creator><prism:publicationName>Journal of Vocational Behavior</prism:publicationName><prism:issn>00018791</prism:issn><prism:volume>88</prism:volume><prism:pageRange>38-46</prism:pageRange><prism:coverDate>2015-06-01</prism:coverDate><prism:coverDisplayDate>June 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jvb.2015.02.009</prism:doi><pii>S0001879115000160</pii><dc:description>© 2015 Elsevier Inc. Using self-determination theory and research on temporal aspects of work (e.g., time of day), this study investigates dynamic effects of task-specific motivation on well-being throughout the workday. We argue that the effects of task-specific intrinsic and extrinsic motivations on well-being outcomes (psychological vitality, job satisfaction) depend on the time of day in which the task is encountered, referred to here as workday accumulation. Our results showed that time of day interacted with intrinsic sources of motivation to predict job satisfaction, such that the relation was strong and positive early in the day and weak and positive later in the day. Time of day did not moderate the relationship of intrinsic task motivation with vitality, which was consistently positive throughout the day. The effects of extrinsic reasons for task pursuit on satisfaction and vitality were moderated by time of day, with extrinsic motivation having positive effects early in the day, but negative effects later in the day.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115021628</affiliation-url><afid>115021628</afid><affilname>College of Arts and Sciences Building</affilname><name-variant>College of Arts and Sciences Building</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Department of Management</affilname><affiliation-city>Richmond</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname/><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56528995900</author-url><authid>56528995900</authid><authname>Benedetti A.</authname><surname>Benedetti</surname><given-name>Alison A.</given-name><initials>A.A.</initials><afid>115021628</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603611400</author-url><authid>6603611400</authid><authname>Diefendorff J.</authname><surname>Diefendorff</surname><given-name>James M.</given-name><initials>J.M.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36348310500</author-url><authid>36348310500</authid><authname>Gabriel A.</authname><surname>Gabriel</surname><given-name>Allison S.</given-name><initials>A.S.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56120494600</author-url><authid>56120494600</authid><authname>Chandler M.</authname><surname>Chandler</surname><given-name>Megan M.</given-name><initials>M.M.</initials><afid/></author><authkeywords>Experience sampling | Motivation | Self-determination theory | Well-being | Workday accumulation</authkeywords><intid>2034998495</intid><source-id>12006</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930259988"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930259988?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930259988&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930259988&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930259988</prism:url><dc:identifier>SCOPUS_ID:84930259988</dc:identifier><eid>2-s2.0-84930259988</eid><dc:title>Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy</dc:title><dc:creator>Haghikia A.</dc:creator><prism:publicationName>Clinical Research in Cardiology</prism:publicationName><prism:issn>18610684</prism:issn><prism:eIssn>18610692</prism:eIssn><prism:coverDate>2015-05-31</prism:coverDate><prism:coverDisplayDate>31 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00392-015-0869-5</prism:doi><dc:description>© 2015 The Author(s) Background: Peripartum cardiomyopathy (PPCM) is an idiopathic heart disease that develops in the last month of pregnancy and/or the first months following delivery in previously healthy women and may lead to acute heart failure. A cleaved fragment of the nursing hormone prolactin is considered essential in the pathophysiology of PPCM. To date, no specific therapy has been tested for PPCM in a randomized controlled trial of adequate size. Aims: The purpose of this trial is to investigate the safety of the dopamin-D2-receptor agonist bromocriptine and its effects on left ventricular (LV) function in women with PPCM. Methods: This is an 11 center German trial with a prospective randomized controlled open-label design. The trial enrolls females with newly diagnosed PPCM according to European Society of Cardiology criteria with a LV ejection fraction (LVEF) &lt;35 %. Patients are randomized 1:1 to either best supportive care (BSC) including standard heart failure therapy plus 8 weeks of bromocriptine therapy (2.5 mg b.i.d. for 14 days and 2.5 mg q.d. from day 15 to 56) or to BSC plus 1 week of low-dose bromocriptine (2.5 mg q.d.) with anticoagulant therapy at a prophylactic dose administered during the period of bromocriptine treatment in both groups. The primary endpoint is change in LVEF from baseline to 6 months follow-up as assessed by cardiac magnetic resonance imaging (or echocardiography if CMR is not tolerated). The secondary endpoints are hospitalization for worsening heart failure, heart transplantation, and all-cause mortality during follow-up or a combination of these endpoints. A total of 60 patients will be recruited (including 6 potential dropouts) giving a power of 0.9 for an expected LVEF change of 10.8 % between treatment groups at 6 months. Perspective: This trial will provide important knowledge on potential benefits and safety of prolonged inhibition of prolactin release with bromocriptine in addition to standard heart failure therapy in newly diagnosed PPCM. Trial registration: ClinicalTrials.gov Identifier: NCT00998556.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Hannover Medical School</affilname><name-variant>Department of Cardiology and Angiology</name-variant><affiliation-city>Hannover</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University Hospital Muenster</affilname><name-variant>Department of Cardiology and Angiology</name-variant><affiliation-city>Muenster</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University Hospital of Wuerzburg</affilname><name-variant>Department of Internal Medicine I</name-variant><name-variant>Comprehensive Heart Failure Center</name-variant><affiliation-city>Würzburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University Hospital of Saarland</affilname><name-variant>Department of Internal Medicine III</name-variant><affiliation-city>Homburg/Saar</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26324864500</author-url><authid>26324864500</authid><authname>Haghikia A.</authname><surname>Haghikia</surname><given-name>Arash</given-name><initials>A.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506916880</author-url><authid>6506916880</authid><authname>Podewski E.</authname><surname>Podewski</surname><given-name>Edith</given-name><initials>E.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35763672200</author-url><authid>35763672200</authid><authname>Berliner D.</authname><surname>Berliner</surname><given-name>Dominik</given-name><initials>D.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6506738742</author-url><authid>6506738742</authid><authname>Sonnenschein K.</authname><surname>Sonnenschein</surname><given-name>Kristina</given-name><initials>K.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7402955052</author-url><authid>7402955052</authid><authname>Fischer D.</authname><surname>Fischer</surname><given-name>Dieter</given-name><initials>D.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7004276575</author-url><authid>7004276575</authid><authname>Angermann C.</authname><surname>Angermann</surname><given-name>Christiane E.</given-name><initials>C.E.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56663849400</author-url><authid>56663849400</authid><authname>Böhm M.</authname><surname>Böhm</surname><given-name>Michael</given-name><initials>M.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6507481747</author-url><authid>6507481747</authid><authname>Röntgen P.</authname><surname>Röntgen</surname><given-name>Philipp</given-name><initials>P.</initials><afid/></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004626054</author-url><authid>7004626054</authid><authname>Bauersachs J.</authname><surname>Bauersachs</surname><given-name>Johann</given-name><initials>J.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6602676885</author-url><authid>6602676885</authid><authname>Hilfiker-Kleiner D.</authname><surname>Hilfiker-Kleiner</surname><given-name>Denise</given-name><initials>D.</initials><afid/></author><authkeywords>Bromocriptine | Heart failure | Peripartum cardiomyopathy | Prolactin</authkeywords><intid>1786093834</intid><source-id>3100147501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930268930"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930268930?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930268930&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930268930&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930268930</prism:url><dc:identifier>SCOPUS_ID:84930268930</dc:identifier><eid>2-s2.0-84930268930</eid><dc:title>Total Cavopulmonary Connection is Superior to Atriopulmonary Connection Fontan in Preventing Thrombus Formation: Computer Simulation of Flow-Related Blood Coagulation</dc:title><dc:creator>Sughimoto K.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-31</prism:coverDate><prism:coverDisplayDate>31 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1180-y</prism:doi><dc:description>© 2015 Springer Science+Business Media New York The classical Fontan route, namely the atriopulmonary connection (APC), continues to be associated with a risk of thrombus formation in the atrium. A conversion to a total cavopulmonary connection (TCPC) from the APC can ameliorate hemodynamics for the failed Fontan; however, the impact of these surgical operations on thrombus formation remains elusive. This study elucidates the underlying mechanism of thrombus formation in the Fontan route by using a two-dimensional computer hemodynamic simulation based on a simple blood coagulation rule. Hemodynamics in the Fontan route was simulated with Navier–Stokes equations. The blood coagulation and the hemodynamics were combined using a particle method. Three models were created: APC with a square atrium, APC with a round atrium, and TCPC. To examine the effects of the venous blood flow velocity, the velocity at rest and during exercise (0.5 and 1.0 W/kg) was measured. The total area of the thrombi increased over time. The APC square model showed the highest incidence for thrombus formation, followed by the APC round, whereas no thrombus was formed in the TCPC model. Slower blood flow at rest was associated with a higher incidence of thrombus formation. The TCPC was superior to the classical APC in terms of preventing thrombus formation, due to significant blood flow stagnation in the atrium of the APC. Thus, local hemodynamic behavior associated with the complex channel geometry plays a major role in thrombus formation in the Fontan route.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>The Royal Children’s Hospital</affilname><name-variant>Department of Cardiac Surgery</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Chiba University</affilname><name-variant>Department of Mechanical Engineering</name-variant><name-variant>Graduate School of Engineering</name-variant><affiliation-city>Chiba</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Hitachi Construction Machinery</affilname><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Murdoch Childrens Research Institute</affilname><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Shanghai Jiao Tong University</affilname><name-variant>School of Naval Architecture</name-variant><name-variant>Ocean and Civil Engineering (NAOCE)</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Shanghai Jiao Tong University</affilname><name-variant>Shanghai Jiao Tong University and Chiba University International Cooperative Research Centre (SJTU-CU ICRC)</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24169936500</author-url><authid>24169936500</authid><authname>Sughimoto K.</authname><surname>Sughimoto</surname><given-name>Koichi</given-name><initials>K.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664344900</author-url><authid>56664344900</authid><authname>Okauchi K.</authname><surname>Okauchi</surname><given-name>Kazuki</given-name><initials>K.</initials><afid/><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664344900</author-url><authid>56664344900</authid><authname>Okauchi K.</authname><surname>Okauchi</surname><given-name>Kazuki</given-name><initials>K.</initials><afid/><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56664359200</author-url><authid>56664359200</authid><authname>Zannino D.</authname><surname>Zannino</surname><given-name>Diana</given-name><initials>D.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005514351</author-url><authid>7005514351</authid><authname>Brizard C.</authname><surname>Brizard</surname><given-name>Christian P.</given-name><initials>C.P.</initials><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005514351</author-url><authid>7005514351</authid><authname>Brizard C.</authname><surname>Brizard</surname><given-name>Christian P.</given-name><initials>C.P.</initials><afid/><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663804400</author-url><authid>56663804400</authid><authname>Liang F.</authname><surname>Liang</surname><given-name>Fuyou</given-name><initials>F.</initials><afid/><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663804400</author-url><authid>56663804400</authid><authname>Liang F.</authname><surname>Liang</surname><given-name>Fuyou</given-name><initials>F.</initials><afid/><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663860000</author-url><authid>56663860000</authid><authname>Sugawara M.</authname><surname>Sugawara</surname><given-name>Michiko</given-name><initials>M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56663821300</author-url><authid>56663821300</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hao</given-name><initials>H.</initials><afid/><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56663821300</author-url><authid>56663821300</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hao</given-name><initials>H.</initials><afid/><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7103256638</author-url><authid>7103256638</authid><authname>Tsubota K.</authname><surname>Tsubota</surname><given-name>Ken ichi</given-name><initials>K.i.</initials><afid/></author><authkeywords>Computer simulation | Congenital heart disease | Fontan | Hemodynamics | Thrombus</authkeywords><intid>536093874</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930267933"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930267933?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930267933&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930267933&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930267933</prism:url><dc:identifier>SCOPUS_ID:84930267933</dc:identifier><eid>2-s2.0-84930267933</eid><dc:title>Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario</dc:title><dc:creator>Torres S.</dc:creator><prism:publicationName>Breast Cancer Research and Treatment</prism:publicationName><prism:issn>01676806</prism:issn><prism:eIssn>15737217</prism:eIssn><prism:coverDate>2015-05-31</prism:coverDate><prism:coverDisplayDate>31 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10549-015-3441-0</prism:doi><dc:description>© 2015 Springer Science+Business Media New York The purpose of this study was to compare survival and risk of adverse events in women with early stage breast cancer (BC) treated with (1) doxorubicin (A), cyclophosphamide (C) + paclitaxel (P), (2) fluorouracil (F), epirubicin (E), cyclophosphamide (C) + docetaxel (D), or (3) dose-dense AC-P. Retrospective cohort study including 8462 women aged ≥18 years, with resected stage I–III BC, diagnosed between 2003 and 2009 in Ontario, identified through linkage of administrative databases. Primary outcome is overall survival (OS). Secondary outcomes are emergency room (ER) visits/hospitalizations, heart failure (HF), and leukemia. 4710 women were treated with FEC-D, 2065 with AC-P, and 1687 with dd AC-P. Adjusted 5-year OS was 92.1, 87.7, and 90.3 %, for each regimen, respectively (p = 0.0006). There was no difference in OS for FEC-D and dd AC-P in the propensity score-matched analyses (HR 1.24, 95 % CI 0.99–1.55). Five-year risk of HF was also similar (HR 1.09; 0.66–1.791.4 % for dd AC-P and 1.3 % for FEC-D and, p = 0.72). Treatment with FEC-D was significantly associated with ER visits and hospital admissions (p &lt; 0.0001). The risks of leukemia were low and similar among the 3 groups (AC-P: 0.34 %, FEC-D: 0.08 %, dd AC-P: 0.12 %; p = 0.09). Although the efficacy of the three regimens was similar to that observed in randomized trials, we report higher toxicity with the use of these regimens in clinical practice. This was especially concerning for the docetaxel-containing regimen.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Sunnybrook Health Sciences Centre</affilname><name-variant>Sunnybrook Odette Cancer Centre</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Institute for Clinical Evaluative Sciences</affilname><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Ontario Institute for Cancer Research</affilname><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Toronto</affilname><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663932200</author-url><authid>56663932200</authid><authname>Torres S.</authname><surname>Torres</surname><given-name>Sofia</given-name><initials>S.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35449257500</author-url><authid>35449257500</authid><authname>Trudeau M.</authname><surname>Trudeau</surname><given-name>Maureen</given-name><initials>M.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7102974049</author-url><authid>7102974049</authid><authname>Eisen A.</authname><surname>Eisen</surname><given-name>Andrea</given-name><initials>A.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005938947</author-url><authid>7005938947</authid><authname>Earle C.</authname><surname>Earle</surname><given-name>Craig C.</given-name><initials>C.C.</initials><afid/><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005938947</author-url><authid>7005938947</authid><authname>Earle C.</authname><surname>Earle</surname><given-name>Craig C.</given-name><initials>C.C.</initials><afid/><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005938947</author-url><authid>7005938947</authid><authname>Earle C.</authname><surname>Earle</surname><given-name>Craig C.</given-name><initials>C.C.</initials><afid/><afid/><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55614943100</author-url><authid>55614943100</authid><authname>Chan K.</authname><surname>Chan</surname><given-name>Kelvin K W</given-name><initials>K.K.W.</initials><afid/><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55614943100</author-url><authid>55614943100</authid><authname>Chan K.</authname><surname>Chan</surname><given-name>Kelvin K W</given-name><initials>K.K.W.</initials><afid/><afid/></author><authkeywords>Adjuvant chemotherapy | Breast cancer | Randomized trials | Taxanes</authkeywords><intid>1786093630</intid><source-id>28766</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930260448"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930260448?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930260448&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930260448&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930260448</prism:url><dc:identifier>SCOPUS_ID:84930260448</dc:identifier><eid>2-s2.0-84930260448</eid><dc:title>Accelerated failure time model with quantile information</dc:title><dc:creator>Zhao M.</dc:creator><prism:publicationName>Annals of the Institute of Statistical Mathematics</prism:publicationName><prism:issn>00203157</prism:issn><prism:eIssn>15729052</prism:eIssn><prism:coverDate>2015-05-31</prism:coverDate><prism:coverDisplayDate>31 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10463-015-0522-0</prism:doi><dc:description>© 2015 The Institute of Statistical Mathematics, Tokyo The censored linear regression model, also referred to as the accelerated failure time model, is a useful alternative to the popular Cox model in the analysis of censored survival data. In this paper, we combine the quantile information with censored least-squares normal equations to get estimators with smaller estimated standard error for regression parameters. An inverse probability-weighted method is proposed to construct unbiased estimating equations with censored data and the lack of smoothness of the objective equations is overcome by replacing them with smooth approximations. The proposed estimators are established based on the empirical likelihood method and generalized method of moments, respectively, and their asymptotic properties are studied under some regular conditions. We also conduct some simulation experiments to investigate the finite-sample properties of the proposed estimators. The Stanford Heart Transplant data are used to illustrate the proposed estimating method.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Zhongnan University of Economics and Law</affilname><name-variant>School of Statistics and Mathematics</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Shanghai University of Finance and Economics</affilname><name-variant>School of Statistics and Management</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Chinese Academy of Sciences</affilname><name-variant>Academy of Mathematics and Systems Science</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663516000</author-url><authid>56663516000</authid><authname>Zhao M.</authname><surname>Zhao</surname><given-name>Mu</given-name><initials>M.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56283374100</author-url><authid>56283374100</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yixin</given-name><initials>Y.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35473905300</author-url><authid>35473905300</authid><authname>Zhou Y.</authname><surname>Zhou</surname><given-name>Yong</given-name><initials>Y.</initials><afid/><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35473905300</author-url><authid>35473905300</authid><authname>Zhou Y.</authname><surname>Zhou</surname><given-name>Yong</given-name><initials>Y.</initials><afid/><afid/></author><authkeywords>AFT model | Empirical likelihood | Generalized moment method | Inverse probability weighted | Non-smooth estimating equation</authkeywords><intid>1786093673</intid><source-id>23213</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211224"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211224?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211224&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211224&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211224</prism:url><dc:identifier>SCOPUS_ID:84930211224</dc:identifier><eid>2-s2.0-84930211224</eid><dc:title>Activating schoolyards: Study design of a quasi-experimental schoolyard intervention study</dc:title><dc:creator>Andersen H.</dc:creator><prism:publicationName>BMC Public Health</prism:publicationName><prism:eIssn>14712458</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-31</prism:coverDate><prism:coverDisplayDate>31 May 2015</prism:coverDisplayDate><prism:doi>10.1186/s12889-015-1828-9</prism:doi><dc:description>© 2015 Andersen et al.; licensee BioMed Central. Background: The aim of the Activating Schoolyards Study is to develop, implement, document and assess a comprehensive schoolyard intervention to promote physical activity (PA) during school recess for primary school children (grade 4-8). The intervention is designed to implement organizational and structural changes in the physical environment. Method: The study builds on a quasi-experimental study design using a mixed method approach including: 1) an exploratory study aimed at providing input for the developing process; 2) an evaluation of the effect of the interventions using a combination of accelerometer, GPS and GIS; 3) a process evaluation facilitating the intervention development process and identifying barriers and facilitators in the implementation process; 4) a post-intervention end-user evaluation aimed at exploring who uses the schoolyards and how the schoolyards are used. The seven project schools (cases) were selected by means of an open competition and the interventions were developed using a participatory bottom-up approach. Discussion: The participatory approach and case selection strategy make the study design novel. The use of a mixed methods design including qualitative as well as quantitative methods can be seen as a strength, as the different types of data complement each other and results of one part of the study informed the following parts. A unique aspect of our study is the use of accelerometers in combination with GPS and GIS in the effect evaluation to objectively determine where and how active the students are in the schoolyard, before and after the intervention. This provides a type of data that, to our knowledge, has not been used before in schoolyard interventions. Exploring the change in behavior in relation to specific intervention elements in the schoolyard will lead to recommendations for schools undergoing schoolyard renovations at some point in the future.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019160</affiliation-url><afid>60019160</afid><affilname>Syddansk Universitet</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Odense</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020191</affiliation-url><afid>60020191</afid><affilname>Statens Institut for Folkesundhed</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017743</affiliation-url><afid>60017743</afid><affilname>Kraeftens Bekaempelse</affilname><name-variant>Danish Cancer Society</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020191</affiliation-url><afid>60020191</afid><affilname>Statens Institut for Folkesundhed</affilname><name-variant>University of Southern Denmark</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56414046600</author-url><authid>56414046600</authid><authname>Andersen H.</authname><surname>Andersen</surname><given-name>Henriette Bondo</given-name><initials>H.B.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56414046600</author-url><authid>56414046600</authid><authname>Andersen H.</authname><surname>Andersen</surname><given-name>Henriette Bondo</given-name><initials>H.B.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56215590200</author-url><authid>56215590200</authid><authname>Pawlowski C.</authname><surname>Pawlowski</surname><given-name>Charlotte Skau</given-name><initials>C.S.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56215590200</author-url><authid>56215590200</authid><authname>Pawlowski C.</authname><surname>Pawlowski</surname><given-name>Charlotte Skau</given-name><initials>C.S.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56660441400</author-url><authid>56660441400</authid><authname>Scheller H.</authname><surname>Scheller</surname><given-name>Hanne Bebendorf</given-name><initials>H.B.</initials><afid>60017743</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8264695700</author-url><authid>8264695700</authid><authname>Troelsen J.</authname><surname>Troelsen</surname><given-name>Jens</given-name><initials>J.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8264695700</author-url><authid>8264695700</authid><authname>Troelsen J.</authname><surname>Troelsen</surname><given-name>Jens</given-name><initials>J.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35238558300</author-url><authid>35238558300</authid><authname>Toftager M.</authname><surname>Toftager</surname><given-name>Mette</given-name><initials>M.</initials><afid>60020191</afid><afid>60020191</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35238558300</author-url><authid>35238558300</authid><authname>Toftager M.</authname><surname>Toftager</surname><given-name>Mette</given-name><initials>M.</initials><afid>60020191</afid><afid>60020191</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22836203700</author-url><authid>22836203700</authid><authname>Schipperijn J.</authname><surname>Schipperijn</surname><given-name>Jasper</given-name><initials>J.</initials><afid>60019160</afid><afid>60020191</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22836203700</author-url><authid>22836203700</authid><authname>Schipperijn J.</authname><surname>Schipperijn</surname><given-name>Jasper</given-name><initials>J.</initials><afid>60019160</afid><afid>60020191</afid></author><authkeywords>Accelerometer | Go-along interview | GPS | Mixed method | Observations | Participatory intervention development | Physical activity | Process | Schoolyards | Study design</authkeywords><intid>2036082399</intid><article-number>523</article-number><source-id>19621</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216588"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216588?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216588&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216588&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008037"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216588</prism:url><dc:identifier>SCOPUS_ID:84930216588</dc:identifier><eid>2-s2.0-84930216588</eid><dc:title>Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy</dc:title><dc:creator>Libhaber E.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>376-382</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.081</prism:doi><pii>S0167527315008037</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Patients with peripartum cardiomyopathy (PPCM) present with low blood pressure (SBP) often preventing uptitration of heart failure medication. We aimed to study prediction of risk and the contribution of high resting heart rate (HR) and low SBP to risk in recent onset of PPCM. Methods Clinical assessment with HR and SBP, echocardiography and laboratory results were obtained at baseline and at six months on 206 patients with recent onset PPCM enrolled at two tertiary care centers in South Africa. Poor outcome was defined as the combined endpoint of death, LVEF &lt; 35% or remaining in New York Heart Association (NYHA) functional class III/IV at six months. Complete LV recovery was defined as LVEF &lt; 55% at six months. Results Poor outcome was observed in 110 of 220 patients (53%), with 26 patients dying at six months (12.6%). There were 98 (47.5%) patients with SBP ≤ 110 mm Hg. Patients with high HR (HR &lt; 100) and low SBP ≤ 110 mm Hg) tended to have worse outcomes than patients below the HR median and high SBP. PPCM patients with low SBP and high HR were less likely to be on ACE-inhibitors (n = 35, 69% versus n = 129, 84%, p = 0.024) and on the beta blocker carvedilol (n = 24, 47% versus n = 98, 64%, p = 0.047). Low SBP, high HR and left ventricular end diastolic diameter at baseline were predictors of poor outcome. Patients with low SBP and high HR had the highest mortality (p = 0.0023). Conclusions These findings suggest increased risk in patients with PPCM presenting with low SBP and high HR on standard heart failure medication possibly having implications on HF management.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016218</affiliation-url><afid>60016218</afid><affilname>University of Witwatersrand</affilname><name-variant>University of the Witwatersrand</name-variant><affiliation-city>Johannesburg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023686</affiliation-url><afid>60023686</afid><affilname>Universitatsklinikum des Saarlandes Medizinische Fakultat der Universitat des Saarlandes</affilname><name-variant>University of Saarland</name-variant><affiliation-city>Homburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507030715</author-url><authid>6507030715</authid><authname>Libhaber E.</authname><surname>Libhaber</surname><given-name>Elena</given-name><initials>E.</initials><afid>60016218</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004147531</author-url><authid>7004147531</authid><authname>Sliwa K.</authname><surname>Sliwa</surname><given-name>Karen</given-name><initials>K.</initials><afid>60016218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55892942800</author-url><authid>55892942800</authid><authname>Bachelier K.</authname><surname>Bachelier</surname><given-name>Katrin</given-name><initials>K.</initials><afid>60023686</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:37034330700</author-url><authid>37034330700</authid><authname>Lamont K.</authname><surname>Lamont</surname><given-name>Kim</given-name><initials>K.</initials><afid>60016218</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35392235500</author-url><authid>35392235500</authid><authname>Böhm M.</authname><surname>Böhm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60023686</afid></author><authkeywords>Cardiomyopathy | Heart rate | PPCM | Pregnancy</authkeywords><intid>1786088231</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930200492"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930200492?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930200492&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930200492&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008438"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930200492</prism:url><dc:identifier>SCOPUS_ID:84930200492</dc:identifier><eid>2-s2.0-84930200492</eid><dc:title>Amitriptyline pharmacologically preconditions rat hearts against cardiac ischemic-reperfusion injury</dc:title><dc:creator>Lee S.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>353-359</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.120</prism:doi><pii>S0167527315008438</pii><dc:description>© 2015 Published by Elsevier Ireland Ltd. All rights reserved. Background/objectives Amitriptyline (AMY) is a tricyclic anti-depressant that has recently been shown to have anti-inflammatory properties. We investigated whether AMY is cardioprotective against reperfusion injury in ex-vivo rat hearts. Methods Thirty adult Sprague-Dawley rat hearts were perfused ex-vivo in a Langendorff apparatus. All hearts except SHAM (n = 6, perfused for 110 min.) received 30 min no-flow ischemia followed by 40 min reperfusion (I-R). One group (n = 6) was untreated before I-R (non-preconditioned; NPC), another non-preconditioned group was perfused with 10 μM amitriptyline for 30 min before I-R (NPC-AMY, n = 6). One group was preconditioned with 3 × 5-minute periods of ischemia before I-R (PC, n = 6) and a fifth group was preconditioned in the presence of 10 μM amitriptyline (PC-AMY, n = 6). p38 phosphorylation and HMGB1 levels were quantified using Western blots. Data was analysed using multiway ANOVAs with Tukey HSD and linear regression models with Sobel mediator tests. Results NPC hearts recovered poorly (LVDP recovered to 26.5 ± 10.5% of pre-ischemic values, compared to PC hearts (82.8 ± 14.9%: P &lt; 0.05)). PC-AMY (69.9 ± 6.16%) and NPC-AMY (90.3 ± 10.0%) groups both recovered well (P &lt; 0.05). The Sobel mediator test suggested that p38 activity may be indirectly involved in the amitriptyline induced cardioprotection (P &lt; 0.05). HMGB1 was lower in amitriptyline treated hearts compared to the non-preconditioned hearts (P &lt; 0.05) but the multiway ANOVA test suggests that HMGB1 was not involved in amitriptyline induced protection. Conclusions Amitriptyline at 10 μM protects hearts against ischemic-reperfusion injury which may be partially mediated through p38 phosphorylation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009512</affiliation-url><afid>60009512</afid><affilname>University of Adelaide</affilname><name-variant>University of Adelaide</name-variant><affiliation-city>Adelaide</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662542600</author-url><authid>56662542600</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>S. M.</given-name><initials>S.M.</initials><afid>60009512</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35580729400</author-url><authid>35580729400</authid><authname>Hutchinson M.</authname><surname>Hutchinson</surname><given-name>M.</given-name><initials>M.</initials><afid>60009512</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8689920300</author-url><authid>8689920300</authid><authname>Staikopoulos V.</authname><surname>Staikopoulos</surname><given-name>V.</given-name><initials>V.</initials><afid>60009512</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003378587</author-url><authid>7003378587</authid><authname>Saint D.</authname><surname>Saint</surname><given-name>D. A.</given-name><initials>D.A.</initials><afid>60009512</afid></author><authkeywords>Cardioprotection | Ischemia-reperfusion | Preconditioning | Reperfusion injury | Tricyclic-anti-depressant</authkeywords><intid>1536087561</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212017"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212017?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212017&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212017&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315007032"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212017</prism:url><dc:identifier>SCOPUS_ID:84930212017</dc:identifier><eid>2-s2.0-84930212017</eid><dc:title>Being cast into the shade of β blockers for concomitant heart failure and atrial fibrillation?</dc:title><dc:creator>Long D.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>35</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.431</prism:doi><pii>S0167527315007032</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082822</affiliation-url><afid>60082822</afid><affilname>Second Xiangya Hospital of Central-South University</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640517100</author-url><authid>56640517100</authid><authname>Long D.</authname><surname>Long</surname><given-name>Da</given-name><initials>D.</initials><afid>60082822</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55437328300</author-url><authid>55437328300</authid><authname>Xiao Y.</authname><surname>Xiao</surname><given-name>Yichao</given-name><initials>Y.</initials><afid>60082822</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56305125400</author-url><authid>56305125400</authid><authname>Dong B.</authname><surname>Dong</surname><given-name>Bin</given-name><initials>B.</initials><afid>60082822</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7404165288</author-url><authid>7404165288</authid><authname>Zhou S.</authname><surname>Zhou</surname><given-name>Shenghua</given-name><initials>S.</initials><afid>60082822</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55712203000</author-url><authid>55712203000</authid><authname>Liu Q.</authname><surname>Liu</surname><given-name>Qiming</given-name><initials>Q.</initials><afid>60082822</afid></author><authkeywords>Atrial fibrillation | Heart failure | β blockers</authkeywords><intid>1536088090</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930260126"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930260126?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930260126&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930260126&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930260126</prism:url><dc:identifier>SCOPUS_ID:84930260126</dc:identifier><eid>2-s2.0-84930260126</eid><dc:title>Validity of the mediastinum as a reference region to evaluate cardiac accumulation of iodine-123 metaiodobenzylguanidine</dc:title><dc:creator>Inoue Y.</dc:creator><prism:publicationName>Annals of Nuclear Medicine</prism:publicationName><prism:issn>09147187</prism:issn><prism:eIssn>18646433</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s12149-015-0989-z</prism:doi><dc:description>© 2015 The Japanese Society of Nuclear Medicine Objective: The heart-to-mediastinum (H/M) ratio, the heart count normalized for the mediastinum count, is commonly used in cardiac &lt;sup&gt;123&lt;/sup&gt;I-metaiodobenzylguanidine (MIBG) imaging. However, there are reports describing age-dependent increases in the mediastinum count with or without correction for the injected dose (ID) and a poor correlation between the H/M ratio and heart count normalized for ID. We evaluated the validity of the mediastinum count as a reference in comparison with the ID. Methods: Results of cardiac &lt;sup&gt;123&lt;/sup&gt;I-MIBG imaging in 200 patients were analyzed. The mean counts for the heart and mediastinum were estimated to calculate the H/M ratio. Additionally, the heart and mediastinum counts were normalized for ID measured with a dose calibrator. ID was corrected for body size represented by body weight, body surface area, or lean body mass. Results: The coefficient of variance of the ID-normalized mediastinum count was reduced by correcting ID for body size. The indicators of body size showed significant negative correlations with age. Although a positive correlation was found between age and the ID-normalized mediastinum counts, the age-dependence was reduced by body size correction. There was a close correlation between the H/M ratio and ID-normalized heart counts, and body size correction improved the correlation. Conclusion: The results of this study indicate the validity of the mediastinum as a reference region and support the use of the H/M ratio as an index of cardiac accumulation of &lt;sup&gt;123&lt;/sup&gt;I-MIBG.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Kitasato University School of Medicine</affilname><name-variant>Department of Diagnostic Radiology</name-variant><affiliation-city>Sagamihara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Kitasato University Hospital</affilname><name-variant>Department of Radiology</name-variant><affiliation-city>Sagamihara</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35375768400</author-url><authid>35375768400</authid><authname>Inoue Y.</authname><surname>Inoue</surname><given-name>Yusuke</given-name><initials>Y.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663650600</author-url><authid>56663650600</authid><authname>Abe Y.</authname><surname>Abe</surname><given-name>Yutaka</given-name><initials>Y.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663803400</author-url><authid>56663803400</authid><authname>Asano Y.</authname><surname>Asano</surname><given-name>Yuji</given-name><initials>Y.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663686000</author-url><authid>56663686000</authid><authname>Kikuchi K.</authname><surname>Kikuchi</surname><given-name>Kei</given-name><initials>K.</initials><afid/></author><authkeywords>&lt;sup&gt;123&lt;/sup&gt;I-metaiodobenzylguanidine (MIBG) | Heart-to-mediastinum (H/M) ratio | Injected dose | Quantitative evaluation</authkeywords><intid>536093904</intid><source-id>16558</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930150825"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930150825?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930150825&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930150825&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930150825</prism:url><dc:identifier>SCOPUS_ID:84930150825</dc:identifier><eid>2-s2.0-84930150825</eid><dc:title>Association of TGFBR2 rs6785358 Polymorphism with Increased Risk of Congenital Ventricular Septal Defect in a Chinese Population</dc:title><dc:creator>Li X.</dc:creator><prism:publicationName>Pediatric Cardiology</prism:publicationName><prism:issn>01720643</prism:issn><prism:eIssn>14321971</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00246-015-1189-2</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Transforming growth factor beta receptor 2 (TGFBR2) plays a central role in normal heart development, and we investigated whether TGFBR2 polymorphism confers the risk of congenital ventricular septal defect (CVSD). The case–control study included 115 CVSD children and 188 healthy children in a Chinese population. TGFBR2 rs6785358 polymorphism was genotyped with polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Enzyme-linked immunoassay (ELISA) was used to detect serum TGFBR2 levels. The genotype and allele frequency of TGFBR2 rs6785358 were significantly higher in the CVSD group than in the controls (all P &lt; 0.05). The G allele carriers were associated with increased CVSD risk compared with the A allele carriers in CVSD group (OR 3.503, 95 % CI 2.670–4.596). Stratified analysis by gender revealed that the TGFBR2 rs6785358 genotype and allele frequency were significantly different between the CVSD case and controls, in both the male subgroup and the female subgroup (all P &lt; 0.001). The G allele carriers were more susceptible to CVSD risk than the A allele carriers in both the male subgroup (OR 9.096, 95 % CI 5.398–15.33) and the female subgroup (OR 3.148, 95 % CI 1.764–5.618). Logistic regression analysis revealed that age, gender and genotype were associated with the risk of CVSD (all P &lt; 0.05). The study findings revealed that TGFBR2 rs6785358 polymorphism contributes to CVSD susceptibility, and the G allele may increase the risk of CVSD.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032477</affiliation-url><afid>60032477</afid><affilname>Jining Medical College</affilname><name-variant>Jining Medical College</name-variant><affiliation-city>Jining</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032477</affiliation-url><afid>60032477</afid><affilname>Jining Medical College</affilname><name-variant>Jining Medical College</name-variant><affiliation-city>Jining</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114746073</affiliation-url><afid>114746073</afid><affilname>Jining No. 1 People’s Hospital</affilname><name-variant>Jining No. 1 People’s Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087830</affiliation-url><afid>60087830</afid><affilname>First Affiliated Hospital of Harbin Medical University</affilname><name-variant>First Affiliated Hospital of Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661618400</author-url><authid>56661618400</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiang Ting</given-name><initials>X.T.</initials><afid>60032477</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661582500</author-url><authid>56661582500</authid><authname>Shen C.</authname><surname>Shen</surname><given-name>Chang Qing</given-name><initials>C.Q.</initials><afid>60032477</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661445100</author-url><authid>56661445100</authid><authname>Zhang R.</authname><surname>Zhang</surname><given-name>Rui</given-name><initials>R.</initials><afid>60032477</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56661485900</author-url><authid>56661485900</authid><authname>Shi J.</authname><surname>Shi</surname><given-name>Ji Kui</given-name><initials>J.K.</initials><afid>114746073</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56661583100</author-url><authid>56661583100</authid><authname>Li Z.</authname><surname>Li</surname><given-name>Zong Hong</given-name><initials>Z.H.</initials><afid>60087830</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56661643700</author-url><authid>56661643700</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hong Yu</given-name><initials>H.Y.</initials><afid>60087830</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56661571000</author-url><authid>56661571000</authid><authname>Sun B.</authname><surname>Sun</surname><given-name>Bo</given-name><initials>B.</initials><afid>60087830</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56661390200</author-url><authid>56661390200</authid><authname>Wang K.</authname><surname>Wang</surname><given-name>Kai</given-name><initials>K.</initials><afid>60087830</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56661567500</author-url><authid>56661567500</authid><authname>Yan L.</authname><surname>Yan</surname><given-name>Li Ru</given-name><initials>L.R.</initials><afid>60087830</afid></author><authkeywords>Congenital heart disease | Congenital ventricular septal defect | Endothelial–mesenchymal transformation | Polymorphism | Transforming growth factor beta receptor 2</authkeywords><intid>1786078183</intid><source-id>20526</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210682"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210682?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210682&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210682&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315007469"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210682</prism:url><dc:identifier>SCOPUS_ID:84930210682</dc:identifier><eid>2-s2.0-84930210682</eid><dc:title>Normal values of right pulmonary to left pulmonary flow ratio in healthy individuals determined by cardiovascular magnetic resonance</dc:title><dc:creator>Fratz S.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>84-85</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.027 Letter to the Editor</prism:doi><pii>S0167527315007469</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019722</affiliation-url><afid>60019722</afid><affilname>Technische Universitat Munchen</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019722</affiliation-url><afid>60019722</afid><affilname>Technische Universitat Munchen</affilname><name-variant>Technische Universität München</name-variant><affiliation-city>Munich</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023561</affiliation-url><afid>60023561</afid><affilname>Centre Hospitalier Universitaire Vaudois</affilname><name-variant>CHUV</name-variant><affiliation-city>Lausanne</affiliation-city><affiliation-country>Switzerland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602514238</author-url><authid>6602514238</authid><authname>Fratz S.</authname><surname>Fratz</surname><given-name>Sohrab</given-name><initials>S.</initials><afid>60019722</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602331049</author-url><authid>6602331049</authid><authname>Meierhofer C.</authname><surname>Meierhofer</surname><given-name>Christian</given-name><initials>C.</initials><afid>60019722</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602435225</author-url><authid>6602435225</authid><authname>Martinoff S.</authname><surname>Martinoff</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60019722</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7004344110</author-url><authid>7004344110</authid><authname>Ewert P.</authname><surname>Ewert</surname><given-name>Peter</given-name><initials>P.</initials><afid>60019722</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7202088072</author-url><authid>7202088072</authid><authname>Stern H.</authname><surname>Stern</surname><given-name>Heiko</given-name><initials>H.</initials><afid>60019722</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26640716300</author-url><authid>26640716300</authid><authname>Rutz T.</authname><surname>Rutz</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60019722</afid><afid>60023561</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:26640716300</author-url><authid>26640716300</authid><authname>Rutz T.</authname><surname>Rutz</surname><given-name>Tobias</given-name><initials>T.</initials><afid>60019722</afid><afid>60023561</afid></author><authkeywords>Cardiac magnetic resonance | Congenital heart disease | Pulmonary flow ratio</authkeywords><intid>1036081600</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930196581"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930196581?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930196581&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930196581&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930196581</prism:url><dc:identifier>SCOPUS_ID:84930196581</dc:identifier><eid>2-s2.0-84930196581</eid><dc:title>Quantification of three-dimensional computed tomography angiography for evaluating coronary luminal stenosis using digital subtraction angiography as the standard of reference</dc:title><dc:creator>Guo W.</dc:creator><prism:publicationName>BioMedical Engineering Online</prism:publicationName><prism:eIssn>1475925X</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>May 30, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12938-015-0048-y</prism:doi><dc:description>© Guo et al. Objective: We sought to evaluate the accuracy of quantitative three-dimensional (3D) CT angiography (CTA) for the assessment of coronary luminal stenosis using digital subtraction angiography (DSA) as the standard of reference. Method: Twenty-three patients with 54 lesions were referred for CTA followed by DSA. The CTA scans were performed with 256-slice spiral CT. 3D CTA were reconstructed from two-dimensional CTA imaging sequences in order to extract the following quantitative indices: minimal lumen diameter, percent diameter stenosis (%DS), minimal lumen area, and percent area stenosis (%AS). Correlation and limits of agreement were calculated using Pearson correlation and Bland-Altman analysis, respectively. The diagnostic performance and the diagnostic concordance of 3D CTA-derived anatomic parameters (%DS, %AS) for the detection of severe coronary arterial stenosis (as assessed by DSA) were presented as sensitivity, specificity, diagnostic accuracy, and Kappa statistics. Of which vessels with %DS &gt;50% or with %AS &gt;75% were identified as severe coronary arterial lesions. Result: The correlations of the anatomic parameters between 3D CTA and DSA were significant (r = 0.51-0.74, P &lt; 0.001). Bland-Altman analysis confirmed that the mean differences were small (from -1.11 to 27.39%), whereas the limits of agreement were relatively wide (from ±28.07 to ±138.64%). Otherwise, the diagnostic accuracy (74.1% with 58.3% sensitivity and 86.7% specificity for DS%; 74.1% with 45.8% sensitivity and 96.7% specificity for %AS) and the diagnostic concordance (k = 0.46 for DS%; 0.45 for %AS) of 3D CTA-derived anatomic parameters for the detection of severe stenosis were moderate. Conclusion: 3D advanced imaging reconstruction technique is a helpful tool to promote the use of CTA as an alternative to assess luminal stenosis in clinical practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073529</affiliation-url><afid>60073529</afid><affilname>Guangzhou General Hospital of Guangzhou Command</affilname><name-variant>Guangzhou General Hospital of Guangzhou Military Command</name-variant><affiliation-city>Guangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112805041</affiliation-url><afid>112805041</afid><affilname>Institute of Biomedical and Health Engineering</affilname><name-variant>Institute of Biomedical and Health Engineering</name-variant><affiliation-city>Zhengzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002593</affiliation-url><afid>60002593</afid><affilname>Southern Medical University</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>TongHe</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56416889700</author-url><authid>56416889700</authid><authname>Guo W.</authname><surname>Guo</surname><given-name>Wei</given-name><initials>W.</initials><afid>60073529</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417339000</author-url><authid>56417339000</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xin</given-name><initials>X.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417339000</author-url><authid>56417339000</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xin</given-name><initials>X.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>112805041</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55709665500</author-url><authid>55709665500</authid><authname>Huang W.</authname><surname>Huang</surname><given-name>Wenhua</given-name><initials>W.</initials><afid>60002593</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36717896600</author-url><authid>36717896600</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wan Hua</given-name><initials>W.H.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36717896600</author-url><authid>36717896600</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wan Hua</given-name><initials>W.H.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14827559100</author-url><authid>14827559100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Heye</given-name><initials>H.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14827559100</author-url><authid>14827559100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Heye</given-name><initials>H.</initials><afid>112805041</afid><afid>60019499</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36438776000</author-url><authid>36438776000</authid><authname>Tan N.</authname><surname>Tan</surname><given-name>Ning</given-name><initials>N.</initials><afid>60073529</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>112805041</afid><afid>60019499</afid><afid>60002798</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>112805041</afid><afid>60019499</afid><afid>60002798</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>112805041</afid><afid>60019499</afid><afid>60002798</afid></author><authkeywords>Coronary luminal stenosis | Digital subtraction angiography | Three-dimensional (3D) CT angiography</authkeywords><intid>1536087168</intid><article-number>50</article-number><source-id>28586</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930082728"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930082728?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930082728&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930082728&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000479"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930082728</prism:url><dc:identifier>SCOPUS_ID:84930082728</dc:identifier><eid>2-s2.0-84930082728</eid><dc:title>The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease</dc:title><dc:creator>Kim J.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>8-15</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.02.003</prism:doi><pii>S0163725815000479</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Cardiovascular disease (CVD) can be separated into two broad etiological categories, based on the presence or absence of ischemia as a causative factor. In both ischemic and non-ischemic heart disease, myocardial dysfunction or damage frequently results in the development of heart failure, characterized by dyspnea, fatigue and reduced survival. As one of the least regenerative organs in the human body, current standards of care are limited to mitigating loss and preventing recurrence of damage, rather than stimulating actual regeneration of functional heart tissue. Cell based therapies using progenitor cells from bone marrow and the heart itself have been evaluated in preclinical models, and have demonstrated some promise. Accordingly, several clinical trials using autologous stem and progenitor cells have been performed, showing that these cells can be used safely in humans, and suggesting that they may improve relevant clinical parameters in patients with heart disease. Two specific cell populations that are particularly promising are the bone marrow derived mesenchymal stem cell (MSC) and the heart muscle derived cardiac stem cell (CSC). This review will summarize preclinical studies evaluating these stem cell populations and will discuss the clinical application of these cells in contemporary clinical trials, and potential future investigations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000209</affiliation-url><afid>60000209</afid><affilname>University of Connecticut Health Center</affilname><name-variant>Univ. of Connecticut Health Center</name-variant><affiliation-city>Farmington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018395</affiliation-url><afid>60018395</afid><affilname>Hartford Hospital</affilname><name-variant>Hartford Hospital</name-variant><affiliation-city>Hartford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000209</affiliation-url><afid>60000209</afid><affilname>University of Connecticut Health Center</affilname><name-variant>Univ. of Connecticut Health Center</name-variant><affiliation-city>Farmington</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56536020900</author-url><authid>56536020900</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jiyeon</given-name><initials>J.</initials><afid>60000209</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56535938200</author-url><authid>56535938200</authid><authname>Shapiro L.</authname><surname>Shapiro</surname><given-name>Linda</given-name><initials>L.</initials><afid>60000209</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56536132900</author-url><authid>56536132900</authid><authname>Flynn A.</authname><surname>Flynn</surname><given-name>Aidan</given-name><initials>A.</initials><afid>60018395</afid><afid>60000209</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56536132900</author-url><authid>56536132900</authid><authname>Flynn A.</authname><surname>Flynn</surname><given-name>Aidan</given-name><initials>A.</initials><afid>60018395</afid><afid>60000209</afid></author><authkeywords>Cardiac stem cell | Cardiovascular disease | Clinical trial | Mesenchymal stem cell | Pre-conditioning | Therapy</authkeywords><intid>1786064095</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226956"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226956?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226956&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226956&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008852"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226956</prism:url><dc:identifier>SCOPUS_ID:84930226956</dc:identifier><eid>2-s2.0-84930226956</eid><dc:title>Is patient-prosthesis mismatch a predictor of survival or a surrogate marker of co-morbidities in cardiac surgery?</dc:title><dc:creator>Dayan V.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>389-392</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.161</prism:doi><pii>S0167527315008852</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Patient-prosthesis mismatch (PPM) has ignited much debate and no definite conclusions have been drawn on the outcome of these patients. Therefore, additional large studies with long-term follow-up are required to help the cardiologist and surgeon outline the best therapeutic strategy for patients with high risk for PPM. Methods Patients who underwent aortic valve replacement (AVR) from 2000 to 2013 were identified. Baseline and operative data was extracted and indexed effective orifice area calculated for each patient. The presence of PPM was defined in those patients with an iEOA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100824957</affiliation-url><afid>100824957</afid><affilname>Instituto Nacional de Cirugía Cardíaca</affilname><name-variant>Instituto Nacional de Cirugia Cardiaca</name-variant><affiliation-city>Montevideo</affiliation-city><affiliation-country>Uruguay</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23501422100</author-url><authid>23501422100</authid><authname>Dayan V.</authname><surname>Dayan</surname><given-name>Victor</given-name><initials>V.</initials><afid>100824957</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26538203900</author-url><authid>26538203900</authid><authname>Soca G.</authname><surname>Soca</surname><given-name>Gerardo</given-name><initials>G.</initials><afid>100824957</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663302000</author-url><authid>56663302000</authid><authname>Stanham R.</authname><surname>Stanham</surname><given-name>Roberto</given-name><initials>R.</initials><afid>100824957</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7102402996</author-url><authid>7102402996</authid><authname>Lorenzo A.</authname><surname>Lorenzo</surname><given-name>Alvaro</given-name><initials>A.</initials><afid>100824957</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22950683700</author-url><authid>22950683700</authid><authname>Ferreiro A.</authname><surname>Ferreiro</surname><given-name>Alejandro</given-name><initials>A.</initials><afid>100824957</afid></author><authkeywords>Aortic valve replacement | Patient-prosthesis mismatch</authkeywords><intid>1786088399</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929319924"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929319924?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929319924&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929319924&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929319924</prism:url><dc:identifier>SCOPUS_ID:84929319924</dc:identifier><eid>2-s2.0-84929319924</eid><dc:title>Cardiac output measurement using a modified carbon dioxide fick method: Comparison analysis with pulmonary artery catheter method and pulse induced contour cardiac output method</dc:title><dc:creator>Li T.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3530-3537</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Objectives: In the present study, cardiac output in mechanically ventilated patients were determined using three methods including modified CO&lt;inf&gt;2&lt;/inf&gt;-Fick (mCO&lt;inf&gt;2&lt;/inf&gt;F), pulmonary artery catheter (PAC), and pulse induced contour cardiac output (PiCCO) methods and the results were compared to assess the effectiveness of mCO2F method in measuring the cardiac output. Method: Mechanically ventilated and hemodynamically unstable patients (n=39) were sedated and intubated with Swan-Ganz or PiCCO arterial catheters. At the beginning of the experiment and at 4 h after the experiment, the CO&lt;inf&gt;2&lt;/inf&gt; concentration in expiratory air was measured through a CO2 monitor and it was used further in the cardiac output calculation using mCO&lt;inf&gt;2&lt;/inf&gt;F method. The cardiac output was also determined using PAC and PiCCO methods. Results: The cardiac output determined by PAC and mCO&lt;inf&gt;2&lt;/inf&gt;F method was not significantly (P&gt;0.05) different [5.53±2.85 L.min&lt;sup&gt;-1&lt;/sup&gt; (PAC) and 5.96±2.92 L.min-1 (mCO&lt;inf&gt;2&lt;/inf&gt;F)] at the beginning of the experiment and [6.22±2.7 L.min-1 (PAC) and 6.36±2.35 L.min&lt;sup&gt;-1&lt;/sup&gt; (mCO2F)] at 4 h after the experiment; however, they were highly correlated (r=0.939 and 0.908, P&lt;0.001). The cardiac output determined by PiCCO and mCO&lt;inf&gt;2&lt;/inf&gt;F method was also not significantly (P&gt;0.05) different [6.05±2.49 L.min-1 (PiCCO) and 5.44±1.64 L.min-1 (mCO&lt;inf&gt;2&lt;/inf&gt;F)] at the beginning of the experiment, and [6.17±2.04 L.min&lt;sup&gt;-1&lt;/sup&gt; (PiCCO) and 5.70±1.72 L.min&lt;sup&gt;-1&lt;/sup&gt; (mCO&lt;inf&gt;2&lt;/inf&gt;F)] at 4 h after the experiment; however, they were highly correlated (r=0.776 and 0.832, P&lt;0.001). Conclusion: The mCO&lt;inf&gt;2&lt;/inf&gt;F method could accurately measure the cardiac output in mechanically ventilated patients without using any expensive equipment’s and invasive procedures.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003970</affiliation-url><afid>60003970</afid><affilname>Zhejiang University</affilname><name-variant>Zhejiang University</name-variant><affiliation-city>Hangzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56564412800</author-url><authid>56564412800</authid><authname>Li T.</authname><surname>Li</surname><given-name>Tong</given-name><initials>T.</initials><afid>60003970</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14627076300</author-url><authid>14627076300</authid><authname>Cai H.</authname><surname>Cai</surname><given-name>Hongliu</given-name><initials>H.</initials><afid>60003970</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643677500</author-url><authid>56643677500</authid><authname>Pan H.</authname><surname>Pan</surname><given-name>Hui</given-name><initials>H.</initials><afid>60003970</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56644235900</author-url><authid>56644235900</authid><authname>Pu Q.</authname><surname>Pu</surname><given-name>Qibin</given-name><initials>Q.</initials><afid>60003970</afid></author><authkeywords>Cardiac output | Mechanical ventilation | Modified Fick method | Pulmonary artery catheter | Pulse induced contour cardiac output | Thermo dilution</authkeywords><intid>2035939257</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930077278"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930077278?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930077278&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930077278&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930077278</prism:url><dc:identifier>SCOPUS_ID:84930077278</dc:identifier><eid>2-s2.0-84930077278</eid><dc:title>Quantification of three-dimensional computed tomography angiography for evaluating coronary luminal stenosis using digital subtraction angiography as the standard of reference</dc:title><dc:creator>Guo W.</dc:creator><prism:publicationName>BioMedical Engineering Online</prism:publicationName><prism:eIssn>1475925X</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>May 30, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12938-015-0048-y</prism:doi><dc:description>© 2015 Guo et al. Objective: We sought to evaluate the accuracy of quantitative three-dimensional (3D) CT angiography (CTA) for the assessment of coronary luminal stenosis using digital subtraction angiography (DSA) as the standard of reference. Method: Twenty-three patients with 54 lesions were referred for CTA followed by DSA. The CTA scans were performed with 256-slice spiral CT. 3D CTA were reconstructed from two-dimensional CTA imaging sequences in order to extract the following quantitative indices: minimal lumen diameter, percent diameter stenosis (%DS), minimal lumen area, and percent area stenosis (%AS). Correlation and limits of agreement were calculated using Pearson correlation and Bland-Altman analysis, respectively. The diagnostic performance and the diagnostic concordance of 3D CTA-derived anatomic parameters (%DS, %AS) for the detection of severe coronary arterial stenosis (as assessed by DSA) were presented as sensitivity, specificity, diagnostic accuracy, and Kappa statistics. Of which vessels with %DS &gt;50% or with %AS &gt;75% were identified as severe coronary arterial lesions. Result: The correlations of the anatomic parameters between 3D CTA and DSA were significant (r = 0.51-0.74, P &lt; 0.001). Bland-Altman analysis confirmed that the mean differences were small (from -1.11 to 27.39%), whereas the limits of agreement were relatively wide (from ±28.07 to ±138.64%). Otherwise, the diagnostic accuracy (74.1% with 58.3% sensitivity and 86.7% specificity for DS%; 74.1% with 45.8% sensitivity and 96.7% specificity for %AS) and the diagnostic concordance (k = 0.46 for DS%; 0.45 for %AS) of 3D CTA-derived anatomic parameters for the detection of severe stenosis were moderate. Conclusion: 3D advanced imaging reconstruction technique is a helpful tool to promote the use of CTA as an alternative to assess luminal stenosis in clinical practice.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114799727</affiliation-url><afid>114799727</afid><affilname>Guangdong General Hospital</affilname><name-variant>Guangdong General Hospital</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:109487458</affiliation-url><afid>109487458</afid><affilname>Institute of Biomedical and Health Engineering</affilname><name-variant>Institute of Biomedical and Health Engineering</name-variant><affiliation-city>Qingshuihe, Shenzhen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002593</affiliation-url><afid>60002593</afid><affilname>Southern Medical University</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>TongHe</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019499</affiliation-url><afid>60019499</afid><affilname>Chinese Academy of Sciences</affilname><name-variant>Chinese Academy of Sciences</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">18</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56416889700</author-url><authid>56416889700</authid><authname>Guo W.</authname><surname>Guo</surname><given-name>Wei</given-name><initials>W.</initials><afid>114799727</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417339000</author-url><authid>56417339000</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xin</given-name><initials>X.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56417339000</author-url><authid>56417339000</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xin</given-name><initials>X.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55320405200</author-url><authid>55320405200</authid><authname>Gao Z.</authname><surname>Gao</surname><given-name>Zhifan</given-name><initials>Z.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56660655500</author-url><authid>56660655500</authid><authname>Pirbhulal S.</authname><surname>Pirbhulal</surname><given-name>Sandeep</given-name><initials>S.</initials><afid>109487458</afid><afid>60019499</afid><afid>60019499</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55709665500</author-url><authid>55709665500</authid><authname>Huang W.</authname><surname>Huang</surname><given-name>Wenhua</given-name><initials>W.</initials><afid>60002593</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36717896600</author-url><authid>36717896600</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wan Hua</given-name><initials>W.H.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36717896600</author-url><authid>36717896600</authid><authname>Lin W.</authname><surname>Lin</surname><given-name>Wan Hua</given-name><initials>W.H.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14827559100</author-url><authid>14827559100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Heye</given-name><initials>H.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:14827559100</author-url><authid>14827559100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>Heye</given-name><initials>H.</initials><afid>109487458</afid><afid>60019499</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36438776000</author-url><authid>36438776000</authid><authname>Tan N.</authname><surname>Tan</surname><given-name>Ning</given-name><initials>N.</initials><afid>114799727</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>109487458</afid><afid>60019499</afid><afid>60002798</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>109487458</afid><afid>60019499</afid><afid>60002798</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7601312279</author-url><authid>7601312279</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yuan Ting</given-name><initials>Y.T.</initials><afid>109487458</afid><afid>60019499</afid><afid>60002798</afid></author><authkeywords>Coronary luminal stenosis | Digital subtraction angiography | Three-dimensional (3D) CT angiography</authkeywords><intid>536061736</intid><source-id>28586</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930268460"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930268460?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930268460&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930268460&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930268460</prism:url><dc:identifier>SCOPUS_ID:84930268460</dc:identifier><eid>2-s2.0-84930268460</eid><dc:title>Insulin regulates Rab3–Noc2 complex dissociation to promote GLUT4 translocation in rat adipocytes</dc:title><dc:creator>Koumanov F.</dc:creator><prism:publicationName>Diabetologia</prism:publicationName><prism:issn>0012186X</prism:issn><prism:eIssn>14320428</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00125-015-3627-3</prism:doi><dc:description>© 2015 The Author(s) Aims/hypothesis: The glucose transporter GLUT4 is present mainly in insulin-responsive tissues of fat, heart and skeletal muscle and is translocated from intracellular membrane compartments to the plasma membrane (PM) upon insulin stimulation. The transit of GLUT4 to the PM is known to be dependent on a series of Rab proteins. However, the extent to which the activity of these Rabs is regulated by the action of insulin action is still unknown. We sought to identify insulin-activated Rab proteins and Rab effectors that facilitate GLUT4 translocation. Methods: We developed a new photoaffinity reagent (Bio-ATB-GTP) that allows GTP-binding proteomes to be explored. Using this approach we screened for insulin-responsive GTP loading of Rabs in primary rat adipocytes. Results: We identified Rab3B as a new candidate insulin-stimulated G-protein in adipocytes. Using constitutively active and dominant negative mutants and Rab3 knockdown we provide evidence that Rab3 isoforms are key regulators of GLUT4 translocation in adipocytes. Insulin-stimulated Rab3 GTP binding is associated with disruption of the interaction between Rab3 and its negative effector Noc2. Disruption of the Rab3–Noc2 complex leads to displacement of Noc2 from the PM. This relieves the inhibitory effect of Noc2, facilitating GLUT4 translocation. Conclusions/interpretation: The discovery of the involvement of Rab3 and Noc2 in an insulin-regulated step in GLUT4 translocation suggests that the control of this translocation process is unexpectedly similar to regulated secretion and particularly pancreatic insulin-vesicle release.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Bath</affilname><name-variant>Department of Biology and Biochemistry</name-variant><affiliation-city>Bath</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>The University of Sydney</affilname><name-variant>Charles Perkins Centre</name-variant><name-variant>School of Molecular Bioscience</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6602609561</author-url><authid>6602609561</authid><authname>Koumanov F.</authname><surname>Koumanov</surname><given-name>Francoise</given-name><initials>F.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55366931600</author-url><authid>55366931600</authid><authname>Pereira V.</authname><surname>Pereira</surname><given-name>Vinit J.</given-name><initials>V.J.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663600100</author-url><authid>56663600100</authid><authname>Richardson J.</authname><surname>Richardson</surname><given-name>Judith D.</given-name><initials>J.D.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56664118600</author-url><authid>56664118600</authid><authname>Sargent S.</authname><surname>Sargent</surname><given-name>Samantha L.</given-name><initials>S.L.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:26635119400</author-url><authid>26635119400</authid><authname>Fazakerley D.</authname><surname>Fazakerley</surname><given-name>Daniel J.</given-name><initials>D.J.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7101738852</author-url><authid>7101738852</authid><authname>Holman G.</authname><surname>Holman</surname><given-name>Geoffrey D.</given-name><initials>G.D.</initials><afid/></author><authkeywords>G-protein photolabel | GLUT4 | Insulin | Noc2 | Rab3 | Rph3al</authkeywords><intid>1536093722</intid><source-id>25584</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930257627"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930257627?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930257627&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930257627&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930257627</prism:url><dc:identifier>SCOPUS_ID:84930257627</dc:identifier><eid>2-s2.0-84930257627</eid><dc:title>The Use of Ultrasound to Measure Dislocation Density</dc:title><dc:creator>Barra F.</dc:creator><prism:publicationName>JOM</prism:publicationName><prism:issn>10474838</prism:issn><prism:eIssn>15431851</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11837-015-1458-9</prism:doi><dc:description>© 2015 The Minerals, Metals &amp; Materials Society Dislocations are at the heart of the plastic behavior of materials yet they are very difficult to probe experimentally. Lack of a practical nonintrusive measuring tool for, say, dislocation density, seriously hampers modeling efforts, as there is little guidance from data in the form of quantitative measurements, as opposed to visualizations. Dislocation density can be measured using transmission electron microscopy (TEM) and x-ray diffraction (XRD). TEM can directly show the strain field around dislocations, which allows for the counting of the number of dislocations in a micrograph. This procedure is very laborious and local, since samples have to be very small and thin, and is difficult to apply when dislocation densities are high. XRD relies on the broadening of diffraction peaks induced by the loss of crystalline order induced by the dislocations. This broadening can be very small, and finding the dislocation density involves unknown parameters that have to be fitted with the data. Both methods, but especially TEM, are intrusive, in the sense that samples must be especially treated, mechanically and chemically. A nonintrusive method to measure dislocation density would be desirable. This paper reviews recent developments in the theoretical treatment of the interaction of an elastic wave with dislocations that have led to formulae that relate dislocation density to quantities that can be measured with samples of cm size. Experimental results that use resonant ultrasound spectroscopy supporting this assertion are reported, and the outlook for the development of a practical, nonintrusive, method to measure dislocation density is discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Universidad de Chile</affilname><name-variant>Departamento de Física and CIMAT</name-variant><name-variant>Facultad de Ciencias Físicas y Matemáticas</name-variant><affiliation-city>Santiago</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Universidad de Chile</affilname><name-variant>Departamento de Ciencia de los Materiales</name-variant><name-variant>Facultad de Ciencias Físicas y Matemáticas</name-variant><affiliation-city>Santiago</affiliation-city><affiliation-country>Chile</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Institut Langevin</affilname><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>UMR CNRS 6613</affilname><affiliation-city>Le Mans Cedex 9</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56664202200</author-url><authid>56664202200</authid><authname>Barra F.</authname><surname>Barra</surname><given-name>Felipe</given-name><initials>F.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664369800</author-url><authid>56664369800</authid><authname>Espinoza-González R.</authname><surname>Espinoza-González</surname><given-name>Rodrigo</given-name><initials>R.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663877800</author-url><authid>56663877800</authid><authname>Fernández H.</authname><surname>Fernández</surname><given-name>Henry</given-name><initials>H.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006541837</author-url><authid>7006541837</authid><authname>Lund F.</authname><surname>Lund</surname><given-name>Fernando</given-name><initials>F.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005051149</author-url><authid>7005051149</authid><authname>Maurel A.</authname><surname>Maurel</surname><given-name>Agnès</given-name><initials>A.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55885535800</author-url><authid>55885535800</authid><authname>Pagneux V.</authname><surname>Pagneux</surname><given-name>Vincent</given-name><initials>V.</initials><afid/></author><intid>1036087766</intid><source-id>12302</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929192347"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929192347?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929192347&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929192347&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929192347</prism:url><dc:identifier>SCOPUS_ID:84929192347</dc:identifier><eid>2-s2.0-84929192347</eid><dc:title>Balanced oxidative status by nesfatin-1 in intestinal ischemia-reperfusion</dc:title><dc:creator>Ayada C.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3318-3324</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Objective: Ischemia causes reversible or irreversible cell or tissue damage and reperfusion can exaggerate cellular damage. Microvascular dysfunction is induced and causes enhanced fluid filtration in capillaries. At the acute phase of reperfusion more oxygen radicals are activated. Nesfatin-1 protects brain against oxidative damage and heart against ischemia/reperfusion damage. In our study, we aimed to investigate the acute effect of chronic peripheral nesfatin-1 administration in intestinal ischemia/reperfusion created rats. Method: Two-months-old, 28 Wistar Albino male rats, weighing an average of 200-250 g, were used and randomly divided into four experimental groups (n=7) as; Laparotomy, Ischemia/Reperfusion, Nesfatin-1+Laparotomy, Nesfatin-1+Ischemia/Reperfusion. Serum levels of total oxidant status (TOS) and total antioxidant status (TAS) were determined by colorimetric measurement method. The plasma levels of endotelin-1 and endothelial nitric oxide syntheses (eNOS) were analyzed by rat ELISA assay kits. Results: Plasma levels of endothelin-1 significantly increased, plasma level of eNOS, serum levels of TOS and TAS significantly decreased in nesfatin-1 applied groups. Additionally, The oxidative stress index (OSI) parameters decreased significantly in three groups compared to laparotomy. Conclusion: Chronic peripheral nesfatin-1 administration can decrease eNOS level and OSI at the acute phase of ischemia/reperfusion. We suppose that it can be protective for ischemia/reperfusion injury by balancing oxidant capacity. On the other hand, this effect of nesfatin-1 is not related with micro-circular compensation and increases anti-oxidant capacity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017437</affiliation-url><afid>60017437</afid><affilname>Dumlupinar Universitesi</affilname><name-variant>Dumlupinar University</name-variant><affiliation-city>Kutahya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017437</affiliation-url><afid>60017437</afid><affilname>Dumlupinar Universitesi</affilname><name-variant>Dumlupinar University</name-variant><affiliation-city>Kutahya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017437</affiliation-url><afid>60017437</afid><affilname>Dumlupinar Universitesi</affilname><name-variant>Dumlupinar University</name-variant><affiliation-city>Kutahya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35764237900</author-url><authid>35764237900</authid><authname>Ayada C.</authname><surname>Ayada</surname><given-name>Ceylan</given-name><initials>C.</initials><afid>60017437</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54994557100</author-url><authid>54994557100</authid><authname>Toru Ü.</authname><surname>Toru</surname><given-name>Ümran</given-name><initials>Ü.</initials><afid>60017437</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004250545</author-url><authid>7004250545</authid><authname>Genç O.</authname><surname>Genç</surname><given-name>Osman</given-name><initials>O.</initials><afid>60017437</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56641656500</author-url><authid>56641656500</authid><authname>Akcılar1 R.</authname><surname>Akcılar1</surname><given-name>Raziye</given-name><initials>R.</initials><afid>60017437</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56446376200</author-url><authid>56446376200</authid><authname>Şahin S.</authname><surname>Şahin</surname><given-name>Server</given-name><initials>S.</initials><afid>60017437</afid></author><authkeywords>Endothelin-1 | ENOS | Ischemia/reperfusion | Nesfatin-1 | Total antioxidant capacity | Total oxidant capacity</authkeywords><intid>1785917617</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198944"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198944?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198944&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198944&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915300352"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198944</prism:url><dc:identifier>SCOPUS_ID:84930198944</dc:identifier><eid>2-s2.0-84930198944</eid><dc:title>Geraniol attenuates fibrosis and exerts anti-inflammatory effects on diet induced atherogenesis by NF-κB signaling pathway</dc:title><dc:creator>Jayachandran M.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>762</prism:volume><prism:pageRange>102-111</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.05.039</prism:doi><pii>S0014299915300352</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Atherosclerosis is now generally accepted as a chronic inflammatory condition. The transcription factor nuclear factor kappa B (NF-κB) is a key regulator of inflammation, immune responses, cell survival and cell proliferation. Tissue remodeling plays a significant role during the phase of inflammation and oxidative stress. In our study we have evaluated the effect of geraniol (GOH), a natural terpenoid on oxidative stress, inflammation and tissue remodeling in experimental animals. Experimental animals (hamsters) were divided into four groups; group 1 were control animals; group 2 were animals fed GOH alone (100 mg/kg b.w. p.o); group 3 were animals fed atherogenic diet (standard pellet diet+10% coconut oil+0.25% cholesterol); group 4 animals were fed atherogenic diet as in group 3+GOH (100 mg/kg b.w). At the end of the experimental period animals were killed and liver, heart and aorta tissues were analyzed for lipid peroxidation markers, non enzymic antioxidants and collagen distribution using histological studies like Milligan's trichrome and Picrosirius red staining. As inflammation plays a key role in tissue remodeling we also targeted the key inflammatory cytokine, NF-κB. GOH supplementation greatly prevented the remodeling of tissues by enhancing the free radical scavenging and anti-inflammatory effects. Thus in conclusion it can be suggested that GOH (100 mg/kg b.w) prevents the atherogenic diet induced fibrosis in experimental hamsters.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027171</affiliation-url><afid>60027171</afid><affilname>Annamalai University</affilname><name-variant>Annamalai University</name-variant><affiliation-city>Annamalai Nagar</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56459779500</author-url><authid>56459779500</authid><authname>Jayachandran M.</authname><surname>Jayachandran</surname><given-name>Muthukumaran</given-name><initials>M.</initials><afid>60027171</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56459770400</author-url><authid>56459770400</authid><authname>Chandrasekaran B.</authname><surname>Chandrasekaran</surname><given-name>Balaji</given-name><initials>B.</initials><afid>60027171</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507514405</author-url><authid>6507514405</authid><authname>Namasivayam N.</authname><surname>Namasivayam</surname><given-name>Nalini</given-name><initials>N.</initials><afid>60027171</afid></author><authkeywords>Atherogenic diet | Fibrosis | Geraniol | NF-κB | Non enzymic antioxidants</authkeywords><intid>2036081903</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207920"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207920?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207920&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207920&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008360"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207920</prism:url><dc:identifier>SCOPUS_ID:84930207920</dc:identifier><eid>2-s2.0-84930207920</eid><dc:title>Right ventricular lead perforation complicating late pacemaker infection</dc:title><dc:creator>Gurunathan S.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>47-48</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.113|</prism:doi><pii>S0167527315008360</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009009</affiliation-url><afid>60009009</afid><affilname>Royal Brompton Hospital</affilname><name-variant>Brompton Hospital</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010719</affiliation-url><afid>60010719</afid><affilname>National Heart and Lung Institute</affilname><name-variant>National Heart and Lung Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55560289300</author-url><authid>55560289300</authid><authname>Gurunathan S.</authname><surname>Gurunathan</surname><given-name>Sothinathan</given-name><initials>S.</initials><afid>60009009</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55165129300</author-url><authid>55165129300</authid><authname>Senior R.</authname><surname>Senior</surname><given-name>Roxy</given-name><initials>R.</initials><afid>60009009</afid><afid>60010719</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55165129300</author-url><authid>55165129300</authid><authname>Senior R.</authname><surname>Senior</surname><given-name>Roxy</given-name><initials>R.</initials><afid>60009009</afid><afid>60010719</afid></author><authkeywords>Cardiac perforation | Echocardiography | Pacemaker infection</authkeywords><intid>2036082585</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199629"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199629?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199629&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199629&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016752731500813X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199629</prism:url><dc:identifier>SCOPUS_ID:84930199629</dc:identifier><eid>2-s2.0-84930199629</eid><dc:title>Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome</dc:title><dc:creator>Harrell D.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>393-402</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.090</prism:doi><pii>S016752731500813X</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Short QT syndrome (SQTS) is a rare inheritable arrhythmia, associated with atrial and ventricular fibrillations, caused by mutations in six cardiac ion channel genes with high penetrance. However, genotype-specific clinical differences between SQTS patients remain to be elucidated. Methods and results We screened five unrelated Japanese SQTS families, and identified three mutations in KCNH2 and KCNQ1. A novel mutation KCNH2-I560T, when expressed in COS-7 cells, showed a 2.5-fold increase in peak current density, and a positive shift (+ 14 mV) of the inactivation curve compared with wild type. Computer simulations recapitulated the action potential shortening and created an arrhythmogenic substrate for ventricular fibrillation. In another family carrying the mutation KCNQ1-V141M, affected members showed earlier onset of manifestation and frequent complications of bradyarrhythmia. To determine genotype-specific phenotypes in SQT1 (KCNH2), SQT2 (KCNQ1), and other subtypes SQT3-6, we analyzed clinical variables in 65 mutation-positive patients among all the 132 SQTS cases previously reported. The age of manifestation was significantly later in SQT1 (SQT1: 35 ± 19 years, n = 30; SQT2: 17 ± 25 years, n = 8, SQT3-6: 19 ± 15 years, n = 15; p = 0.011). SQT2 exhibited a higher prevalence of bradyarrhythmia (SQT2: 6/8, 75%; non-SQT2: 5/57, 9%; p &lt; 0.001) and atrial fibrillation (SQT2: 5/8, 63%; non-SQT2: 12/57, 21%; p = 0.012). Of 51 mutation-positive individuals from 16 SQTS families, nine did not manifest short QT, but exhibited other ECG abnormalities such as atrial fibrillation. The resulting penetrance, 82%, was lower than previously recognized. Conclusion We propose that SQTS patients may exhibit different clinical manifestations depending upon their genotype.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011846</affiliation-url><afid>60011846</afid><affilname>Nagasaki University</affilname><name-variant>Nagasaki University Graduate School of Biomedical Sciences</name-variant><affiliation-city>Nagasaki</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007524</affiliation-url><afid>60007524</afid><affilname>Shiga University of Medical Science</affilname><name-variant>Shiga University of Medical Science</name-variant><affiliation-city>Otsu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018722</affiliation-url><afid>60018722</afid><affilname>IRCCS Fondazione Salvatore Maugeri</affilname><name-variant>IRCCS</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112598123</affiliation-url><afid>112598123</afid><affilname>Okinawa Children’s Medical Center</affilname><name-variant>Children's Medical Center</name-variant><affiliation-city>Okinawa</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002775</affiliation-url><afid>60002775</afid><affilname>University of Occupational and Environmental Health</affilname><name-variant>Univ. of Occup. and Environ. Health</name-variant><affiliation-city>Kitakyushu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002775</affiliation-url><afid>60002775</afid><affilname>University of Occupational and Environmental Health</affilname><name-variant>Univ. of Occup. and Environ. Health</name-variant><affiliation-city>Kitakyushu</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011846</affiliation-url><afid>60011846</afid><affilname>Nagasaki University</affilname><name-variant>Nagasaki University Graduate School of Biomedical Sciences</name-variant><affiliation-city>Nagasaki</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112937246</affiliation-url><afid>112937246</afid><affilname>Saitama International Medical Center</affilname><name-variant>Saitama International Medical Center</name-variant><affiliation-city>Hidaka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112745406</affiliation-url><afid>112745406</afid><affilname>Sapporo Medical Center</affilname><name-variant>Sapporo Heart Center</name-variant><affiliation-city>Sapporo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001377</affiliation-url><afid>60001377</afid><affilname>Kurume University School of Medicine</affilname><name-variant>Kurume Univ. Sch. Med.</name-variant><affiliation-city>Kurume</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>Università di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">15</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56319829200</author-url><authid>56319829200</authid><authname>Harrell D.</authname><surname>Harrell</surname><given-name>Daniel Toshio</given-name><initials>D.T.</initials><afid>60011846</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005403360</author-url><authid>7005403360</authid><authname>Ashihara T.</authname><surname>Ashihara</surname><given-name>Takashi</given-name><initials>T.</initials><afid>60007524</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35487749000</author-url><authid>35487749000</authid><authname>Ishikawa T.</authname><surname>Ishikawa</surname><given-name>Taisuke</given-name><initials>T.</initials><afid>60011846</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662967600</author-url><authid>56662967600</authid><authname>Tominaga I.</authname><surname>Tominaga</surname><given-name>Ichiko</given-name><initials>I.</initials><afid>60011846</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36480298200</author-url><authid>36480298200</authid><authname>Mazzanti A.</authname><surname>Mazzanti</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60018722</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662585300</author-url><authid>56662585300</authid><authname>Takahashi K.</authname><surname>Takahashi</surname><given-name>Kazuhiro</given-name><initials>K.</initials><afid>112598123</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602529021</author-url><authid>6602529021</authid><authname>Oginosawa Y.</authname><surname>Oginosawa</surname><given-name>Yasushi</given-name><initials>Y.</initials><afid>60002775</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56525874600</author-url><authid>56525874600</authid><authname>Abe H.</authname><surname>Abe</surname><given-name>Haruhiko</given-name><initials>H.</initials><afid>60002775</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56600097300</author-url><authid>56600097300</authid><authname>Maemura K.</authname><surname>Maemura</surname><given-name>Koji</given-name><initials>K.</initials><afid>60011846</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003528873</author-url><authid>7003528873</authid><authname>Sumitomo N.</authname><surname>Sumitomo</surname><given-name>Naokata</given-name><initials>N.</initials><afid>112937246</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56662772700</author-url><authid>56662772700</authid><authname>Uno K.</authname><surname>Uno</surname><given-name>Kikuya</given-name><initials>K.</initials><afid>112745406</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56482742200</author-url><authid>56482742200</authid><authname>Takano M.</authname><surname>Takano</surname><given-name>Makoto</given-name><initials>M.</initials><afid>60001377</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55244828500</author-url><authid>55244828500</authid><authname>Priori S.</authname><surname>Priori</surname><given-name>Silvia G.</given-name><initials>S.G.</initials><afid>60018722</afid><afid>60015197</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55244828500</author-url><authid>55244828500</authid><authname>Priori S.</authname><surname>Priori</surname><given-name>Silvia G.</given-name><initials>S.G.</initials><afid>60018722</afid><afid>60015197</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003273333</author-url><authid>7003273333</authid><authname>Makita N.</authname><surname>Makita</surname><given-name>Naomasa</given-name><initials>N.</initials><afid>60011846</afid></author><authkeywords>Computer simulation | Meta-analysis | Mutation | Patch clamp | Short QT syndrome</authkeywords><intid>1786088203</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930086048"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930086048?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930086048&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930086048&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000753"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930086048</prism:url><dc:identifier>SCOPUS_ID:84930086048</dc:identifier><eid>2-s2.0-84930086048</eid><dc:title>Pericytes, mesenchymal stem cells and their contributions to tissue repair</dc:title><dc:creator>Wong S.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>107-120</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.03.006</prism:doi><pii>S0163725815000753</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Regenerative medicine using mesenchymal stem cells for the purposes of tissue repair has garnered considerable public attention due to the potential of returning tissues and organs to a normal, healthy state after injury or damage has occurred. To achieve this, progenitor cells such as pericytes and bone marrow-derived mesenchymal stem cells can be delivered exogenously, mobilised and recruited from within the body or transplanted in the form organs and tissues grown in the laboratory from stem cells. In this review, we summarise the recent evidence supporting the use of endogenously mobilised stem cell populations to enhance tissue repair along with the use of mesenchymal stem cells and pericytes in the development of engineered tissues. Finally, we conclude with an overview of currently available therapeutic options to manipulate endogenous stem cells to promote tissue repair.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010719</affiliation-url><afid>60010719</afid><affilname>National Heart and Lung Institute</affilname><name-variant>National Heart and Lung Institute</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56591131400</author-url><authid>56591131400</authid><authname>Wong S.</authname><surname>Wong</surname><given-name>Suet Ping</given-name><initials>S.P.</initials><afid>60010719</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56270682200</author-url><authid>56270682200</authid><authname>Rowley J.</authname><surname>Rowley</surname><given-name>Jessica E.</given-name><initials>J.E.</initials><afid>60010719</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55305763200</author-url><authid>55305763200</authid><authname>Redpath A.</authname><surname>Redpath</surname><given-name>Andia N.</given-name><initials>A.N.</initials><afid>60010719</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56469568900</author-url><authid>56469568900</authid><authname>Tilman J.</authname><surname>Tilman</surname><given-name>Jessica D.</given-name><initials>J.D.</initials><afid>60010719</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:14007836800</author-url><authid>14007836800</authid><authname>Fellous T.</authname><surname>Fellous</surname><given-name>Tariq G.</given-name><initials>T.G.</initials><afid>60010719</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56590882100</author-url><authid>56590882100</authid><authname>Johnson J.</authname><surname>Johnson</surname><given-name>Jill R.</given-name><initials>J.R.</initials><afid>60010719</afid></author><authkeywords>Fibrosis | Mesenchymal stem cell | Pericyte | Regenerative medicine | Tissue engineering | Tissue repair</authkeywords><intid>2036058405</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930194935"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930194935?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930194935&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930194935&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315009134"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930194935</prism:url><dc:identifier>SCOPUS_ID:84930194935</dc:identifier><eid>2-s2.0-84930194935</eid><dc:title>Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated inhibition of platelet aggregation, inflammation and myonecrosis by adjunctive cilostazol loading in patients with acute coronary syndrome) study</dc:title><dc:creator>Lee K.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>370-375</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.180</prism:doi><pii>S0167527315009134</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080734</affiliation-url><afid>60080734</afid><affilname>Gachon University</affilname><name-variant>Gachon University</name-variant><affiliation-city>Seongnam-si, Gyeonggi-do</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032624</affiliation-url><afid>60032624</afid><affilname>Ulsan University</affilname><name-variant>University of Ulsan</name-variant><affiliation-city>Ulsan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025615</affiliation-url><afid>60025615</afid><affilname>Soonchunhyang University</affilname><name-variant>Soonchunhyang University</name-variant><affiliation-city>Asan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:108036540</affiliation-url><afid>108036540</afid><affilname>National University Hospital</affilname><name-variant>National University Hospital</name-variant><affiliation-city>Gwangju</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009471</affiliation-url><afid>60009471</afid><affilname>Gyeongsang National University (GSNU), College of Medicine</affilname><name-variant>Gyeongsang National University College of Medicine</name-variant><affiliation-city>Jinju</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001995</affiliation-url><afid>60001995</afid><affilname>Sinai Center for Thrombosis Research</affilname><name-variant>Sinai Center for Thrombosis Research</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005732</affiliation-url><afid>60005732</afid><affilname>Chungnam National University, College of Medicine</affilname><name-variant>Chungnam National University Hospital</name-variant><affiliation-city>Yusong</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024615</affiliation-url><afid>60024615</afid><affilname>Ludwik Rydygier Collegium Medicum in Bydgoszcz</affilname><name-variant>Nicolaus Copernicus University</name-variant><affiliation-city>Bydgoszcz</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023075</affiliation-url><afid>60023075</afid><affilname>Gyeongsang National University</affilname><name-variant>Gyeongsang National University</name-variant><affiliation-city>Jinju</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">22</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23089026800</author-url><authid>23089026800</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Kyounghoon</given-name><initials>K.</initials><afid>60080734</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14631314800</author-url><authid>14631314800</authid><authname>Yoo S.</authname><surname>Yoo</surname><given-name>Sang Yong</given-name><initials>S.Y.</initials><afid>60032624</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56662700700</author-url><authid>56662700700</authid><authname>Suh J.</authname><surname>Suh</surname><given-name>Jon</given-name><initials>J.</initials><afid>60025615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662582300</author-url><authid>56662582300</authid><authname>Park K.</authname><surname>Park</surname><given-name>Keun Ho</given-name><initials>K.H.</initials><afid>108036540</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15051080300</author-url><authid>15051080300</authid><authname>Park Y.</authname><surname>Park</surname><given-name>Yongwhi</given-name><initials>Y.</initials><afid>60009471</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602488679</author-url><authid>6602488679</authid><authname>Tantry U.</authname><surname>Tantry</surname><given-name>Udaya S.</given-name><initials>U.S.</initials><afid>60001995</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662586100</author-url><authid>56662586100</authid><authname>Park K.</authname><surname>Park</surname><given-name>Ki Soo</given-name><initials>K.S.</initials><afid>60009471</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35224863200</author-url><authid>35224863200</authid><authname>Han S.</authname><surname>Han</surname><given-name>Seung Hwan</given-name><initials>S.H.</initials><afid>60080734</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7202402157</author-url><authid>7202402157</authid><authname>Kang W.</authname><surname>Kang</surname><given-name>Woong Chol</given-name><initials>W.C.</initials><afid>60080734</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56662638700</author-url><authid>56662638700</authid><authname>Shin D.</authname><surname>Shin</surname><given-name>Dae Hee</given-name><initials>D.H.</initials><afid>60032624</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:26650958300</author-url><authid>26650958300</authid><authname>Lee C.</authname><surname>Lee</surname><given-name>Changkun</given-name><initials>C.</initials><afid>60032624</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7408122278</author-url><authid>7408122278</authid><authname>Choi S.</authname><surname>Choi</surname><given-name>Si Wan</given-name><initials>S.W.</initials><afid>60005732</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:36066387900</author-url><authid>36066387900</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Jae Hwan</given-name><initials>J.H.</initials><afid>60005732</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:35261557400</author-url><authid>35261557400</authid><authname>Cho Y.</authname><surname>Cho</surname><given-name>Yoon Haeng</given-name><initials>Y.H.</initials><afid>60025615</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7402721998</author-url><authid>7402721998</authid><authname>Lee N.</authname><surname>Lee</surname><given-name>Nae Hee</given-name><initials>N.H.</initials><afid>60025615</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7102344356</author-url><authid>7102344356</authid><authname>Jeong M.</authname><surname>Jeong</surname><given-name>Myung Ho</given-name><initials>M.H.</initials><afid>108036540</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7202402413</author-url><authid>7202402413</authid><authname>Ahn Y.</authname><surname>Ahn</surname><given-name>Youngkeun</given-name><initials>Y.</initials><afid>108036540</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:7006463778</author-url><authid>7006463778</authid><authname>Kubica J.</authname><surname>Kubica</surname><given-name>Jacek</given-name><initials>J.</initials><afid>60024615</afid></author><author seq="19"><author-url>http://api.elsevier.com/content/author/author_id:56664664900</author-url><authid>56664664900</authid><authname>Gurbel P.</authname><surname>Gurbel</surname><given-name>Paul A.</given-name><initials>P.A.</initials><afid>60009471</afid></author><author seq="20"><author-url>http://api.elsevier.com/content/author/author_id:36063048400</author-url><authid>36063048400</authid><authname>Park J.</authname><surname>Park</surname><given-name>Jae Hyeong</given-name><initials>J.H.</initials><afid>60005732</afid></author><author seq="21"><author-url>http://api.elsevier.com/content/author/author_id:24758957500</author-url><authid>24758957500</authid><authname>Jeong Y.</authname><surname>Jeong</surname><given-name>Young Hoon</given-name><initials>Y.H.</initials><afid>60009471</afid><afid>60023075</afid></author><author seq="21"><author-url>http://api.elsevier.com/content/author/author_id:24758957500</author-url><authid>24758957500</authid><authname>Jeong Y.</authname><surname>Jeong</surname><given-name>Young Hoon</given-name><initials>Y.H.</initials><afid>60009471</afid><afid>60023075</afid></author><authkeywords>Acute coronary syndrome | Cilostazol | Inflammation | Myonecrosis | Platelet</authkeywords><intid>1786088228</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930212054"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930212054?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930212054&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930212054&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315006713"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930212054</prism:url><dc:identifier>SCOPUS_ID:84930212054</dc:identifier><eid>2-s2.0-84930212054</eid><dc:title>Empiric slow pathway ablation in suspected but not proven AVNRT: Reply to letter from Dr. Yetkin</dc:title><dc:creator>Shurrab M.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>40</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.408</prism:doi><pii>S0167527315006713</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016849</affiliation-url><afid>60016849</afid><affilname>University of Toronto</affilname><name-variant>University of Toronto</name-variant><affiliation-city>Toronto</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37031998500</author-url><authid>37031998500</authid><authname>Shurrab M.</authname><surname>Shurrab</surname><given-name>Mohammed</given-name><initials>M.</initials><afid>60016849</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56472310500</author-url><authid>56472310500</authid><authname>Newman D.</authname><surname>Newman</surname><given-name>David</given-name><initials>D.</initials><afid>60016849</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35428230600</author-url><authid>35428230600</authid><authname>Crystal E.</authname><surname>Crystal</surname><given-name>Eugene</given-name><initials>E.</initials><afid>60016849</afid></author><authkeywords>AVNRT | Electrophysiology study | Empiric slow pathway ablation</authkeywords><intid>36086404</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930260049"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930260049?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930260049&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930260049&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930260049</prism:url><dc:identifier>SCOPUS_ID:84930260049</dc:identifier><eid>2-s2.0-84930260049</eid><dc:title>Titin mutations: the fall of Goliath</dc:title><dc:creator>Neiva-Sousa M.</dc:creator><prism:publicationName>Heart Failure Reviews</prism:publicationName><prism:issn>13824147</prism:issn><prism:eIssn>15737322</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10741-015-9495-6</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Titin (TTN), the largest protein in the human body, forms powerful elastic filaments along the sarcomere of cardiomyocytes. This multifunctional protein is involved in numerous cellular processes, including sarcomeric assembly, stabilization and mechanosensing. Along physiological sarcomere lengths, TTN is also the most important determinant of the passive tension of cardiac muscle. However, as the giant Goliath was brought down by David’s slingshot, so single-base-pair mutations in the gene encoding TTN (TTN) can ultimately impair to some degree a normal cardiac function. Since the first report on the involvement of TTN mutations in the development of hypertrophic cardiomyopathy, in 1999, dozens of other mutations have been described and associated with the onset of cardiac disease. In this review, we aim to explore some of the mechanisms underlying the functions of TTN, as well as the pathophysiological consequences arising from the expression of abnormal TTN isoforms resulting from mutations located along TTN.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Porto</affilname><name-variant>Department of Physiology and Cardiothoracic Surgery</name-variant><name-variant>Faculty of Medicine</name-variant><affiliation-city>Porto</affiliation-city><affiliation-country>Portugal</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55875468700</author-url><authid>55875468700</authid><authname>Neiva-Sousa M.</authname><surname>Neiva-Sousa</surname><given-name>Manuel</given-name><initials>M.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55875489300</author-url><authid>55875489300</authid><authname>Almeida-Coelho J.</authname><surname>Almeida-Coelho</surname><given-name>João</given-name><initials>J.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:12771795000</author-url><authid>12771795000</authid><authname>Falcão-Pires I.</authname><surname>Falcão-Pires</surname><given-name>Inês</given-name><initials>I.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35448017900</author-url><authid>35448017900</authid><authname>Leite-Moreira A.</authname><surname>Leite-Moreira</surname><given-name>Adelino F.</given-name><initials>A.F.</initials><afid/></author><authkeywords>Cardiomyopathies | Mutations | Sarcomerogenesis | Titin</authkeywords><intid>1036087337</intid><source-id>23234</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930259955"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930259955?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930259955&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930259955&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930259955</prism:url><dc:identifier>SCOPUS_ID:84930259955</dc:identifier><eid>2-s2.0-84930259955</eid><dc:title>Cardiac stem cell therapy: Have we put too much hype in which cell type to use?</dc:title><dc:creator>Ye J.</dc:creator><prism:publicationName>Heart Failure Reviews</prism:publicationName><prism:issn>13824147</prism:issn><prism:eIssn>15737322</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s10741-015-9494-7</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Injection of various stem cells has been tested with the hopes of improving cardiac function after a myocardial infarction (MI). However, there is continued controversy as to which cell type is best for repair. Due to technical differences in cell isolation, processing, delivery, and cardiac functional assessment by various investigators, it has been difficult to directly compare the results of different cells. Using same techniques to evaluate the efficacy of different cell types, we have separately delivered bone marrow cells (BMCs), cardiospheres (CSs), CS-derived Sca-1&lt;sup&gt;+&lt;/sup&gt;/CD45&lt;sup&gt;−&lt;/sup&gt; cells, human embryonic stem cell-derived cardiomyocytes, and BMC extract into infarcted murine myocardium and found that all of these treatments reduce infarct size and improve cardiac function post-MI similarly without one regimen being superior to another. The beneficial effects appear to be via paracrine influences. Different progenitors lead to improved cardiac function post-MI, but it is premature to hype any specific cell type at this time.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of California</affilname><name-variant>Division of Cardiology</name-variant><name-variant>Department of Medicine</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of California</affilname><name-variant>Cardiovascular Research Institute</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of California</affilname><name-variant>Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663533300</author-url><authid>56663533300</authid><authname>Ye J.</authname><surname>Ye</surname><given-name>Jianqin</given-name><initials>J.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8723082700</author-url><authid>8723082700</authid><authname>Yeghiazarians Y.</authname><surname>Yeghiazarians</surname><given-name>Yerem</given-name><initials>Y.</initials><afid/><afid/><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8723082700</author-url><authid>8723082700</authid><authname>Yeghiazarians Y.</authname><surname>Yeghiazarians</surname><given-name>Yerem</given-name><initials>Y.</initials><afid/><afid/><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8723082700</author-url><authid>8723082700</authid><authname>Yeghiazarians Y.</authname><surname>Yeghiazarians</surname><given-name>Yerem</given-name><initials>Y.</initials><afid/><afid/><afid/></author><authkeywords>Bone marrow cells | Cardiac progenitor cells | Cardiosphere | Cell therapy | Human embryonic stem cells</authkeywords><intid>36091383</intid><source-id>23234</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930255263"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930255263?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930255263&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930255263&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930255263</prism:url><dc:identifier>SCOPUS_ID:84930255263</dc:identifier><eid>2-s2.0-84930255263</eid><dc:title>Association between ventricular arrhythmias and myocardial mechanical dispersion assessed by strain analysis in patients with nonischemic cardiomyopathy</dc:title><dc:creator>Kosiuk J.</dc:creator><prism:publicationName>Clinical Research in Cardiology</prism:publicationName><prism:issn>18610684</prism:issn><prism:eIssn>18610692</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00392-015-0875-7</prism:doi><dc:description>© 2015 Springer-Verlag Berlin Heidelberg Background: Mechanical dispersion (MD), defined as the standard deviation of time to maximum myocardial shortening assessed by 2D speckle tracking echocardiographic strain imaging (2DS), has been recently proposed as a predictor for ventricular tachycardia or fibrillation (VT/VF) in patients with ischemic cardiomyopathy and long QT syndrome. However, the role of MD in patients with non-ischemic cardiomyopathy (NICM) has not yet been studied. Methods and results: In 20 patients with NICM (mean age 62 ± 11 years, 75 % male, mean EF 32 ± 6 %, mean QRS duration 102 ± 14 ms), we measured longitudinal strain by 2DS in a 16-segment left ventricular model and calculated the MD. Patients were divided into two groups, defined by the presence or absence of documented VT/VF. In 11 patients (55 %), VT/VF was documented. The median time from VT/VF to echocardiographic examination was 26 (IQR 15–58) months. There were no significant differences in baseline characteristics between patients with and without index events. MD was significantly greater in patients with VT/VF as compared to those without arrhythmias (84 ± 31 ms vs. 53 ± 16 ms, p = 0.017). The analysis of the ROC curve (AUC 0.81, 95 % CI 0.63–1.00, p = 0.017) revealed that dispersion &gt;50 ms is associated with twelve times higher risk of VT/VF in patients with NICM (OR 12.5, 95 % CI 1.1–143.4, p = 0.024). Conclusions: In this small cohort of NICM patients, greater MD was associated with a higher incidence of VT/VF.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Heart Center Leipzig</affilname><name-variant>Department of Electrophysiology</name-variant><affiliation-city>Leipzig</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Agaplesion Diakonie Kliniken Kassel</affilname><affiliation-city>Kassel</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55237676500</author-url><authid>55237676500</authid><authname>Kosiuk J.</authname><surname>Kosiuk</surname><given-name>Jedrzej</given-name><initials>J.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:13907095400</author-url><authid>13907095400</authid><authname>Dinov B.</authname><surname>Dinov</surname><given-name>Borislav</given-name><initials>B.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003870797</author-url><authid>7003870797</authid><authname>Bollmann A.</authname><surname>Bollmann</surname><given-name>Andreas</given-name><initials>A.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23467507300</author-url><authid>23467507300</authid><authname>Koutalas E.</authname><surname>Koutalas</surname><given-name>Emmanuel</given-name><initials>E.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36466949300</author-url><authid>36466949300</authid><authname>Mussigbrodt A.</authname><surname>Mussigbrodt</surname><given-name>Andreas</given-name><initials>A.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56509138700</author-url><authid>56509138700</authid><authname>Sommer P.</authname><surname>Sommer</surname><given-name>Phillipp</given-name><initials>P.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8561680800</author-url><authid>8561680800</authid><authname>Arya A.</authname><surname>Arya</surname><given-name>Arash</given-name><initials>A.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:9238883300</author-url><authid>9238883300</authid><authname>Richter S.</authname><surname>Richter</surname><given-name>Sergio</given-name><initials>S.</initials><afid/></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56427679300</author-url><authid>56427679300</authid><authname>Hindricks G.</authname><surname>Hindricks</surname><given-name>Gerhard</given-name><initials>G.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6604004683</author-url><authid>6604004683</authid><authname>Breithardt O.</authname><surname>Breithardt</surname><given-name>Ole A.</given-name><initials>O.A.</initials><afid/><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6604004683</author-url><authid>6604004683</authid><authname>Breithardt O.</authname><surname>Breithardt</surname><given-name>Ole A.</given-name><initials>O.A.</initials><afid/><afid/></author><authkeywords>Echocardiography | Mechanical dispersion | Speckle tracking | Ventricular arrhythmias</authkeywords><intid>1036087333</intid><source-id>3100147501</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930260878"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930260878?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930260878&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930260878&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930260878</prism:url><dc:identifier>SCOPUS_ID:84930260878</dc:identifier><eid>2-s2.0-84930260878</eid><dc:title>Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials</dc:title><dc:creator>Angiolillo D.</dc:creator><prism:publicationName>Journal of Thrombosis and Thrombolysis</prism:publicationName><prism:issn>09295305</prism:issn><prism:eIssn>1573742X</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11239-015-1233-3</prism:doi><dc:description>© 2015 Springer Science+Business Media New York Overdosing of parenteral antithrombotic therapies can increase the risk of bleeding. Cangrelor is a potent intravenous platelet P2Y&lt;inf&gt;12&lt;/inf&gt; receptor antagonist with rapid onset and offset of action. In patients undergoing percutaneous coronary interventions (PCI), compared with control, cangrelor (30 µg/kg bolus, followed immediately by a 4 µg/kg per minute infusion for 2–4 h or until the conclusion of the index PCI, whichever was longer) reduces periprocedural thrombotic complications without an increase in major bleeding complications, although minor bleeding is increased. The impact of cangrelor overdosing on bleeding is unknown and represented the aim of this analysis. Patients with cangrelor overdosing were identified among safety population patients enrolled in the CHAMPION program (n = 25,107). Overdose was defined as administration of an excess &gt;20 % of the bolus dose (30 μg/kg) and/or infusion rate (4 μg/kg per min). Bleeding complications were assessed. Among the safety analysis population in the CHAMPION program, 12,565 patients received cangrelor. A total of 36 overdosed cangrelor patients (0.29 %) were identified in this pooled analysis (20 with both bolus and infusion, 5 with bolus only, and 11 with infusion only). In the majority of patients, the dose did not exceed 2.5 times the recommended dose. Bleeding events were balanced between treatment arms and were consistent with those in the overall CHAMPION program. Only one overdosed patient experienced a serious bleed. There was no correlation between bleeding and magnitude of cangrelor overdose. In a large clinical trial program of patients undergoing PCI, cangrelor overdosing was rare and not associated with an increase in bleeding complications, an observation that may be attributed to its very short-half life and rapid offset of action.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Florida College of Medicine–Jacksonville</affilname><affiliation-city>Jacksonville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Brigham and Women’s Hospital Heart &amp; Vascular Center and Harvard Medical School</affilname><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>INSERM U1148</affilname><name-variant>Université Paris-Diderot</name-variant><name-variant>DHU FIRE</name-variant><name-variant>Hôpital Bichat</name-variant><name-variant>AP-HP</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Royal Brompton Hospital</affilname><name-variant>NHLI</name-variant><name-variant>Imperial College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Columbia University Medical Center and the Cardiovascular Research Foundation</affilname><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Auckland City Hospital and Green Lane Cardiovascular Service</affilname><affiliation-city>Auckland</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Beth Israel Deaconess Medical Center</affilname><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Kerckhoff Heart Center</affilname><affiliation-city>Bad Nauheim</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Scripps Clinic</affilname><affiliation-city>La Jolla</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>The Medicines Company</affilname><affiliation-city>Parsippany</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Stanford University Medical School</affilname><affiliation-city>Stanford</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701541904</author-url><authid>6701541904</authid><authname>Angiolillo D.</authname><surname>Angiolillo</surname><given-name>Dominick J.</given-name><initials>D.J.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663943300</author-url><authid>56663943300</authid><authname>Bhatt D.</authname><surname>Bhatt</surname><given-name>Deepak L.</given-name><initials>D.L.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35373935400</author-url><authid>35373935400</authid><authname>Steg P.</authname><surname>Steg</surname><given-name>Ph Gabriel</given-name><initials>P.G.</initials><afid/><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35373935400</author-url><authid>35373935400</authid><authname>Steg P.</authname><surname>Steg</surname><given-name>Ph Gabriel</given-name><initials>P.G.</initials><afid/><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663851000</author-url><authid>56663851000</authid><authname>Stone G.</authname><surname>Stone</surname><given-name>Gregg W.</given-name><initials>G.W.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55102122700</author-url><authid>55102122700</authid><authname>White H.</authname><surname>White</surname><given-name>Harvey D.</given-name><initials>H.D.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:13407121600</author-url><authid>13407121600</authid><authname>Gibson C.</authname><surname>Gibson</surname><given-name>C. Michael</given-name><initials>C.M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56657201400</author-url><authid>56657201400</authid><authname>Hamm C.</authname><surname>Hamm</surname><given-name>Christian W.</given-name><initials>C.W.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8632925300</author-url><authid>8632925300</authid><authname>Price M.</authname><surname>Price</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid/></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:54900643000</author-url><authid>54900643000</authid><authname>Prats J.</authname><surname>Prats</surname><given-name>Jayne</given-name><initials>J.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55492917600</author-url><authid>55492917600</authid><authname>Liu T.</authname><surname>Liu</surname><given-name>Tiepu</given-name><initials>T.</initials><afid/></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:55603917500</author-url><authid>55603917500</authid><authname>Mahaffey K.</authname><surname>Mahaffey</surname><given-name>Kenneth W.</given-name><initials>K.W.</initials><afid/></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56663844400</author-url><authid>56663844400</authid><authname>Harrington R.</authname><surname>Harrington</surname><given-name>Robert A.</given-name><initials>R.A.</initials><afid/></author><authkeywords>Antiplatelet | Cangrelor | Overdosing | PCI</authkeywords><intid>536093737</intid><source-id>23899</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930170727"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930170727?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930170727&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930170727&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930170727</prism:url><dc:identifier>SCOPUS_ID:84930170727</dc:identifier><eid>2-s2.0-84930170727</eid><dc:title>Type 2 diabetes mellitus and myocardial ischemic preconditioning in symptomatic coronary artery disease patients</dc:title><dc:creator>Rezende P.</dc:creator><prism:publicationName>Cardiovascular Diabetology</prism:publicationName><prism:eIssn>14752840</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>May 30, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12933-015-0228-x</prism:doi><dc:description>© 2015 Rezende et al. Background: The influence of diabetes mellitus on myocardial ischemic preconditioning is not clearly defined. Experimental studies are conflicting and human studies are scarce and inconclusive. Objectives: Identify whether diabetes mellitus intervenes on ischemic preconditioning in symptomatic coronary artery disease patients. Methods: Symptomatic multivessel coronary artery disease patients with preserved systolic ventricular function and a positive exercise test underwent two sequential exercise tests to demonstrate ischemic preconditioning. Ischemic parameters were compared among patients with and without type 2 diabetes mellitus. Ischemic preconditioning was considered present when the time to 1.0 mm ST deviation and rate pressure-product were greater in the second of 2 exercise tests. Sequential exercise tests were analyzed by 2 independent cardiologists. Results: Of the 2,140 consecutive coronary artery disease patients screened, 361 met inclusion criteria, and 174 patients (64.2 ± 7.6 years) completed the study protocol. Of these, 86 had the diagnosis of type 2 diabetes. Among diabetic patients, 62 (72 %) manifested an improvement in ischemic parameters consistent with ischemic preconditioning, whereas among nondiabetic patients, 60 (68 %) manifested ischemic preconditioning (p = 0.62). The analysis of patients who demonstrated ischemic preconditioning showed similar improvement in the time to 1.0 mm ST deviation between diabetic and nondiabetic groups (79.4 ± 47.6 vs 65.5 ± 36.4 s, respectively, p = 0.12). Regarding rate pressure-product, the improvement was greater in diabetic compared to nondiabetic patients (3011 ± 2430 vs 2081 ± 2139 bpm x mmHg, respectively, p = 0.01). Conclusions: In this study, diabetes mellitus was not associated with impairment in ischemic preconditioning in symptomatic coronary artery disease patients. Furthermore, diabetic patients experienced an improvement in this significant mechanism of myocardial protection.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of São Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">14</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36545178300</author-url><authid>36545178300</authid><authname>Rezende P.</authname><surname>Rezende</surname><given-name>Paulo Cury</given-name><initials>P.C.</initials><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55989137600</author-url><authid>55989137600</authid><authname>Rahmi R.</authname><surname>Rahmi</surname><given-name>Rosa Maria</given-name><initials>R.M.</initials><afid>60008088</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202071538</author-url><authid>7202071538</authid><authname>Uchida A.</authname><surname>Uchida</surname><given-name>Augusto Hiroshi</given-name><initials>A.H.</initials><afid>60008088</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55990082800</author-url><authid>55990082800</authid><authname>da Costa L.</authname><surname>da Costa</surname><given-name>Leandro Menezes Alves</given-name><initials>L.M.A.</initials><afid>60008088</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55855260800</author-url><authid>55855260800</authid><authname>Scudeler T.</authname><surname>Scudeler</surname><given-name>Thiago Luis</given-name><initials>T.L.</initials><afid>60008088</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602745346</author-url><authid>6602745346</authid><authname>Garzillo C.</authname><surname>Garzillo</surname><given-name>Cibele Larrosa</given-name><initials>C.L.</initials><afid>60008088</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36573050800</author-url><authid>36573050800</authid><authname>Lima E.</authname><surname>Lima</surname><given-name>Eduardo Gomes</given-name><initials>E.G.</initials><afid>60008088</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:14025921300</author-url><authid>14025921300</authid><authname>Segre C.</authname><surname>Segre</surname><given-name>Carlos Alexandre Wainrober</given-name><initials>C.A.W.</initials><afid>60008088</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:16743603700</author-url><authid>16743603700</authid><authname>Girardi P.</authname><surname>Girardi</surname><given-name>Priscyla</given-name><initials>P.</initials><afid>60008088</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:15926585600</author-url><authid>15926585600</authid><authname>Takiuti M.</authname><surname>Takiuti</surname><given-name>Myrthes</given-name><initials>M.</initials><afid>60008088</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56661603200</author-url><authid>56661603200</authid><authname>Silva M.</authname><surname>Silva</surname><given-name>Marcela Francisca</given-name><initials>M.F.</initials><afid>60008088</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7004252687</author-url><authid>7004252687</authid><authname>Hueb W.</authname><surname>Hueb</surname><given-name>Whady</given-name><initials>W.</initials><afid>60008088</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:19435615400</author-url><authid>19435615400</authid><authname>Ramires J.</authname><surname>Ramires</surname><given-name>Jose Antonio Franchini</given-name><initials>J.A.F.</initials><afid>60008088</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:36570334700</author-url><authid>36570334700</authid><authname>Filho R.</authname><surname>Filho</surname><given-name>Roberto Kalil</given-name><initials>R.K.</initials><afid>60008088</afid></author><authkeywords>Coronary artery disease | Diabetes mellitus | Ischemic preconditioning | Myocardial ischemia</authkeywords><intid>2036071870</intid><source-id>25441</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930255253"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930255253?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930255253&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930255253&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930255253</prism:url><dc:identifier>SCOPUS_ID:84930255253</dc:identifier><eid>2-s2.0-84930255253</eid><dc:title>Serum hyaluronic acid in chronic viral hepatitis B and C: a biomarker for assessing liver fibrosis in chronic hemodialysis patients</dc:title><dc:creator>Orăşan O.</dc:creator><prism:publicationName>International Urology and Nephrology</prism:publicationName><prism:issn>03011623</prism:issn><prism:eIssn>15732584</prism:eIssn><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11255-015-1017-x</prism:doi><dc:description>© 2015 Springer Science+Business Media Dordrecht Purpose: Serum hyaluronic acid (sHA) is studied as a noninvasive marker of liver fibrosis (F) in chronic B and C viral hepatitis in general population but less in end-stage renal disease patients undergoing hemodialysis.Methods: We evaluated sHA as a noninvasive biomarker of F in a multicenter prospective, transversal, and observational study which included 52 end-stage renal disease patients with chronic B (14) and C (38) viral hepatitis (age 55.57 ± 14.46 years, dialysis vintage 132.59 ± 86.02 months).Results: Of the noninvasive tests analyzed, only sHA, APRI, and FIB4 index were able to differentiate patients with F1 (sHA p = 0.006; APRI p = 0.031; FIB4 p = 0.016). No statistically significant differences were found between sHA and APRI, ASAT/ALAT ratio, and FIB4 index in detecting F1 a (p &gt; 0.02). sHA seemed to be more efficient than APRI, ASAT/ALAT ratio, and FIB4 index, having the highest estimated AUC value. The sHA threshold value for F1 was equal to 33.46 ng/mL, with the following estimated values of the performance indicators: Se 88.46 % and Sp 50 %. sHA was the only noninvasive test of the studied tests that could determine F2 (p = 0.002), with a threshold value of 80.24 ng/mL (Se 63 %, Sp 88 %), and F3 (p = 0.008), with a threshold value of 88.54 ng/mL (Se 60 %, Sp 84 %). None of the studied noninvasive tests could determine F4. Conclusions: In patients with chronic B and C viral hepatitis undergoing hemodialysis, sHA may be a useful biomarker for the liver fibrosis grades: F1—mild, F2—moderate, and F3—severe, but it does not differentiate between chronic hepatitis (F1–F3) and liver cirrhosis (F4).</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><name-variant>4th Medical Department</name-variant><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><name-variant>Medical Informatics and Biostatistics</name-variant><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><name-variant>Heart Institute</name-variant><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><name-variant>4th Surgical Department</name-variant><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Nefromed Dialysis Centers</affilname><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>University of Medicine and Pharmacy</affilname><name-variant>2nd Medical Department</name-variant><affiliation-city>Cluj-Napoca</affiliation-city><affiliation-country>Romania</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35743577200</author-url><authid>35743577200</authid><authname>Orăşan O.</authname><surname>Orăşan</surname><given-name>Olga Hilda</given-name><initials>O.H.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664209500</author-url><authid>56664209500</authid><authname>Sava M.</authname><surname>Sava</surname><given-name>Mădălina</given-name><initials>M.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56664225900</author-url><authid>56664225900</authid><authname>Iancu M.</authname><surname>Iancu</surname><given-name>Mihaela</given-name><initials>M.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8251934500</author-url><authid>8251934500</authid><authname>Cozma A.</authname><surname>Cozma</surname><given-name>Angela</given-name><initials>A.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56260833900</author-url><authid>56260833900</authid><authname>Saplonţai-Pop A.</authname><surname>Saplonţai-Pop</surname><given-name>Aniela</given-name><initials>A.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56664478400</author-url><authid>56664478400</authid><authname>Sarlea Ţărmure S.</authname><surname>Sarlea Ţărmure</surname><given-name>Simina</given-name><initials>S.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6506609517</author-url><authid>6506609517</authid><authname>Lungoci C.</authname><surname>Lungoci</surname><given-name>Corneliu</given-name><initials>C.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56621475300</author-url><authid>56621475300</authid><authname>Orăşan R.</authname><surname>Orăşan</surname><given-name>Remus Aurel</given-name><initials>R.A.</initials><afid/></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6603360910</author-url><authid>6603360910</authid><authname>Patiu I.</authname><surname>Patiu</surname><given-name>Ioan Mihai</given-name><initials>I.M.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56664091400</author-url><authid>56664091400</authid><authname>Dumitraşcu D.</authname><surname>Dumitraşcu</surname><given-name>Dan Lucian</given-name><initials>D.L.</initials><afid/></author><authkeywords>Biomarker for fibrosis | Chronic viral hepatitis | Hemodialysis | Serum hyaluronic acid</authkeywords><intid>2036087500</intid><source-id>19946</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929207734"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929207734?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929207734&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929207734&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929207734</prism:url><dc:identifier>SCOPUS_ID:84929207734</dc:identifier><eid>2-s2.0-84929207734</eid><dc:title>Clinical analysis of pulmonary cryptococcosis in non-HIV patients in south China</dc:title><dc:creator>Xie X.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3114-3119</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Aims: The aim of this study was to investigate the clinical characteristics of pulmonary cryptococcosis occurring in non-HIV patients, and to develop early diagnosis of pulmonary cryptococcosis in immunocompetent cases as well. Methods: We retrospectively reviewed the clinical data of 41 non-HIV infected patients with pulmonary cryptococcosis who were admitted to the First Affiliated Hospital of Wenzhou Medical University from January 2006 to April 2014. Results: The study included a total of 41 patients (23 males and 18 females) with mean age of 47 years. 12.19% of patients had a history of direct exposure to pigeon droppings; 31.70% of the patients’ working or living environments were potentially contaminated by fungal spores. Almost one-third of the patients involved into the study were asymptomatic. The most common clinical manifestations were cough, expectoration and hemoptysis. The most common radiological manifestation was single node or mass in lung, which was described as untypical. Of all cases, 11 patients were diagnosed by CT-guided percutaneous cutting needle biopsy (PCNB), 5 patients were diagnosed by operation, and Crytococcus spore was found in 7 patients’ cerebrospinal fluid. 8 patients’ blood Cryptococcus Neoformans capsular polysaccharide antigens latex agglutination tests were positive. 36 patients received antifungal therapy. 5 patients underwent surgical resection. During 6 to 24 months follow-up, 40 cases showed total recovery and 1 cases showed improvement. Conclusions: Pulmonary cryptococcosis in non-HIV subjects might be related to fungus-contaminated environmental exposure. The great variations and protean manifestations of its clinical features often lead to misdiagnosis. Recognition and invasive examination of non-HIV infected patients’ pulmonary cryptococcosis in the early stage may help with improvement of its diagnosis and prognosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008073</affiliation-url><afid>60008073</afid><affilname>Wenzhou Medical College</affilname><name-variant>Wenzhou Medical College</name-variant><affiliation-city>Wenzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008073</affiliation-url><afid>60008073</afid><affilname>Wenzhou Medical College</affilname><name-variant>Wenzhou Medical College</name-variant><affiliation-city>Wenzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008073</affiliation-url><afid>60008073</afid><affilname>Wenzhou Medical College</affilname><name-variant>Wenzhou Medical College</name-variant><affiliation-city>Wenzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640274700</author-url><authid>56640274700</authid><authname>Xie X.</authname><surname>Xie</surname><given-name>Xiaona</given-name><initials>X.</initials><afid>60008073</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640218700</author-url><authid>56640218700</authid><authname>Xu B.</authname><surname>Xu</surname><given-name>Botao</given-name><initials>B.</initials><afid>60008073</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24279168000</author-url><authid>24279168000</authid><authname>Yu C.</authname><surname>Yu</surname><given-name>Chang</given-name><initials>C.</initials><afid>60008073</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56580604800</author-url><authid>56580604800</authid><authname>Chen M.</authname><surname>Chen</surname><given-name>Mayun</given-name><initials>M.</initials><afid>60008073</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35286107700</author-url><authid>35286107700</authid><authname>Yao D.</authname><surname>Yao</surname><given-name>Dan</given-name><initials>D.</initials><afid>60008073</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55706277700</author-url><authid>55706277700</authid><authname>Xu X.</authname><surname>Xu</surname><given-name>Xiaomei</given-name><initials>X.</initials><afid>60008073</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55212060000</author-url><authid>55212060000</authid><authname>Cai X.</authname><surname>Cai</surname><given-name>Xueding</given-name><initials>X.</initials><afid>60008073</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55128478400</author-url><authid>55128478400</authid><authname>Ding C.</authname><surname>Ding</surname><given-name>Cheng</given-name><initials>C.</initials><afid>60008073</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55949780100</author-url><authid>55949780100</authid><authname>Wang L.</authname><surname>Wang</surname><given-name>Liangxing</given-name><initials>L.</initials><afid>60008073</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7410247144</author-url><authid>7410247144</authid><authname>Huang X.</authname><surname>Huang</surname><given-name>Xiaoying</given-name><initials>X.</initials><afid>60008073</afid></author><authkeywords>Clinical characteristics | Diagnosis | Non-HIV patients | Pulmonary cryptococcosis | Radiographic features</authkeywords><intid>35916493</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930082128"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930082128?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930082128&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930082128&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000613"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930082128</prism:url><dc:identifier>SCOPUS_ID:84930082128</dc:identifier><eid>2-s2.0-84930082128</eid><dc:title>Targeting caveolin-3 for the treatment of diabetic cardiomyopathy</dc:title><dc:creator>Murfitt L.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>50-71</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.03.002</prism:doi><pii>S0163725815000613</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Diabetes is a global health problem with more than 550 million people predicted to be diabetic by 2030. A major complication of diabetes is cardiovascular disease, which accounts for over two-thirds of mortality and morbidity in diabetic patients. This increased risk has led to the definition of a diabetic cardiomyopathy phenotype characterised by early left ventricular dysfunction with normal ejection fraction. Here we review the aetiology of diabetic cardiomyopathy and explore the involvement of the protein caveolin-3 (Cav3). Cav3 forms part of a complex mechanism regulating insulin signalling and glucose uptake, processes that are impaired in diabetes. Further, Cav3 is key for stabilisation and trafficking of cardiac ion channels to the plasma membrane and so contributes to the cardiac action potential shape and duration. In addition, Cav3 has direct and indirect interactions with proteins involved in excitation-contraction coupling and so has the potential to influence cardiac contractility. Significantly, both impaired contractility and rhythm disturbances are hallmarks of diabetic cardiomyopathy. We review here how changes to Cav3 expression levels and altered relationships with interacting partners may be contributory factors to several of the pathological features identified in diabetic cardiomyopathy. Finally, the review concludes by considering ways in which levels of Cav3 may be manipulated in order to develop novel therapeutic approaches for treating diabetic cardiomyopathy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003771</affiliation-url><afid>60003771</afid><affilname>University of Manchester</affilname><name-variant>University of Manchester</name-variant><affiliation-city>Manchester</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020934</affiliation-url><afid>60020934</afid><affilname>Liverpool School of Tropical Medicine</affilname><name-variant>Liverpool School of Tropical Medicine</name-variant><affiliation-city>Liverpool</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:51562223300</author-url><authid>51562223300</authid><authname>Murfitt L.</authname><surname>Murfitt</surname><given-name>Lucy</given-name><initials>L.</initials><afid>60003771</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55502376900</author-url><authid>55502376900</authid><authname>Whiteley G.</authname><surname>Whiteley</surname><given-name>Gareth</given-name><initials>G.</initials><afid>60003771</afid><afid>60020934</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55502376900</author-url><authid>55502376900</authid><authname>Whiteley G.</authname><surname>Whiteley</surname><given-name>Gareth</given-name><initials>G.</initials><afid>60003771</afid><afid>60020934</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56572010500</author-url><authid>56572010500</authid><authname>Iqbal M.</authname><surname>Iqbal</surname><given-name>Mohammad M.</given-name><initials>M.M.</initials><afid>60003771</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6602176564</author-url><authid>6602176564</authid><authname>Kitmitto A.</authname><surname>Kitmitto</surname><given-name>Ashraf</given-name><initials>A.</initials><afid>60003771</afid></author><authkeywords>Cardiac remodelling | Caveolin-3 | Diabetes | Diabetic cardiomyopathy | Excitation-contraction coupling</authkeywords><intid>36062106</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930048372"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930048372?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930048372&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930048372&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930048372</prism:url><dc:identifier>SCOPUS_ID:84930048372</dc:identifier><eid>2-s2.0-84930048372</eid><dc:title>Functional Characterization of Oscillatory and Excitable Media</dc:title><dc:creator>Glass L.</dc:creator><prism:publicationName>Bulletin of Mathematical Biology</prism:publicationName><prism:issn>00928240</prism:issn><prism:eIssn>15229602</prism:eIssn><prism:volume>77</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>782-795</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s11538-014-0015-y</prism:doi><dc:description>© 2014, Society for Mathematical Biology. Cardiac and neural systems share common features of intrinsic oscillation in some cells as well as the ability to propagate excitation. One theoretical approach to study such systems is to develop realistic models for the tissue. This involves first developing detailed ionic “Hodgkin–Huxley”-type models of individual cells and then connecting the individual cells via synaptic and gap junctions in realistic geometries. An alternative approach is to characterize tissue in terms of functional properties such as phase resetting curves and restitution curves. Using simple models based on one-dimensional difference equations, the measured functional curves can be used to predict, analyze, and interpret nonlinear dynamical phenomena. This approach offers the prospects of providing simplified descriptions that offer insight into the experimental and clinical cardiac dynamics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002494</affiliation-url><afid>60002494</afid><affilname>McGill University</affilname><name-variant>McGill University</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7101922454</author-url><authid>7101922454</authid><authname>Glass L.</authname><surname>Glass</surname><given-name>Leon</given-name><initials>L.</initials><afid>60002494</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005657095</author-url><authid>7005657095</authid><authname>Shrier A.</authname><surname>Shrier</surname><given-name>Alvin</given-name><initials>A.</initials><afid>60002494</afid></author><authkeywords>Phase resetting | Recovery | Restitution</authkeywords><intid>1036052779</intid><source-id>13845</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211298"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211298?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211298&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211298&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315009249"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211298</prism:url><dc:identifier>SCOPUS_ID:84930211298</dc:identifier><eid>2-s2.0-84930211298</eid><dc:title>The effectiveness of perindopril vs. lisinopril on reducing the incidence of diabetes and renal diseases: A cohort study of 20,252 patients</dc:title><dc:creator>Wong M.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>384-388</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.191</prism:doi><pii>S0167527315009249</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Lisinopril and perindopril are two commonly used first-line antihypertensive agents. Few studies compared their effectiveness in reducing the incidence of renal diseases and diabetes. Methods Adult patients who received new prescriptions of lisinopril or perindopril from 2001 to 2005 in all public hospitals and clinics in Hong Kong were included, and followed up for at least 2 years. Patients prescribed the angiotensin converting enzyme inhibitors (ACEIs) for &lt; 1 month were excluded. The incidence of admissions due to renal diseases and diabetes was evaluated. We used Cox proportional hazard regression models to assess hospital admissions as the outcome measures, adjusting for age, sex, socioeconomic status, service types, and the proportion of days covered as a measure of medication adherence. The regression models were constructed with propensity score matching to minimize indication biases. Results 20,252 eligible patients with an average age of 64.5 years (SD 15.0) were included. The admission rates 24 months within the date of index prescription due to renal diseases were 3.1% (lisinopril) and 2.3% (perindopril); and 9.6% (lisinopril) and 7.2% (perindopril) for diabetes. Except for admissions due to diabetes at 6 months, lisinopril users were significantly more likely to be admitted due to renal diseases (adjusted hazard ratios: 1.304 to 1.378) and diabetes (1.146 to 1.231) than perindopril users at all time points. Conclusions Patients prescribed different ACEIs might have a different incidence of hospital admissions. Future studies should be conducted to evaluate the comparative effectiveness of different ACEIs on various patient-centered outcomes by head-to-head randomized controlled trials.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026680</affiliation-url><afid>60026680</afid><affilname>Yong Loo Lin School of Medicine</affilname><name-variant>National University of</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001490</affiliation-url><afid>60001490</afid><affilname>University of Glasgow</affilname><name-variant>University of Glasgow</name-variant><affiliation-city>Glasgow</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60081583</affiliation-url><afid>60081583</afid><affilname>Hong Kong Hospital Authority</affilname><name-variant>Hong Kong Hospital Authority</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002798</affiliation-url><afid>60002798</afid><affilname>Chinese University of Hong Kong</affilname><name-variant>The Chinese University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16945015000</author-url><authid>16945015000</authid><authname>Wong M.</authname><surname>Wong</surname><given-name>Martin C S</given-name><initials>M.C.S.</initials><afid>60002798</afid><afid>60002798</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16945015000</author-url><authid>16945015000</authid><authname>Wong M.</authname><surname>Wong</surname><given-name>Martin C S</given-name><initials>M.C.S.</initials><afid>60002798</afid><afid>60002798</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:9740867000</author-url><authid>9740867000</authid><authname>Tam W.</authname><surname>Tam</surname><given-name>Wilson W S</given-name><initials>W.W.S.</initials><afid>60026680</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54786103800</author-url><authid>54786103800</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Harry H X</given-name><initials>H.H.X.</initials><afid>60002798</afid><afid>60001490</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:54786103800</author-url><authid>54786103800</authid><authname>Wang H.</authname><surname>Wang</surname><given-name>Harry H X</given-name><initials>H.H.X.</initials><afid>60002798</afid><afid>60001490</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662535900</author-url><authid>56662535900</authid><authname>Zhang D.</authname><surname>Zhang</surname><given-name>Dexing</given-name><initials>D.</initials><afid>60002798</afid><afid>60002798</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662535900</author-url><authid>56662535900</authid><authname>Zhang D.</authname><surname>Zhang</surname><given-name>Dexing</given-name><initials>D.</initials><afid>60002798</afid><afid>60002798</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:23471726500</author-url><authid>23471726500</authid><authname>Cheung C.</authname><surname>Cheung</surname><given-name>Clement S K</given-name><initials>C.S.K.</initials><afid>60081583</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7201858670</author-url><authid>7201858670</authid><authname>Yan B.</authname><surname>Yan</surname><given-name>Bryan P.</given-name><initials>B.P.</initials><afid>60002798</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:19635485200</author-url><authid>19635485200</authid><authname>Leeder S.</authname><surname>Leeder</surname><given-name>Stephen R.</given-name><initials>S.R.</initials><afid>60025709</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35233240400</author-url><authid>35233240400</authid><authname>Griffiths S.</authname><surname>Griffiths</surname><given-name>Sian M.</given-name><initials>S.M.</initials><afid>60002798</afid></author><authkeywords>Diabetes | Hospital admission | Incidence | Lisinopril | Perindopril | Renal disease</authkeywords><intid>1536087332</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930090055"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930090055?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930090055&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930090055&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000455"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930090055</prism:url><dc:identifier>SCOPUS_ID:84930090055</dc:identifier><eid>2-s2.0-84930090055</eid><dc:title>The organ-protective effect of N-type Ca&lt;sup&gt;2+&lt;/sup&gt; channel blockade</dc:title><dc:creator>Kuwahara K.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>1-7</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.02.001</prism:doi><pii>S0163725815000455</pii><dc:description>© 2015 Published by Elsevier Inc. The six subtypes of voltage-dependent Ca&lt;sup&gt;2+&lt;/sup&gt; channels (VDCCs) mediate a wide range of physiological responses. N-type VDCCs (NCCs) were originally identified as a high voltage-activated Ca&lt;sup&gt;2+&lt;/sup&gt; channel selectively blocked by omega-conotoxin (ω-CTX)-GVIA. Predominantly localized in the nervous system, NCCs are key regulators of neurotransmitter release. Both pharmacological blockade with ω-CTX-GVIA and, more recently, mice lacking CNCNA1B, encoding the α1B subunit of NCC, have been used to assess the physiological and pathophysiological functions of NCCs, revealing in part their significant roles in sympathetic nerve activation and nociceptive transmission. The evidence now available indicates that NCCs are a potentially useful therapeutic target for the treatment of several pathological conditions. Efforts are therefore being made to develop effective NCC blockers, including both synthetic ω-CTX-GVIA derivatives and small-molecule inhibitors. Cilnidipine, for example, is a dihydropyridine L-type VDCC blocking agent that also possesses significant NCC blocking ability. As over-activation of the sympathetic nervous system appears to contribute to the pathological processes underlying cardiovascular, renal and metabolic diseases, NCC blockade could be a useful approach to treating these ailments. In this review article, we provide an overview of what is currently known about the physiological and pathophysiological activities of NCCs and the potentially beneficial effects of NCC blockade in several disease conditions, in particular cardiovascular diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030354</affiliation-url><afid>60030354</afid><affilname>Kyoto University Faculty of Medicine</affilname><name-variant>Kyoto University School of Medicine</name-variant><affiliation-city>Kyoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7103119223</author-url><authid>7103119223</authid><authname>Kuwahara K.</authname><surname>Kuwahara</surname><given-name>Koichiro</given-name><initials>K.</initials><afid>60030354</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56431748600</author-url><authid>56431748600</authid><authname>Kimura T.</authname><surname>Kimura</surname><given-name>Takeshi</given-name><initials>T.</initials><afid>60030354</afid></author><authkeywords>Hypertension | N-type Ca&lt;sup&gt;2+&lt;/sup&gt; channel | Sympathetic nerve | Voltage-dependent Ca&lt;sup&gt;2+&lt;/sup&gt; channel</authkeywords><intid>1036058468</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199132"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199132?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199132&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199132&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315007548"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199132</prism:url><dc:identifier>SCOPUS_ID:84930199132</dc:identifier><eid>2-s2.0-84930199132</eid><dc:title>Digoxin use may increase the relative risk of acute pancreatitis</dc:title><dc:creator>Aksu U.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>33</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.035</prism:doi><pii>S0167527315007548</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015566</affiliation-url><afid>60015566</afid><affilname>Ataturk University, Faculty of Medicine</affilname><name-variant>Atatürk University</name-variant><affiliation-city>Erzurum</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113149498</affiliation-url><afid>113149498</afid><affilname>Malkara State Hospital</affilname><name-variant>Malkara State Hospital</name-variant><affiliation-city>Tekirdag</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56644623400</author-url><authid>56644623400</authid><authname>Aksu U.</authname><surname>Aksu</surname><given-name>Ugur</given-name><initials>U.</initials><afid>60015566</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55355185600</author-url><authid>55355185600</authid><authname>Kalkan K.</authname><surname>Kalkan</surname><given-name>Kamuran</given-name><initials>K.</initials><afid>113149498</afid></author><authkeywords>Digoxin | Pancreatitis</authkeywords><intid>1036082153</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193208"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193208?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193208&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193208&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008451"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193208</prism:url><dc:identifier>SCOPUS_ID:84930193208</dc:identifier><eid>2-s2.0-84930193208</eid><dc:title>Metabolic syndrome, major depression, generalized anxiety disorder, and ten-year all-cause and cardiovascular mortality in middle aged and elderly patients</dc:title><dc:creator>Butnoriene J.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>360-366</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.122</prism:doi><pii>S0167527315008451</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Studies investigating specifically whether metabolic syndrome (MetS) and common psychiatric disorders are independently associated with mortality are lacking. In a middle-aged general population, we investigated the association of the MetS, current major depressive episode (MDE), lifetime MDE, and generalized anxiety disorder (GAD) with ten-year all-cause and cardiovascular disease mortality. Methods From February 2003 until January 2004, 1115 individuals aged 45 years and older were randomly selected from a primary care practice and prospectively evaluated for: (1) MetS (The World Health Organization [WHO], National Cholesterol Education Program/Adult Treatment Panel III and International Diabetes Federation [IDF] definitions); (2) current MDE and GAD, and lifetime MDE (Mini International Neuropsychiatric Interview); and (3) conventional cardiovascular risk factors. Follow-up continued through January, 2013. Results During the 9.32 ± 0.47 years of follow-up, there were 248 deaths, of which 148 deaths were attributed to cardiovascular causes. In women, WHO-MetS and IDF-MetS were associated with greater all-cause (HR-values range from 1.77 to 1.91; p-values ≤ 0.012) and cardiovascular (HR-values range from 1.83 to 2.77; p-values ≤ 0.013) mortality independent of cardiovascular risk factors and MDE/GAD. Current GAD predicted greater cardiovascular mortality (HR-values range from 1.86 to 1.99; p-values ≤ 0.025) independently from MetS and cardiovascular risk factors. In men, the MetS and MDE/GAD were not associated with mortality. Conclusions In middle aged women, the MetS and GAD predicted greater 10-year cardiovascular mortality independently from each other; 10-year all-cause mortality was independently predicted by the MetS. MetS and GAD should be considered important and independent mortality risk factors in women.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112198263</affiliation-url><afid>112198263</afid><affilname>Lithuanian University of Health Sciences</affilname><name-variant>Lithuanian University of Health Sciences</name-variant><affiliation-city>Kaunas</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112198263</affiliation-url><afid>112198263</afid><affilname>Lithuanian University of Health Sciences</affilname><name-variant>Lithuanian University of Health Sciences</name-variant><affiliation-city>Kaunas</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60060664</affiliation-url><afid>60060664</afid><affilname>Vytautas Magnus University</affilname><name-variant>Vytautas Magnus University</name-variant><affiliation-city>Kaunas</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021519</affiliation-url><afid>60021519</afid><affilname>University of Miami Leonard M. Miller School of Medicine</affilname><name-variant>University of Miami</name-variant><affiliation-city>Miami</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100344701</affiliation-url><afid>100344701</afid><affilname>Institute of Hygiene</affilname><name-variant>Institute of Hygiene</name-variant><affiliation-city>Vilnius</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112198263</affiliation-url><afid>112198263</afid><affilname>Lithuanian University of Health Sciences</affilname><name-variant>Lithuanian University of Health Sciences</name-variant><affiliation-city>Kaunas</affiliation-city><affiliation-country>Lithuania</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15821938300</author-url><authid>15821938300</authid><authname>Butnoriene J.</authname><surname>Butnoriene</surname><given-name>Jurate</given-name><initials>J.</initials><afid>112198263</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:15623265300</author-url><authid>15623265300</authid><authname>Bunevicius A.</authname><surname>Bunevicius</surname><given-name>Adomas</given-name><initials>A.</initials><afid>112198263</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56121380200</author-url><authid>56121380200</authid><authname>Saudargiene A.</authname><surname>Saudargiene</surname><given-name>Ausra</given-name><initials>A.</initials><afid>60060664</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35355232200</author-url><authid>35355232200</authid><authname>Nemeroff C.</authname><surname>Nemeroff</surname><given-name>Charles B.</given-name><initials>C.B.</initials><afid>60021519</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6603061547</author-url><authid>6603061547</authid><authname>Norkus A.</authname><surname>Norkus</surname><given-name>Antanas</given-name><initials>A.</initials><afid>112198263</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56663301300</author-url><authid>56663301300</authid><authname>Ciceniene V.</authname><surname>Ciceniene</surname><given-name>Vile</given-name><initials>V.</initials><afid>100344701</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602766639</author-url><authid>6602766639</authid><authname>Bunevicius R.</authname><surname>Bunevicius</surname><given-name>Robertas</given-name><initials>R.</initials><afid>112198263</afid></author><authkeywords>Anxiety | Cardiovascular mortality | Depression | Metabolic syndrome</authkeywords><intid>36085524</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226874"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226874?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226874&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226874&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226874</prism:url><dc:identifier>SCOPUS_ID:84930226874</dc:identifier><eid>2-s2.0-84930226874</eid><dc:title>Therapy of hypertension - 2015 | Hochdrucktherapie 2015</dc:title><dc:creator>Kintscher U.</dc:creator><prism:publicationName>Deutsche Medizinische Wochenschrift</prism:publicationName><prism:issn>00120472</prism:issn><prism:eIssn>14394413</prism:eIssn><prism:volume>140</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>835-844</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-102097</prism:doi><dc:description>With an prevalence of 32%, arterial hypertension remains on of the most common diseases among adults in Germany. The ESH/ESC-guidelines from 2013 and the corresponding pocket guidelines of the DHL&lt;sup&gt;®&lt;/sup&gt;/DGK from 2014 contain multiple modifications in diagnosis and therapy that are discussed in the present review. Target blood pressure recommendations have been simplified to &lt;140/90mmHg for almost all hypertensive patients. Exceptions include: diabetic patients, elderly, and patients with chronic kidney disease and proteinuria. The recommentations for pharmacological antihypertensive therapy remained mainly unchanged. Critical evaluation of renal denervation in therapy resistant hypertension requires additional randomized controlled trials in Germany to finally assess the clinical relevance of this intervention. Currently, renal denervation does not provide an alternative strategy for an establihed pharmacological or non-pharmacological approach.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026245</affiliation-url><afid>60026245</afid><affilname>Charite - Universitatsmedizin Berlin</affilname><affiliation-city>Berlin</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023686</affiliation-url><afid>60023686</afid><affilname>Universitatsklinikum des Saarlandes Medizinische Fakultat der Universitat des Saarlandes</affilname><name-variant>University of Saarland</name-variant><affiliation-city>Homburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004012758</author-url><authid>7004012758</authid><authname>Kintscher U.</authname><surname>Kintscher</surname><given-name>Ulrich</given-name><initials>U.</initials><afid>60026245</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26428326200</author-url><authid>26428326200</authid><authname>Mahfoud F.</authname><surname>Mahfoud</surname><given-name>Felix</given-name><initials>F.</initials><afid>60023686</afid></author><authkeywords>hypertension | renal denervation | target blood pressure | therapy resistance</authkeywords><intid>1536087220</intid><source-id>12445</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226876"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226876?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226876&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226876&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226876</prism:url><dc:identifier>SCOPUS_ID:84930226876</dc:identifier><eid>2-s2.0-84930226876</eid><dc:title>Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA&lt;sup&gt;®&lt;/sup&gt; trial | Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse: Rationale für die aktiv kontrollierte CAROLINA&lt;sup&gt;®&lt;/sup&gt;-Studie</dc:title><dc:creator>Gallwitz B.</dc:creator><prism:publicationName>Deutsche Medizinische Wochenschrift</prism:publicationName><prism:issn>00120472</prism:issn><prism:eIssn>14394413</prism:eIssn><prism:volume>140</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>831-834</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-102194</prism:doi><dc:description>© Georg Thieme Verlag KG Stuttgart, New York. Sulphonylureas (SUs) are antidiabetic agents widely used in patients with Type 2 Diabetes Mellitus (T2DM). Observational retrospective studies have raised concerns regarding the cardiovascular (CV) safety of this class of drugs, and data from observational and registry studies are conflicting. To address the SU controversy, this review looked at longer-term RCTs, where SUs were compared in a head-to-head fashion with active comparators. An analysis of 18 studies did not find any increase in the incidence of CV events with SU therapy. However, the available data are limited and most importantly, there is a lack of prospective, adequately powered, formal head-to-head CV outcome trials. Since SUs are still being used as second-line therapy in combination with metformin and in some cases as first-line treatment of T2DM, there is a definite need for CV safety data from a prospective RCT. The CAROLINA&lt;sup&gt;®&lt;/sup&gt; study is currently the largest CV outcome study with a direct comparison of an SU and a dipeptidyl peptidase-4 inhibitor (DPP-4). Based on the study design and statistical power of CAROLINA&lt;sup&gt;®&lt;/sup&gt;, its results will provide a unique perspective regarding CV outcomes of these 2 commonly used agents.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022653</affiliation-url><afid>60022653</afid><affilname>Universitatsklinikum Tubingen Medizinische Fakultat</affilname><affiliation-city>Tubingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011807</affiliation-url><afid>60011807</afid><affilname>Boehringer Ingelheim Pharma GmbH &amp; Co. KG</affilname><name-variant>Boehringer Ingelheim Pharma GmbH and Co. KG</name-variant><affiliation-city>Ingelheim am Rhein</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001097</affiliation-url><afid>60001097</afid><affilname>Medizinische Fakultat und Universitats Klinikum Aachen</affilname><name-variant>University Hospital</name-variant><affiliation-city>Aachen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7004763605</author-url><authid>7004763605</authid><authname>Gallwitz B.</authname><surname>Gallwitz</surname><given-name>Baptist</given-name><initials>B.</initials><afid>60022653</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55993191100</author-url><authid>55993191100</authid><authname>Thiemann S.</authname><surname>Thiemann</surname><given-name>Sandra</given-name><initials>S.</initials><afid>60011807</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36860791200</author-url><authid>36860791200</authid><authname>Wörle H.</authname><surname>Wörle</surname><given-name>Hans Jürgen</given-name><initials>H.J.</initials><afid>60011807</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55899501400</author-url><authid>55899501400</authid><authname>Marx N.</authname><surname>Marx</surname><given-name>Nikolaus</given-name><initials>N.</initials><afid>60001097</afid></author><authkeywords>cardiovascular disease | dipeptidyl peptidase-4 inhibitor | oral antidiabetic agents | sulphonylurea | type 2 diabetes</authkeywords><intid>1036081927</intid><source-id>12445</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929224966"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929224966?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929224966&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929224966&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929224966</prism:url><dc:identifier>SCOPUS_ID:84929224966</dc:identifier><eid>2-s2.0-84929224966</eid><dc:title>Elevated glycated hemoglobin levels may increase the risk of atrial fibrillation in patients with diabetes mellitus</dc:title><dc:creator>Yang Y.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3271-3280</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Background: As the most common cardiac arrhythmia, atrial fibrillation (AF) is always accompanied with various complications if without detection and treatment timely. Blood-based pleiotropic molecule biomarkers have now been popularly applied in clinical detection. We hence performed this meta-analysis to evaluate the correlation of serum glycated hemoglobin (HbA1c) levels with the risk of AF in patients with diabetes mellitus (DM). Methods: Covering myriads of computerized databases, we identified potential relevant studies for statistical analysis. We used a standard reporting form to extract data from each included study. Newcastle-Ottawa Scale (NOS) criteria was used for methodological quality assessment. Statistical analyses were conducted with the STATA statistical software. Results: Six cohort studies in full text fulfilled our inclusion criteria, and following overestimation indicated that serum levels of HbA1c in DM patients with AF was higher than that in DM patients without AF (SMD = 0.67, 95% CI: 0.39-0.94, P &lt; 0.001). Subgroup analyses by sample size and detection method implicated that elevated serum HbA1c levels exhibited significant correlations with an increased risk of AF in DM patients in the large-size subgroup (n ≥ 200), the small-size subgroup (n &lt; 200), the high performance liquid chromatography (HPLC) subgroup and the non-HPLC subgroup (Large-size: SMD = 0.70, 95% CI: 0.38-1.03, P &lt; 0.001; Small-size: SMD = 0.64, 95% CI: 0.09-1.19, P = 0.023; HPLC: SMD = 0.81, 95% CI: 0.49-1.12, P &lt; 0.001; Non-HPLC: SMD = 0.36, 95% CI: 0.04-0.68, P = 0.029; respectively). Conclusion: Elevated serum HbA1c levels may be associated with an increased risk of AF in DM patients, possibly reflecting that serum HbA1c level might be a potential biomarker in the prediction of AF in DM patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115235550</affiliation-url><afid>115235550</afid><affilname>Zhong Shan Hospital Attached to Fu Dan University</affilname><name-variant>Zhong Shan Hospital Attached to Fu Dan University</name-variant><affiliation-city/><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56640678600</author-url><authid>56640678600</authid><authname>Yang Y.</authname><surname>Yang</surname><given-name>Yu Fan</given-name><initials>Y.F.</initials><afid>115235550</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640219800</author-url><authid>56640219800</authid><authname>Zhu W.</authname><surname>Zhu</surname><given-name>Wen Qing</given-name><initials>W.Q.</initials><afid>115235550</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56640358300</author-url><authid>56640358300</authid><authname>Cheng K.</authname><surname>Cheng</surname><given-name>Kuan</given-name><initials>K.</initials><afid>115235550</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640165300</author-url><authid>56640165300</authid><authname>Chen Q.</authname><surname>Chen</surname><given-name>Qing Xing</given-name><initials>Q.X.</initials><afid>115235550</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56640130500</author-url><authid>56640130500</authid><authname>Xu Y.</authname><surname>Xu</surname><given-name>Ye</given-name><initials>Y.</initials><afid>115235550</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56640534000</author-url><authid>56640534000</authid><authname>Pang Y.</authname><surname>Pang</surname><given-name>Yang</given-name><initials>Y.</initials><afid>115235550</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56640029300</author-url><authid>56640029300</authid><authname>Liu G.</authname><surname>Liu</surname><given-name>Gui Jian</given-name><initials>G.J.</initials><afid>115235550</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56640473800</author-url><authid>56640473800</authid><authname>Ge J.</authname><surname>Ge</surname><given-name>Jun Bo</given-name><initials>J.B.</initials><afid>115235550</afid></author><authkeywords>Atrial fibrillation | Diabetes mellitus | Glycated hemoglobin | Meta-analysis</authkeywords><intid>1535916454</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226504"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226504?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226504&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226504&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008694"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226504</prism:url><dc:identifier>SCOPUS_ID:84930226504</dc:identifier><eid>2-s2.0-84930226504</eid><dc:title>Catheter ablation of idiopathic ventricular tachycardia without the use of fluoroscopy</dc:title><dc:creator>Lamberti F.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>338-343</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.146</prism:doi><pii>S0167527315008694</pii><dc:description>© 2015 Elsevier Ireland Ltd. All rights reserved. Background Catheter ablation is the treatment of choice for many patients with idiopathic ventricular tachycardia (VT). Unfortunately, conventional catheter ablation is guided by fluoroscopy, which is associated with a small but definite radiation risk for patients and laboratory personnel. The aim of our study is to assess feasibility, success rate and safety of idiopathic VT ablation procedure performed without the use of fluoroscopy. Methods Nineteen consecutive patients undergoing idiopathic VT ablation at our institution have been included. The ablation procedures were performed under the guidance of electroanatomical mapping (EAM) system and intracardiac echocardiography (ICE). Results Nineteen patients (mean age 38.7 years) underwent ablation procedure for idiopathic VT. Twelve (63%) had outflow tract VT, 3 (18%) fascicular tachycardia, 2 (11%) peri-tricuspidal VT, 1 (5%) peri-mitral VT, and 1 (5%) lateral left free-wall VT. The mean procedural time was 170.2 ± 45.7 min. No fluoroscopy was used in any procedural phase. Acute success rate was 100%. No complication was documented in any patients. After a mean follow up of 18 ± 4 months, recurrences occurred in 2 patients. Conclusions In our preliminary experience idiopathic VT ablation without the use of fluoroscopy was feasible and safe, using a combination of EAM and ICE. Success rate was excellent with no complication.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004215</affiliation-url><afid>60004215</afid><affilname>Ospedale S. Eugenio</affilname><name-variant>S. Eugenio Hospital</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Johnson and Johnson Medical</affilname><name-variant>Biosense Webster Italy</name-variant><affiliation-city>Milan</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56223302300</author-url><authid>56223302300</authid><authname>Lamberti F.</authname><surname>Lamberti</surname><given-name>Filippo</given-name><initials>F.</initials><afid>60004215</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24331591900</author-url><authid>24331591900</authid><authname>Di Clemente F.</authname><surname>Di Clemente</surname><given-name>Francesca</given-name><initials>F.</initials><afid>60004215</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8933616500</author-url><authid>8933616500</authid><authname>Remoli R.</authname><surname>Remoli</surname><given-name>Romolo</given-name><initials>R.</initials><afid>60004215</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662830900</author-url><authid>56662830900</authid><authname>Bellini C.</authname><surname>Bellini</surname><given-name>Cesare</given-name><initials>C.</initials><afid>60004215</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:8595604500</author-url><authid>8595604500</authid><authname>De Santis A.</authname><surname>De Santis</surname><given-name>Antonella</given-name><initials>A.</initials><afid>60004215</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56662861400</author-url><authid>56662861400</authid><authname>Mercurio M.</authname><surname>Mercurio</surname><given-name>Marina</given-name><initials>M.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35179230500</author-url><authid>35179230500</authid><authname>Dottori S.</authname><surname>Dottori</surname><given-name>Serena</given-name><initials>S.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:35432482500</author-url><authid>35432482500</authid><authname>Gaspardone A.</authname><surname>Gaspardone</surname><given-name>Achille</given-name><initials>A.</initials><afid>60004215</afid></author><authkeywords>Electro-anatomical mapping | Idiopathic ventricular tachycardia | Intracardiac echocardiography | Non-fluoroscopic catheter ablation | Radiation risk | Radiofrequency</authkeywords><intid>536088204</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929208920"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929208920?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929208920&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929208920&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929208920</prism:url><dc:identifier>SCOPUS_ID:84929208920</dc:identifier><eid>2-s2.0-84929208920</eid><dc:title>Correlation of increased plasma osteoprotegerin and cardiovascular risk factors in patients with adult growth hormone deficiency</dc:title><dc:creator>Xia J.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3184-3192</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Adult growth hormone deficiency (AGHD) is correlated to many adverse effects on metabolism and increases cardiovascular risk. 40 patients with AGHD and 40 healthy subjects were included. Anthropometric parameters such as body mass index, waist circumference, and waist-hip ratio were measured. Meanwhile, plasma levels of total cholesterol, triglyceride, high sensitivity C-relative protein, interleukin-6 and OPG were determined. Homeostasis model assessments for insulin resistance (HOMA-IR) and β-cell function (HOMA-β) were calculated using homeostasis model. Plasma OPG concentrations of AGHD patients were significantly higher than those in healthy subjects (131.82 ± 45.04 versus 81.02 ± 45.04, P &lt; 0.01). Plasma OPG levels were positively correlated with age, body mass index, waist circumference, hip circumference, waist-hip ratio, fasting insulin, total cholesterol, triglyceride, high sensitivity C-relative protein and interleukin-6 (P &lt; 0.05), but negatively correlated with high-density lipoprotein cholesterol (P &lt; 0.05). Multiple linear stepwise regression analysis demonstrated that body mass index, triglyceride, and interleukin-6 were independently related to plasma OPG levels (P &lt; 0.05). The levels of plasma OPG were increased in AGHD patients and were closely correlated with glycolipid metabolism and chronic inflammation. OPG might play an important role in the occurrence and development of cardiovascular diseases in AGHD patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020870</affiliation-url><afid>60020870</afid><affilname>Chongqing University of Medical Sciences</affilname><name-variant>Chongqing Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56531222500</author-url><authid>56531222500</authid><authname>Xia J.</authname><surname>Xia</surname><given-name>Jiajia</given-name><initials>J.</initials><afid>60020870</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:53664088600</author-url><authid>53664088600</authid><authname>Li L.</authname><surname>Li</surname><given-name>Linman</given-name><initials>L.</initials><afid>60020870</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24469107800</author-url><authid>24469107800</authid><authname>Ren W.</authname><surname>Ren</surname><given-name>Wei</given-name><initials>W.</initials><afid>60020870</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36501059900</author-url><authid>36501059900</authid><authname>Zheng X.</authname><surname>Zheng</surname><given-name>Xiaoya</given-name><initials>X.</initials><afid>60020870</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56499609300</author-url><authid>56499609300</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Chan</given-name><initials>C.</initials><afid>60020870</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:37041595100</author-url><authid>37041595100</authid><authname>Li J.</authname><surname>Li</surname><given-name>Jinchao</given-name><initials>J.</initials><afid>60020870</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56499622800</author-url><authid>56499622800</authid><authname>Chen T.</authname><surname>Chen</surname><given-name>Tingying</given-name><initials>T.</initials><afid>60020870</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56500186500</author-url><authid>56500186500</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xiaofeng</given-name><initials>X.</initials><afid>60020870</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55721432200</author-url><authid>55721432200</authid><authname>Wang L.</authname><surname>Wang</surname><given-name>Lingli</given-name><initials>L.</initials><afid>60020870</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55608491200</author-url><authid>55608491200</authid><authname>Hu Y.</authname><surname>Hu</surname><given-name>Yumei</given-name><initials>Y.</initials><afid>60020870</afid></author><authkeywords>Adult growth hormone deficiency | Cardiovascular disease risk | Insulin tolerance test | Osteoprotegerin</authkeywords><intid>35917967</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930208617"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930208617?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930208617&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930208617&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315006658"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930208617</prism:url><dc:identifier>SCOPUS_ID:84930208617</dc:identifier><eid>2-s2.0-84930208617</eid><dc:title>The role of thyroid in Takotsubo cardiomyopathy</dc:title><dc:creator>Aggarwal S.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>34</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.402</prism:doi><pii>S0167527315006658</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000879</affiliation-url><afid>60000879</afid><affilname>Western Michigan University</affilname><name-variant>Western Michigan University</name-variant><affiliation-city>Kalamazoo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114711474</affiliation-url><afid>114711474</afid><affilname>Cardiovascular Research Institute</affilname><name-variant>Cardiovascular Research Institute</name-variant><affiliation-city>Kalamazoo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100497434</affiliation-url><afid>100497434</afid><affilname>Borgess Heart Institute</affilname><name-variant>Heart Institute at Borgess</name-variant><affiliation-city>Kalamazoo</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643972600</author-url><authid>56643972600</authid><authname>Aggarwal S.</authname><surname>Aggarwal</surname><given-name>Sourabh</given-name><initials>S.</initials><afid>60000879</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56644791200</author-url><authid>56644791200</authid><authname>Papani R.</authname><surname>Papani</surname><given-name>Ravikanth</given-name><initials>R.</initials><afid>60014569</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16416542900</author-url><authid>16416542900</authid><authname>Gupta V.</authname><surname>Gupta</surname><given-name>Vishal</given-name><initials>V.</initials><afid>114711474</afid><afid>100497434</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16416542900</author-url><authid>16416542900</authid><authname>Gupta V.</authname><surname>Gupta</surname><given-name>Vishal</given-name><initials>V.</initials><afid>114711474</afid><afid>100497434</afid></author><authkeywords>Autonomic nervous system | Hypothyroid | Levothyroxine | Takotsubo cardiomyopathy | Thyroid pathology</authkeywords><intid>36085522</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209237"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209237?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209237&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209237&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008323"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209237</prism:url><dc:identifier>SCOPUS_ID:84930209237</dc:identifier><eid>2-s2.0-84930209237</eid><dc:title>Reply: Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: A prospective observational study</dc:title><dc:creator>Bo M.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>67</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.109</prism:doi><pii>S0167527315008323</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Città della Salute e della Scienza - Molinette</affilname><name-variant>SCDU Geriatria e Malattie Metaboliche dell'Osso</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106709037</affiliation-url><afid>106709037</afid><affilname>AOU San Luigi Gonzaga</affilname><name-variant>A.O.U. San Luigi Gonzaga</name-variant><affiliation-city>Orbassano</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Città della Salute e della Scienza - Molinette</affilname><name-variant>SCDU Cardiologia</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56539510700</author-url><authid>56539510700</authid><authname>Bo M.</authname><surname>Bo</surname><given-name>M.</given-name><initials>M.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663215300</author-url><authid>56663215300</authid><authname>Li Puma F.</authname><surname>Li Puma</surname><given-name>F.</given-name><initials>F.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56663155900</author-url><authid>56663155900</authid><authname>Badinella Martini M.</authname><surname>Badinella Martini</surname><given-name>M.</given-name><initials>M.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56663046900</author-url><authid>56663046900</authid><authname>Falcone Y.</authname><surname>Falcone</surname><given-name>Y.</given-name><initials>Y.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36666561100</author-url><authid>36666561100</authid><authname>Iacovino M.</authname><surname>Iacovino</surname><given-name>M.</given-name><initials>M.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55885443900</author-url><authid>55885443900</authid><authname>Grisoglio E.</authname><surname>Grisoglio</surname><given-name>E.</given-name><initials>E.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55763499900</author-url><authid>55763499900</authid><authname>Bonetto M.</authname><surname>Bonetto</surname><given-name>M.</given-name><initials>M.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24779415100</author-url><authid>24779415100</authid><authname>Isaia G.</authname><surname>Isaia</surname><given-name>G.</given-name><initials>G.</initials><afid>106709037</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56640989700</author-url><authid>56640989700</authid><authname>Ciccone G.</authname><surname>Ciccone</surname><given-name>G.</given-name><initials>G.</initials><afid/></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:24467983700</author-url><authid>24467983700</authid><authname>Isaia G.</authname><surname>Isaia</surname><given-name>G. C.</given-name><initials>G.C.</initials><afid/></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56233008400</author-url><authid>56233008400</authid><authname>Gaita F.</authname><surname>Gaita</surname><given-name>F.</given-name><initials>F.</initials><afid/></author><authkeywords>Atrial fibrillation | Elderly | Geriatric syndromes | Health status | Older medical in-patients | Oral anticoagulants</authkeywords><intid>1036081694</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198294"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198294?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198294&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198294&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315006695"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198294</prism:url><dc:identifier>SCOPUS_ID:84930198294</dc:identifier><eid>2-s2.0-84930198294</eid><dc:title>Coronary artery fistula from the left circumflex to coronary sinus in infant: Case report with literature review</dc:title><dc:creator>Song G.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>37-39</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.406</prism:doi><pii>S0167527315006695</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008872</affiliation-url><afid>60008872</afid><affilname>China Medical University Shenyang</affilname><name-variant>China Medical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008872</affiliation-url><afid>60008872</afid><affilname>China Medical University Shenyang</affilname><name-variant>China Medical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008872</affiliation-url><afid>60008872</afid><affilname>China Medical University Shenyang</affilname><name-variant>China Medical University</name-variant><affiliation-city>Shenyang</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55850878800</author-url><authid>55850878800</authid><authname>Song G.</authname><surname>Song</surname><given-name>Guang</given-name><initials>G.</initials><afid>60008872</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12778453700</author-url><authid>12778453700</authid><authname>Ren W.</authname><surname>Ren</surname><given-name>Weidong</given-name><initials>W.</initials><afid>60008872</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56643594600</author-url><authid>56643594600</authid><authname>Tang L.</authname><surname>Tang</surname><given-name>Lian</given-name><initials>L.</initials><afid>60008872</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35278028800</author-url><authid>35278028800</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Yang</given-name><initials>Y.</initials><afid>60008872</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56643767500</author-url><authid>56643767500</authid><authname>Zhou K.</authname><surname>Zhou</surname><given-name>Ke</given-name><initials>K.</initials><afid>60008872</afid></author><authkeywords>Coronary artery fistula | Coronary sinus | Extremely low birth weight infant | Left circumflex | Stenosis</authkeywords><intid>36086751</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930193191"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930193191?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930193191&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930193191&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930193191</prism:url><dc:identifier>SCOPUS_ID:84930193191</dc:identifier><eid>2-s2.0-84930193191</eid><dc:title>APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans</dc:title><dc:creator>Bentley A.</dc:creator><prism:publicationName>BMC Genomics</prism:publicationName><prism:eIssn>14712164</prism:eIssn><prism:volume>16</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>May 30, 2015</prism:coverDisplayDate><prism:doi>10.1186/s12864-015-1645-7</prism:doi><dc:description>© 2015 Bentley et al.; licensee BioMed Central. Background: Despite evidence of an association between variants at the apolipoprotein L1 gene (APOL1) locus and a spectrum of related kidney diseases, underlying biological mechanisms remain unknown. An earlier preliminary study published by our group showed that an APOL1 variant (rs73885319) modified the association between high-density lipoprotein cholesterol (HDLC) and estimated glomerular filtration rate (eGFR) in African Americans. To further understand this relationship, we evaluated the interaction in two additional large cohorts of African Americans for a total of 3,592 unrelated individuals from the Howard University Family Study (HUFS), the Natural History of APOL1-Associated Nephropathy Study (NHAAN), and the Atherosclerosis Risk in Communities Study (ARIC). The association between HDLC and eGFR was determined using linear mixed models, and the interaction between rs73885319 genotype and HDLC was evaluated using a multiplicative term. Results: Among individuals homozygous for the risk genotype, a strong inverse HDLC-eGFR association was observed, with a positive association in others (p for the interaction of the rs73885319 × HDLC =0.0001). The interaction was similar in HUFS and NHAAN, and attenuated in ARIC. Given that ARIC participants were older, we investigated an age effect; age was a significant modifier of the observed interaction. When older individuals were excluded, the interaction in ARIC was similar to that in the other studies. Conclusions: Based on these findings, it is clear that the relationship between HDLC and eGFR is strongly influenced by the APOL1 rs73885319 kidney risk genotype. Moreover, the degree to which this variant modifies the association may depend on the age of the individual. More detailed physiological studies are warranted to understand how rs73885319 may affect the relationship between HDLC and eGFR in individuals with and without disease and across the lifespan.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013369</affiliation-url><afid>60013369</afid><affilname>National Human Genome Research Institute</affilname><name-variant>National Human Genome Research Institute</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031437</affiliation-url><afid>60031437</afid><affilname>Wake Forest University School of Medicine</affilname><name-variant>Wake Forest Univ. School of Medicine</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031437</affiliation-url><afid>60031437</afid><affilname>Wake Forest University School of Medicine</affilname><name-variant>Wake Forest Univ. School of Medicine</name-variant><affiliation-city>Winston Salem</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54962480000</author-url><authid>54962480000</authid><authname>Bentley A.</authname><surname>Bentley</surname><given-name>Amy R.</given-name><initials>A.R.</initials><afid>60013369</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24472965200</author-url><authid>24472965200</authid><authname>Divers J.</authname><surname>Divers</surname><given-name>Jasmin</given-name><initials>J.</initials><afid>60031437</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004202273</author-url><authid>7004202273</authid><authname>Shriner D.</authname><surname>Shriner</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60013369</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6507897813</author-url><authid>6507897813</authid><authname>Doumatey A.</authname><surname>Doumatey</surname><given-name>Ayo P.</given-name><initials>A.P.</initials><afid>60013369</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:15729450600</author-url><authid>15729450600</authid><authname>Gutiérrez O.</authname><surname>Gutiérrez</surname><given-name>Orlando M.</given-name><initials>O.M.</initials><afid>60027086</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006809819</author-url><authid>7006809819</authid><authname>Adeyemo A.</authname><surname>Adeyemo</surname><given-name>Adebowale A.</given-name><initials>A.A.</initials><afid>60013369</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7102825752</author-url><authid>7102825752</authid><authname>Freedman B.</authname><surname>Freedman</surname><given-name>Barry I.</given-name><initials>B.I.</initials><afid>60031437</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006238725</author-url><authid>7006238725</authid><authname>Rotimi C.</authname><surname>Rotimi</surname><given-name>Charles N.</given-name><initials>C.N.</initials><afid>60013369</afid></author><authkeywords>African ancestry | Apolipoprotein L1 | Glomerular filtration rate | High-density lipoprotein cholesterol</authkeywords><intid>2036082685</intid><article-number>421</article-number><source-id>21727</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211710"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211710?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211710&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211710&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315006725"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211710</prism:url><dc:identifier>SCOPUS_ID:84930211710</dc:identifier><eid>2-s2.0-84930211710</eid><dc:title>Author's reply to digoxin and risk of acute pancreatitis</dc:title><dc:creator>Lai S.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>188</prism:volume><prism:pageRange>36</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.409</prism:doi><pii>S0167527315006725</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021326</affiliation-url><afid>60021326</afid><affilname>Buddhist Tzu-Chi General Hospital Taiwan</affilname><name-variant>Buddhist Dalin Tzu Chi General Hospital</name-variant><affiliation-city>Hualien</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402935881</author-url><authid>7402935881</authid><authname>Lai S.</authname><surname>Lai</surname><given-name>Shih Wei</given-name><initials>S.W.</initials><afid>60006988</afid><afid>60031941</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402935881</author-url><authid>7402935881</authid><authname>Lai S.</authname><surname>Lai</surname><given-name>Shih Wei</given-name><initials>S.W.</initials><afid>60006988</afid><afid>60031941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55347441700</author-url><authid>55347441700</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>Cheng Li</given-name><initials>C.L.</initials><afid>60006988</afid><afid>60031941</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55347441700</author-url><authid>55347441700</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>Cheng Li</given-name><initials>C.L.</initials><afid>60006988</afid><afid>60031941</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8203700400</author-url><authid>8203700400</authid><authname>Liao K.</authname><surname>Liao</surname><given-name>Kuan Fu</given-name><initials>K.F.</initials><afid>60006988</afid><afid>60021326</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8203700400</author-url><authid>8203700400</authid><authname>Liao K.</authname><surname>Liao</surname><given-name>Kuan Fu</given-name><initials>K.F.</initials><afid>60006988</afid><afid>60021326</afid></author><authkeywords>Acute pancreatitis | Digoxin</authkeywords><intid>36086207</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209193"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209193?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209193&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209193&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016752731500827X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209193</prism:url><dc:identifier>SCOPUS_ID:84930209193</dc:identifier><eid>2-s2.0-84930209193</eid><dc:title>Uninterrupted dabigatran versus warfarin in the treatment of intracardiac thrombus in patients with non-valvular atrial fibrillation</dc:title><dc:creator>Hao L.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>63-66</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.104 Letter to the Editor</prism:doi><pii>S016752731500827X</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092862</affiliation-url><afid>60092862</afid><affilname>Qilu Hospital of Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031031</affiliation-url><afid>60031031</afid><affilname>Shandong University</affilname><name-variant>Shandong University</name-variant><affiliation-city>Jinan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56430417100</author-url><authid>56430417100</authid><authname>Hao L.</authname><surname>Hao</surname><given-name>Li</given-name><initials>L.</initials><afid>60092862</afid><afid>60031031</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56430417100</author-url><authid>56430417100</authid><authname>Hao L.</authname><surname>Hao</surname><given-name>Li</given-name><initials>L.</initials><afid>60092862</afid><afid>60031031</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35314162700</author-url><authid>35314162700</authid><authname>Zhong J.</authname><surname>Zhong</surname><given-name>Jing Quan</given-name><initials>J.Q.</initials><afid>60092862</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56263778400</author-url><authid>56263778400</authid><authname>Zhang W.</authname><surname>Zhang</surname><given-name>Wei</given-name><initials>W.</initials><afid>60092862</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56052053900</author-url><authid>56052053900</authid><authname>Rong B.</authname><surname>Rong</surname><given-name>Bing</given-name><initials>B.</initials><afid>60092862</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56430528900</author-url><authid>56430528900</authid><authname>Xie F.</authname><surname>Xie</surname><given-name>Fei</given-name><initials>F.</initials><afid>60092862</afid><afid>60031031</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56430528900</author-url><authid>56430528900</authid><authname>Xie F.</authname><surname>Xie</surname><given-name>Fei</given-name><initials>F.</initials><afid>60092862</afid><afid>60031031</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56412318000</author-url><authid>56412318000</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jun Tao</given-name><initials>J.T.</initials><afid>60092862</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56051188700</author-url><authid>56051188700</authid><authname>Yue X.</authname><surname>Yue</surname><given-name>Xin</given-name><initials>X.</initials><afid>60092862</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:36122198500</author-url><authid>36122198500</authid><authname>Zheng Z.</authname><surname>Zheng</surname><given-name>Zhao Tong</given-name><initials>Z.T.</initials><afid>60092862</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56412303900</author-url><authid>56412303900</authid><authname>Zhu Q.</authname><surname>Zhu</surname><given-name>Qing</given-name><initials>Q.</initials><afid>60092862</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55929455500</author-url><authid>55929455500</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yun</given-name><initials>Y.</initials><afid>60092862</afid></author><authkeywords>Dabigatran | Intracardiac thrombus | Non-valvular atrial fibrillation | Transesophageal echocardiography | Warfarin</authkeywords><intid>36086780</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216519"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216519?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216519&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216519&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216519</prism:url><dc:identifier>SCOPUS_ID:84930216519</dc:identifier><eid>2-s2.0-84930216519</eid><dc:title>18-year-old patient with meningitis and new dermal phenomena | 18-Jähriger mit Meningitis und unklaren Hautveränderungen</dc:title><dc:creator>Kuhl T.</dc:creator><prism:publicationName>Deutsche Medizinische Wochenschrift</prism:publicationName><prism:issn>00120472</prism:issn><prism:eIssn>14394413</prism:eIssn><prism:volume>140</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:pageRange>795 and 851</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-101506</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293699</affiliation-url><afid>115293699</afid><affilname>Praxis für Kardiologie</affilname><name-variant>Praxis für Kardiologie</name-variant><affiliation-city>Dormagen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100694401</affiliation-url><afid>100694401</afid><affilname>Medizinische Klinik</affilname><name-variant>Medizinische Klinik</name-variant><affiliation-city>Reutlingen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016143</affiliation-url><afid>60016143</afid><affilname>Helios Klinikum Krefeld</affilname><name-variant>Klinikum Krefeld</name-variant><affiliation-city>Krefeld</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>no</subtype><subtypeDescription>Note</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36561828400</author-url><authid>36561828400</authid><authname>Kuhl T.</authname><surname>Kuhl</surname><given-name>Thomas</given-name><initials>T.</initials><afid>115293699</afid><afid>100694401</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36561828400</author-url><authid>36561828400</authid><authname>Kuhl T.</authname><surname>Kuhl</surname><given-name>Thomas</given-name><initials>T.</initials><afid>115293699</afid><afid>100694401</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56657323500</author-url><authid>56657323500</authid><authname>Klues H.</authname><surname>Klues</surname><given-name>Heinrich</given-name><initials>H.</initials><afid>60016143</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56657303400</author-url><authid>56657303400</authid><authname>Bufe A.</authname><surname>Bufe</surname><given-name>Alexander</given-name><initials>A.</initials><afid>60016143</afid></author><authkeywords>infectious endocarditis | Janeway lesions | Osler splints</authkeywords><intid>2036081967</intid><source-id>12445</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926354729"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926354729?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926354729&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926354729&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378517315002872"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926354729</prism:url><dc:identifier>SCOPUS_ID:84926354729</dc:identifier><eid>2-s2.0-84926354729</eid><dc:title>Preparation and characterization of micronized ellagic acid using antisolvent precipitation for oral delivery</dc:title><dc:creator>Li Y.</dc:creator><prism:publicationName>International Journal of Pharmaceutics</prism:publicationName><prism:issn>03785173</prism:issn><prism:eIssn>18733476</prism:eIssn><prism:volume>486</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:pageRange>207-216</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijpharm.2015.03.071</prism:doi><pii>S0378517315002872</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. In this work, poorly water soluble phytochemical ellagic acid (EA) was micronized to increase its solubility and thereby the bioavailability during antisolvent precipitation process using N-methyl pyrrolidone (NMP) as solvent and deionized water as antisolvent. The micronized EA (m-EA) freeze-dried powder was prepared by the subsequent lyophilization process. The effects of various experimental parameters on the mean particle size (MPS) of m-EA suspension (m-EAS) in the antisolvent precipitation process were investigated. MPS and production efficiency were taken into account comprehensively to obtain the optimum conditions of antisolvent precipitation. Under the optimum conditions, m-EA freeze-dried powder with a MPS of 429.2 ± 7.6 nm was obtained. The physico-chemical properties of m-EA freeze-dried powder were detected by scanning electron microscope (SEM), Fourier transform infrared spectroscopy (FTIR), liquid chromatography-tandem mass spectrometry (LC-MS/MS), X-ray diffraction (XRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The results indicated m-EA kept the same chemical structure with raw EA, but the crystallinity was greatly reduced. Furthermore, a comparison of the 50% inhibition concentration (IC&lt;inf&gt;50&lt;/inf&gt;) values revealed that m-EA was more effective than raw EA in scavenging 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical. Meanwhile, m-EA also showed higher reducing power. Moreover, the residual amount of NMP was lower than the International Conference on Harmonization limit (530 ppm) for solvents. The dissolution rate of m-EA was approximately 2 times of raw EA. Moreover, the solubility of m-EA was about 6.5 times of raw EA. Meanwhile, the bioavailability of m-EA increased about 2 times compared with raw EA via oral administration.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006935</affiliation-url><afid>60006935</afid><affilname>Northeast Forestry University</affilname><name-variant>Northeast Forestry University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55822938100</author-url><authid>55822938100</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yong</given-name><initials>Y.</initials><afid>60006935</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:12800017000</author-url><authid>12800017000</authid><authname>Zhao X.</authname><surname>Zhao</surname><given-name>Xiuhua</given-name><initials>X.</initials><afid>60006935</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006348832</author-url><authid>7006348832</authid><authname>Zu Y.</authname><surname>Zu</surname><given-name>Yuangang</given-name><initials>Y.</initials><afid>60006935</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7601314053</author-url><authid>7601314053</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yin</given-name><initials>Y.</initials><afid>60006935</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54779631600</author-url><authid>54779631600</authid><authname>Ge Y.</authname><surname>Ge</surname><given-name>Yunlong</given-name><initials>Y.</initials><afid>60006935</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7202121026</author-url><authid>7202121026</authid><authname>Zhong C.</authname><surname>Zhong</surname><given-name>Chen</given-name><initials>C.</initials><afid>60006935</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:23390866900</author-url><authid>23390866900</authid><authname>Wu W.</authname><surname>Wu</surname><given-name>Weiwei</given-name><initials>W.</initials><afid>60006935</afid></author><authkeywords>Antioxidant activity | Antisolvent precipitation | Bioavailability | Dissolution rate | Ellagic acid</authkeywords><intid>35432296</intid><source-id>22454</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929178311"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929178311?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929178311&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929178311&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929178311</prism:url><dc:identifier>SCOPUS_ID:84929178311</dc:identifier><eid>2-s2.0-84929178311</eid><dc:title>Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: A systemic review and meta-analysis</dc:title><dc:creator>Peng B.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3098-3106</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Neutrophil to Lymphocyte Ratio (NLR) was recently demonstrated as a useful index in predicting the prognosis of Non-Small Cell Lung Cancer (NSCLC). Thus, a meta-analysis was performed to demonstrate the relationship between NLR and overall survival (OS), progress-free survival (PFS) or disease free survival (DFS) in patients with NSCLC. We searched for relevant literatures in PubMed, EMBASE and Cochrane library and pooled the eligible studies and synthesized hazard ratios (HRs) using Stata 12.0. Final analysis of NSCLC patients from 12 eligible studies was performed. Combined HR suggested that high NLR had an unfavorable effect on patients’ OS (n=1700 in 11 studies; HR= 1.43, 95% CI: 1.25-1.64; I^2=80.2%, P&lt;0.01) and PFS (n=664 in 5 studies, HR=1.37, 95% CI: 1.07-1.74; I^2=70.8%, P=0.004). Subgroup analysis based on cutoff shown that, compared with other subgroups, the subgroup with a cutoff of 5 had a significantly poorer survival (HR=1.87, 95% CI 1.49-2.34) with less heterogeneity (I^2=21.3%, P=0.28). However, subgroup analysis based on treatment method indicated that the “surgery” subgroup seemed to have not a significant impact on survival (HR=1.32, 95% CI 0.99-1.77; I^2=80.0%, P=0.063) compared with the chemotherapy subgroup (HR=1.61, 95% CI 1.24-2.10; I^2=82.6%, P&lt;0.01). Additionally, combined odds ratio (OR) suggested high NLR was associated inversely with response to treatment (n = 276 in 2 studies; OR = 1.73, 95% CI: 1.04-2.88; I^2=0%, P=0.40). This study suggests high NLR (especially with a cutoff of 5) seems to be associated with a worse prognosis in patients with NSCLC as well as a worse response to treatments.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56489555100</author-url><authid>56489555100</authid><authname>Peng B.</authname><surname>Peng</surname><given-name>Bin</given-name><initials>B.</initials><afid>60016521</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56491431000</author-url><authid>56491431000</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Yi Han</given-name><initials>Y.H.</initials><afid>60016521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56641908600</author-url><authid>56641908600</authid><authname>Liu Y.</authname><surname>Liu</surname><given-name>Yong Mei</given-name><initials>Y.M.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640176800</author-url><authid>56640176800</authid><authname>Ma L.</authname><surname>Ma</surname><given-name>Lei Xue</given-name><initials>L.X.</initials><afid>60016521</afid></author><authkeywords>Neutrophil to lymphocyte ratio | NLR | Non-small cell lung cancer | NSCLC | Overall survival | Progress-free survival | Treatment response</authkeywords><intid>1035913263</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930089116"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930089116?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930089116&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930089116&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000595"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930089116</prism:url><dc:identifier>SCOPUS_ID:84930089116</dc:identifier><eid>2-s2.0-84930089116</eid><dc:title>Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin</dc:title><dc:creator>Collino M.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>32-40</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.02.005</prism:doi><pii>S0163725815000595</pii><dc:description>© 2015 The Authors. Published by Elsevier Inc. Many disease processes activate a cellular stress response that initiates a cascade of inflammation and damage. However, this process also triggers a tissue protection and repair system mediated by locally-produced hyposialated erythropoietin (hsEPO). Although recombinant EPO is used widely for treating anemia, potential use of recombinant EPO for tissue-protection is limited by rises in hematocrit, platelet activation, and selectin expression resulting in a high risk of thrombosis. Importantly, the erythropoietic and tissue-protective effects of EPO are mediated by different receptors. Whereas EPO stimulates red cell progenitors by binding to an EPO receptor (EPOR) homodimer, a heterodimer receptor complex composed of EPOR and β common receptor (βcR) subunits, termed the innate repair receptor (IRR), activates tissue protection and repair. The IRR is typically not expressed by normal tissues, but instead is rapidly induced by injury or inflammation. Based on this understanding, EPO derivatives have been developed which selectively activate the IRR without interacting with the EPOR homodimer. The latest generation of specific ligands of the IRR includes an 11 amino acid peptide modeled from the three dimensional structure of the EPO in the region of helix B called pyroglutamate helix B surface peptide (pHBSP; ARA-290). Despite a short plasma half-life (~2 min), pHBSP activates a molecular switch that triggers sustained biological effects that have been observed in a number of experimental animal models of disease and in clinical trials. This review summarizes pharmacokinetic and pharmacodynamic data and discusses the molecular mechanisms underlying the long-lasting effects of this short-lived peptide.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012259</affiliation-url><afid>60012259</afid><affilname>Universita degli Studi di Torino</affilname><name-variant>University of Torino</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021435</affiliation-url><afid>60021435</afid><affilname>Barts and The London Queen Mary's School of Medicine and Dentistry</affilname><name-variant>Queen Mary University of London</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114211047</affiliation-url><afid>114211047</afid><affilname>Araim Pharmaceuticals</affilname><name-variant>Araim Pharmaceuticals</name-variant><affiliation-city>Tarrytown</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506832448</author-url><authid>6506832448</authid><authname>Collino M.</authname><surname>Collino</surname><given-name>Massimo</given-name><initials>M.</initials><afid>60012259</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102225147</author-url><authid>7102225147</authid><authname>Thiemermann C.</authname><surname>Thiemermann</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60021435</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36042792000</author-url><authid>36042792000</authid><authname>Cerami A.</authname><surname>Cerami</surname><given-name>Anthony</given-name><initials>A.</initials><afid>114211047</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56031243700</author-url><authid>56031243700</authid><authname>Brines M.</authname><surname>Brines</surname><given-name>Michael</given-name><initials>M.</initials><afid>114211047</afid></author><authkeywords>ARA 290 | Erythropoietin | Innate repair receptor | Pyroglutamate helix B surface protein | β common receptor</authkeywords><intid>1536063740</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210802"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210802?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210802&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210802&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0959804915002890"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210802</prism:url><dc:identifier>SCOPUS_ID:84930210802</dc:identifier><eid>2-s2.0-84930210802</eid><dc:title>Childhood height increases the risk of prostate cancer mortality</dc:title><dc:creator>Aarestrup J.</dc:creator><prism:publicationName>European Journal of Cancer</prism:publicationName><prism:issn>09598049</prism:issn><prism:eIssn>18790852</prism:eIssn><prism:volume>51</prism:volume><prism:issueIdentifier>10</prism:issueIdentifier><prism:pageRange>1340-1345</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejca.2015.03.022</prism:doi><pii>S0959804915002890</pii><dc:description>© 2015 Elsevier Ltd. Background Adult body size is positively associated with aggressive and fatal prostate cancers. It is unknown whether these associations originate in early life. Therefore, we investigated if childhood height, body mass index (BMI; kg/m&lt;sup&gt;2&lt;/sup&gt;) and growth are associated with prostate cancer-specific mortality and survival. Methods Subjects were 125,208 men from the Copenhagen School Health Records Register, born 1930-1969 with height and weight measurements at ages 7-13 years. Linkage to the Danish Cancer Registry and the Register of Causes of Death enabled identification of incident and fatal prostate cancers. Cox proportional hazards regressions were performed. Results 630 men had prostate cancer recorded as the underlying cause of death. Childhood height at age 13 years was positively associated with prostate cancer-specific mortality (hazard ratio [HR]&lt;inf&gt;per z-score&lt;/inf&gt; = 1.2, 95% confidence interval [CI]: 1.1-1.3). Associations were significant at all other childhood ages. Growth analyses showed that height at age 13 years had a stronger association with prostate cancer-specific mortality than height at age 7, suggesting the association at age 7 is largely mediated through later childhood height. The tallest boys at age 13 years had a significantly worse survival, but only when restricted to a diagnosis at &lt;60 years of age (HR&lt;inf&gt;z&lt;/inf&gt;&lt;inf&gt;-score of 1&lt;/inf&gt; = 1.7, 95% CI: 1.3-2.4). These associations were significant at all other childhood ages. Childhood BMI was not associated with prostate cancer mortality or survival. Conclusion Childhood height was positively associated with the hard end-point of prostate cancer-specific mortality, which strengthens prior epidemiologic observations of a positive association with prostate cancer incidence.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60083843</affiliation-url><afid>60083843</afid><affilname>Institut for Sygdomsforebyggelse</affilname><name-variant>Institute of Preventive Medicine</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013409</affiliation-url><afid>60013409</afid><affilname>National Cancer Institute</affilname><name-variant>NIH</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030840</affiliation-url><afid>60030840</afid><affilname>Kobenhavns Universitet</affilname><name-variant>University of Copenhagen</name-variant><affiliation-city>Copenhagen</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54945432600</author-url><authid>54945432600</authid><authname>Aarestrup J.</authname><surname>Aarestrup</surname><given-name>J.</given-name><initials>J.</initials><afid>60083843</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6506798808</author-url><authid>6506798808</authid><authname>Gamborg M.</authname><surname>Gamborg</surname><given-name>M.</given-name><initials>M.</initials><afid>60083843</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:27171765100</author-url><authid>27171765100</authid><authname>Cook M.</authname><surname>Cook</surname><given-name>M. B.</given-name><initials>M.B.</initials><afid>60013409</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8705509600</author-url><authid>8705509600</authid><authname>Baker J.</authname><surname>Baker</surname><given-name>J. L.</given-name><initials>J.L.</initials><afid>60083843</afid><afid>60030840</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8705509600</author-url><authid>8705509600</authid><authname>Baker J.</authname><surname>Baker</surname><given-name>J. L.</given-name><initials>J.L.</initials><afid>60083843</afid><afid>60030840</afid></author><authkeywords>Abbreviations BMI body mass index | CI confidence interval | HR hazard ratio | ICD International Classification of Diseases | ID identification</authkeywords><intid>1786088525</intid><source-id>29761</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930081819"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930081819?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930081819&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930081819&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000480"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930081819</prism:url><dc:identifier>SCOPUS_ID:84930081819</dc:identifier><eid>2-s2.0-84930081819</eid><dc:title>Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer</dc:title><dc:creator>Sampath D.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>16-31</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.02.004</prism:doi><pii>S0163725815000480</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. NAD is a metabolite that is an important cofactor and second messenger for a number of cellular processes such as genomic stability and metabolism that are essential for survival. NAD is generated de novo from tryptophan or recycled from NAM through the NAMPT-dependent salvage pathway. Alternatively, cells can convert NA to NAD through the NAPRT1-dependent salvage pathway. Tumor cells rapidly turn over NAD but do not efficiently utilize the de novo synthesis pathway. Hence, they are more reliant on the NAMPT salvage pathway for NAD regeneration making this enzyme an attractive therapeutic target for cancer. NAMPT is over-expressed in a number of cancer types such as colorectal, ovarian, breast, gastric, prostate, gliomas as well as B-cell lymphomas. A number of novel, potent and selective NAMPT small molecule inhibitors have been synthesized to date that have displayed robust anti-tumor activity in tumor models in vitro and in vivo. These inhibitors efficiently suppress NAD production in a time dependent manner and sustained reduction of NAD levels leads to loss of ATP and ultimately cell death. This review will summarize the chemical properties of these unique NAMPT inhibitors as well as their mechanism of action, pharmacodynamic activity and efficacy in tumor models in vitro and in vivo. An overview of biomarkers that predict response to treatment and mechanisms of resistance to NAMPT inhibitors will also be provided. Additionally, NAMPT inhibitors that have advanced into clinical trials will be reviewed along with experimental strategies tested to potentially increase the therapeutic index of these inhibitors.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026209</affiliation-url><afid>60026209</afid><affilname>Genentech Incorporated</affilname><name-variant>Genentech Inc.</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026209</affiliation-url><afid>60026209</afid><affilname>Genentech Incorporated</affilname><name-variant>Genentech Inc.</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026209</affiliation-url><afid>60026209</afid><affilname>Genentech Incorporated</affilname><name-variant>Genentech Inc.</name-variant><affiliation-city>San Francisco</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35410461100</author-url><authid>35410461100</authid><authname>Sampath D.</authname><surname>Sampath</surname><given-name>Deepak</given-name><initials>D.</initials><afid>60026209</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6508099142</author-url><authid>6508099142</authid><authname>Zabka T.</authname><surname>Zabka</surname><given-name>Tanja S.</given-name><initials>T.S.</initials><afid>60026209</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6505960176</author-url><authid>6505960176</authid><authname>Misner D.</authname><surname>Misner</surname><given-name>Dinah L.</given-name><initials>D.L.</initials><afid>60026209</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7402528658</author-url><authid>7402528658</authid><authname>O'Brien T.</authname><surname>O'Brien</surname><given-name>Thomas</given-name><initials>T.</initials><afid>60026209</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701395250</author-url><authid>6701395250</authid><authname>Dragovich P.</authname><surname>Dragovich</surname><given-name>Peter S.</given-name><initials>P.S.</initials><afid>60026209</afid></author><authkeywords>NAD | NAMPT | NAPRT1 | Targeted agents | Tumor metabolism</authkeywords><intid>1036058793</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929347428"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929347428?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929347428&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929347428&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929347428</prism:url><dc:identifier>SCOPUS_ID:84929347428</dc:identifier><eid>2-s2.0-84929347428</eid><dc:title>Effect of ginkgolide B on brain metabolism and tissue oxygenation in severe haemorrhagic stroke</dc:title><dc:creator>Chi C.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3522-3529</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. Ginkgolide B, a diterpene, is an herbal constituent isolated from the leaves of Ginkgo biloba tree. The present study demonstrates the effect of ginkgolide B in osmotherapy on brain metabolism and tissue oxygenation. Multimodality monitoring including intracranial pressure (ICP), cerebral perfusion pressure (CPP), partial pressure of brain tissue oxygen (PbtO2), lactate/pyruvate ratio (LPR) and microdialysis were employed to study the effect of ginkgolide B osmotherapy. The results demonstrated that administration of 15% solution of ginkgolide B to the comatose patients with raised ICP (&gt; 20 mm Hg) and resistant to standard therapy led to a significant decrease in ICP. The cerebral microdialysis was used to compare mean arterial blood pressure (MAP), ICP, CPP, PbtO2, brain lactate, pyruvate and glucose level after hourly intervals starting 3 h before and up to 4 h after hyperosmolar therapy. There was a decrease in ICP in 45 min from 23 ± 14 mm Hg (P &lt; 0.001) to 18 ± 24 mm Hg and increase in CPP after 1 h of gingkolide B infusion from 74 ± 18 to 85 ± 22 mm Hg (P &lt; 0.002). However there was no significant effect on MAP but PbtO2 was maintained in the range of 22-26. The peak lactate/pyruvate ratio was recorded at the time of initiation of osmotherapy (44 ± 20) with an 18% decrease over 2 h following gingkolide B therapy. Also the brain glucose remained unaffected.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021615</affiliation-url><afid>60021615</afid><affilname>Harbin Medical University</affilname><name-variant>Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021615</affiliation-url><afid>60021615</afid><affilname>Harbin Medical University</affilname><name-variant>Harbin Medical University</name-variant><affiliation-city>Harbin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643924700</author-url><authid>56643924700</authid><authname>Chi C.</authname><surname>Chi</surname><given-name>Chun Ling</given-name><initials>C.L.</initials><afid>60021615</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36640851900</author-url><authid>36640851900</authid><authname>Shen D.</authname><surname>Shen</surname><given-name>Dong Fang</given-name><initials>D.F.</initials><afid>60021615</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55718487200</author-url><authid>55718487200</authid><authname>Wang P.</authname><surname>Wang</surname><given-name>Peng Jun</given-name><initials>P.J.</initials><afid>60021615</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56440944200</author-url><authid>56440944200</authid><authname>Li H.</authname><surname>Li</surname><given-name>Hu Lun</given-name><initials>H.L.</initials><afid>60021615</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56643370100</author-url><authid>56643370100</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Li</given-name><initials>L.</initials><afid>60021615</afid></author><authkeywords>Infusion | Intracranial pressure | Microdialysis | Osmotherapy | Perfusion pressure</authkeywords><intid>1035940749</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930195371"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930195371?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930195371&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930195371&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315008669"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930195371</prism:url><dc:identifier>SCOPUS_ID:84930195371</dc:identifier><eid>2-s2.0-84930195371</eid><dc:title>Influence factors might elevate blood red cell distribution width levels in postoperative atrial fibrillation patients</dc:title><dc:creator>Wang C.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>190</prism:volume><prism:pageRange>53</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.143</prism:doi><pii>S0167527315008669</pii><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010432</affiliation-url><afid>60010432</afid><affilname>Soochow University</affilname><name-variant>Suzhou University</name-variant><affiliation-city>Suzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>le</subtype><subtypeDescription>Letter</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55941619800</author-url><authid>55941619800</authid><authname>Wang C.</authname><surname>Wang</surname><given-name>Chang Guo</given-name><initials>C.G.</initials><afid>60010432</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55241283800</author-url><authid>55241283800</authid><authname>Lei W.</authname><surname>Lei</surname><given-name>Wei</given-name><initials>W.</initials><afid>60010432</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56270102800</author-url><authid>56270102800</authid><authname>Huang J.</authname><surname>Huang</surname><given-name>Jian An</given-name><initials>J.A.</initials><afid>60010432</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:21733833700</author-url><authid>21733833700</authid><authname>Zeng D.</authname><surname>Zeng</surname><given-name>Da Xiong</given-name><initials>D.X.</initials><afid>60010432</afid></author><authkeywords>Influence factor | Postoperative atrial fibrillation | Red cell distribution width</authkeywords><intid>2036082361</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930087450"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930087450?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930087450&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930087450&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0163725815000637"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930087450</prism:url><dc:identifier>SCOPUS_ID:84930087450</dc:identifier><eid>2-s2.0-84930087450</eid><dc:title>DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications</dc:title><dc:creator>Abbassi R.</dc:creator><prism:publicationName>Pharmacology and Therapeutics</prism:publicationName><prism:issn>01637258</prism:issn><prism:eIssn>1879016X</prism:eIssn><prism:volume>151</prism:volume><prism:pageRange>87-98</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.pharmthera.2015.03.004</prism:doi><pii>S0163725815000637</pii><dc:description>© 2015 Elsevier Inc. All rights reserved. Protein kinases are one of the most studied drug targets in current pharmacological research, as evidenced by the vast number of kinase-targeting agents enrolled in active clinical trials. Dual-specificity Tyrosine phosphorylation-Regulated Kinase 1A (DYRK1A) has been much less studied compared to many other kinases. DYRK1A primary function occurs during early development, where this protein regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells. Although most extensively characterised for its role in brain development, DYRK1A is over-expressed in a variety of diseases including a number of human malignancies, such as haematological and brain cancers. Here we review the accumulating molecular studies that support our understanding of how DYRK1A signalling could underlie these pathological functions. The relevance of DYRK1A in a number of diseases is also substantiated with intensive drug discovery efforts to develop potent and selective inhibitors of DYRK1A. Several classes of DYRK1A inhibitors have recently been disclosed and some molecules are promising leads to develop DYRK1A inhibitors as drugs for DYRK1A-dependent diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114153083</affiliation-url><afid>114153083</afid><affilname>MIMR-PHI Institute of Medical Research</affilname><name-variant>MIMR-PHI Institute of Medical Research</name-variant><affiliation-city>Clayton</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56587771200</author-url><authid>56587771200</authid><authname>Abbassi R.</authname><surname>Abbassi</surname><given-name>Ramzi</given-name><initials>R.</initials><afid>60025709</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587558500</author-url><authid>56587558500</authid><authname>Johns T.</authname><surname>Johns</surname><given-name>Terrance G.</given-name><initials>T.G.</initials><afid>114153083</afid><afid>60019578</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56587558500</author-url><authid>56587558500</authid><authname>Johns T.</authname><surname>Johns</surname><given-name>Terrance G.</given-name><initials>T.G.</initials><afid>114153083</afid><afid>60019578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7004711695</author-url><authid>7004711695</authid><authname>Kassiou M.</authname><surname>Kassiou</surname><given-name>Michael</given-name><initials>M.</initials><afid>60025709</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15762955600</author-url><authid>15762955600</authid><authname>Munoz L.</authname><surname>Munoz</surname><given-name>Lenka</given-name><initials>L.</initials><afid>60025709</afid></author><authkeywords>Alzheimer's disease | Cancer | Down syndrome | Dual-specificity kinases | DYRK1A | Kinase inhibitors</authkeywords><intid>2036058340</intid><source-id>21195</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359753"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359753?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359753&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359753&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359753</prism:url><dc:identifier>SCOPUS_ID:84929359753</dc:identifier><eid>2-s2.0-84929359753</eid><dc:title>Neuroprotective effect of ginseng against spinal cord injury induced oxidative stress and inflammatory responses</dc:title><dc:creator>Wang W.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3514-3521</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. The pathophysiological effects of spinal cord injury (SCI) occur as a result of oxidative stress and inflammatory mechanisms. In the present study we analyzed the protective role of ginseng on spinal injury in wistar rats. To evaluate the redox status, we investigated various parameters including estimation of reactive oxygen species, lipid peroxidation content, protein carbonyl and sulphydryl content, myeloperoxidase activity, antioxidant status (superoxide dismutase, catalase, glutathione peroxidase, glutathione-s-transferase). Expression of antioxidant transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) was determined through immunoblot. Inflammatory study was performed by evaluating the expression of nuclear factor-κB, cycloxygenase-2 by western blot analysis. Further the pro-inflammatory cytokines were determined through ELISA (IL-6, TNF-α, IL-1β). We observed a significant enhancement in oxidative stress and inflammatory markers in rats with SCI injury. Ginseng treatment significantly down regulated the oxidative stress by enhancing the antioxidant status in SCI rats. Significant inhibition of inflammation was observed through down regulation of inflammatory proteins and pro-inflammatory cytokines. Thus our findings show that Ginseng significantly ameliorated spinal cord injury in wistar rats by modulating oxidative stress and inflammation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56200126200</author-url><authid>56200126200</authid><authname>Wang W.</authname><surname>Wang</surname><given-name>Wei</given-name><initials>W.</initials><afid>60025084</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56588226100</author-url><authid>56588226100</authid><authname>Shen H.</authname><surname>Shen</surname><given-name>Hao</given-name><initials>H.</initials><afid>60025084</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56062358400</author-url><authid>56062358400</authid><authname>Xie J.</authname><surname>Xie</surname><given-name>Jing Jing</given-name><initials>J.J.</initials><afid>60025084</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643989600</author-url><authid>56643989600</authid><authname>Ling J.</authname><surname>Ling</surname><given-name>Jian</given-name><initials>J.</initials><afid>60025084</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37048310500</author-url><authid>37048310500</authid><authname>Lu H.</authname><surname>Lu</surname><given-name>Hua</given-name><initials>H.</initials><afid>60025084</afid></author><authkeywords>Antioxidant | Antioxidant | Cytokines | Ginseng | Inflammation | Oxidative stress | Spinal cord injury</authkeywords><intid>1535944883</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929380383"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929380383?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929380383&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929380383&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929380383</prism:url><dc:identifier>SCOPUS_ID:84929380383</dc:identifier><eid>2-s2.0-84929380383</eid><dc:title>Biodegradation and biocompatibility of a degradable chitosan vascular prosthesis</dc:title><dc:creator>Kong X.</dc:creator><prism:publicationName>International Journal of Clinical and Experimental Medicine</prism:publicationName><prism:eIssn>19405901</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>3498-3505</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><dc:description>© 2015, E-Century Publishing Corporation. All rights reserved. An instrument made by ourselves was used to fabricate biodegradable chitosan-heparin artificial vascular prosthesis with small internal diameter (2 mm) and different crosslinking degree from biodegradable chitosan, chitosan derivates and heparin. In vivo and in vitro degradation studies, inflammatory analysis and electron microscope scanning of this artificial vascular prosthesis were performed. It was observed that 50% of the prosthesis decomposed in vivo and was replaced by natural tissues. The degradation process of the chitosan-heparin artificial vascular prosthesis of small diameter could be controlled by changing the crosslinking degree. This kind of artificial vascular prosthesis shows good biocompatibility that can be controllability designed to achieve desirable in vascular replacement application.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60088079</affiliation-url><afid>60088079</afid><affilname>Qingdao Agricultural University</affilname><name-variant>Qingdao Agricultural University</name-variant><affiliation-city>Qingdao</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030434</affiliation-url><afid>60030434</afid><affilname>Qingdao University</affilname><name-variant>Qingdao University</name-variant><affiliation-city>Qingdao</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56643723500</author-url><authid>56643723500</authid><authname>Kong X.</authname><surname>Kong</surname><given-name>Xiaoying</given-name><initials>X.</initials><afid>60088079</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56215058600</author-url><authid>56215058600</authid><authname>Xu W.</authname><surname>Xu</surname><given-name>Wenhua</given-name><initials>W.</initials><afid>60030434</afid></author><authkeywords>Artificial vascular prosthesis | Biodegradable | Chitosan | Degradation | Small-diameter</authkeywords><intid>535945196</intid><source-id>17600155122</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930081449"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930081449?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930081449&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930081449&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0001868615000597"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930081449</prism:url><dc:identifier>SCOPUS_ID:84930081449</dc:identifier><eid>2-s2.0-84930081449</eid><dc:title>Beyond the hydrophobic effect: Critical function of water at biological phase boundaries - A hypothesis</dc:title><dc:creator>Damodaran S.</dc:creator><prism:publicationName>Advances in Colloid and Interface Science</prism:publicationName><prism:issn>00018686</prism:issn><prism:volume>221</prism:volume><prism:pageRange>22-33</prism:pageRange><prism:coverDate>2015-05-30</prism:coverDate><prism:coverDisplayDate>30 May 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cis.2015.03.005</prism:doi><pii>S0001868615000597</pii><dc:description>© 2015 Elsevier B.V. All rights reserved. Many life-sustaining processes in living cells occur at the membrane-water interface. The pertinent questions that need to be asked are what is the evolutionary reason for biology to choose the membrane-water interface as the site for performing and/or controlling crucial biological reactions and what is the key physical principle that is singular to the membrane-water interface that biology exploits for regulating metabolic processes in cells? In this review, a hypothesis is developed, which espouses that cells control activities of membrane-bound enzymes and receptor activated processes via manipulating the thermodynamic activity of water at the membrane-water interfacial region. In support of this hypothesis, first we establish that the surface pressure of a lipid monolayer is a direct measure of a reduction in the thermodynamic activity of interfacial water. Second, we show that the surface pressure-dependent activation/inactivation of interfacial enzymes is fundamentally related to their dependence on interfacial water activity. We extend this argument to infer that cells might manipulate activities of membrane-associated biological processes via manipulating the activity of interfacial water via localized compression or expansion of the interface. In this paper, we critically analyze literature data on mechano-activation of large pore ion channels in Escherichia coli spheroplasts and G-proteins in reconstituted lipid vesicles, and show that these pressure-induced activation processes are fundamentally and quantitatively related to changes in the thermodynamic state of interfacial water, caused by mechanical stretching of the bilayer.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032179</affiliation-url><afid>60032179</afid><affilname>University of Wisconsin Madison</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56238633800</author-url><authid>56238633800</authid><authname>Damodaran S.</authname><surname>Damodaran</surname><given-name>Srinivasan</given-name><initials>S.</initials><afid>60032179</afid></author><authkeywords>G-protein activation | Interfacial activation of enzymes | Interfacial water activity | Mechanoactivation | Membrane function</authkeywords><intid>36062276</intid><source-id>26533</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930209048"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930209048?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930209048&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930209048&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930209048</prism:url><dc:identifier>SCOPUS_ID:84930209048</dc:identifier><eid>2-s2.0-84930209048</eid><dc:title>Perioperative heart failure - Anesthetic management and monitoring | Perioperative Herzinsuffizienz - Anästhesieführung und Monitoring</dc:title><dc:creator>Grünewald M.</dc:creator><prism:publicationName>Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie</prism:publicationName><prism:issn>09392661</prism:issn><prism:eIssn>14391074</prism:eIssn><prism:volume>50</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>350-356</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-102297</prism:doi><dc:description>Due to the demographic and medical development, the number of patients with heart failure needing anaesthesiological care will continue to grow in the upcoming years. For the optimal care of these patients close coordination between the surgically treating, the cardiology and the anesthesiological department is important. Cardiac function and structural characters, such as cardiac valve defects should be known preoperatively. Thus, the anaesthetic management, intraoperative monitoring, as well as necessary pharmacological interventions can be tailored. Especially in high-risk patients goal directed hemodynamic therapy is useful. For this, in addition to the established monitoring procedures, less invasive monitoring devices areincreasingly used. During an acutehaemodynamic instability, thetransoesophageal echocardiography is gaining importance due to its wide diagnostic evaluation.</dc:description><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56262908100</author-url><authid>56262908100</authid><authname>Grünewald M.</authname><surname>Grünewald</surname><given-name>Matthias</given-name><initials>M.</initials></author><authkeywords>haemodynamic therapy | heart failure | high-risk patients | monitoring | transoesophageal echocardiography</authkeywords><intid>1036081874</intid><source-id>21394</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210625"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210625?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210625&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210625&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210625</prism:url><dc:identifier>SCOPUS_ID:84930210625</dc:identifier><eid>2-s2.0-84930210625</eid><dc:title>Perioperative heart failure - Acute intraoperative heart failure | Perioperative Herzinsuffizienz - Akute intraoperative Herzinsuffizienz</dc:title><dc:creator>Heringlake M.</dc:creator><prism:publicationName>Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie</prism:publicationName><prism:issn>09392661</prism:issn><prism:eIssn>14391074</prism:eIssn><prism:volume>50</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>340-347</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-101687</prism:doi><dc:description>With respect to the fact that - with the notable exception of patients undergoing cardiac surgery - only sparse data and limited guideline recommendations on optimal treatment strategies in patients with intraoperative acute heart failure are available. Consecutively it is rather difficult to make clear suggestions for the optimal treatment of this complication. However, data based on treatment of medical patients with acute heart failure suggest that it may be reasonable first to echocardiographically determine the specific cardiac pathology, especially with respect to systolic and diastolic function and/or presence of acute myocardial ischemia and subsequently treat the specific problem in a goal-directed approach. Importantly, one has to to take into account that the use of beta-mimetic drugs for the treatment of acute heart failure is increasingly recognized as an isolated mortality factor. This suggests to use inotropes as restrictive as possible, and if inotropic treatment becomes inevitable, to use levosimendan as the only inotrope that has been shown to improve mortality in several meta-analyses.</dc:description><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26643106400</author-url><authid>26643106400</authid><authname>Heringlake M.</authname><surname>Heringlake</surname><given-name>Matthias</given-name><initials>M.</initials></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35750276300</author-url><authid>35750276300</authid><authname>Paarmann H.</authname><surname>Paarmann</surname><given-name>Hauke</given-name><initials>H.</initials></author><authkeywords>anesthesia. | cardiogenic shock | diastolic dysfunction | Left heart failure | low-cardiac output syndrome | pulmonary arterial hypertension | right heart failure</authkeywords><intid>1536087165</intid><source-id>21394</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216538"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216538?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216538&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216538&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216538</prism:url><dc:identifier>SCOPUS_ID:84930216538</dc:identifier><eid>2-s2.0-84930216538</eid><dc:title>Functional effect of Pim1 depends upon intracellular localization in human cardiac progenitor cells</dc:title><dc:creator>Samse K.</dc:creator><prism:publicationName>Journal of Biological Chemistry</prism:publicationName><prism:issn>00219258</prism:issn><prism:eIssn>1083351X</prism:eIssn><prism:volume>290</prism:volume><prism:issueIdentifier>22</prism:issueIdentifier><prism:pageRange>13935-13947</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1074/jbc.M114.617431</prism:doi><dc:description>© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Human cardiac progenitor cells (hCPC) improve heart function after autologous transfer in heart failure patients. Regenerative potential of hCPCs is severely limited with age, requiring genetic modification to enhance therapeutic potential. A legacy of work from our laboratory with Pim1 kinase reveals effects on proliferation, survival, metabolism, and rejuvenation of hCPCs in vitro and in vivo. We demonstrate that subcellular targeting of Pim1 bolsters the distinct cardioprotective effects of this kinase in hCPCs to increase proliferation and survival, and antagonize cellular senescence. Adult hCPCs isolated from patients undergoing left ventricular assist device implantation were engineered to overexpress Pim1 throughout the cell (PimWT) or targeted to either mitochondrial (Mito-Pim1) or nuclear (Nuc-Pim1) compartments. Nuc-Pim1 enhances stem cell youthfulness associated with decreased senescence-associated β-galactosidase activity, preserved telomere length, reduced expression of p16 and p53, and up-regulation of nucleostemin relative to PimWT hCPCs. Alternately, Mito-Pim1 enhances survival by increasing expression of Bcl-2 and Bcl-X&lt;inf&gt;L&lt;/inf&gt;and decreasing cell death after H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; treatment, thereby preserving mitochondrial integrity superior to PimWT. Mito-Pim1 increases the proliferation rate by up-regulation of cell cycle modulators Cyclin D, CDK4, and phospho-Rb. Optimal stem cell traits such as proliferation, survival, and increased youthful properties of aged hCPCs are enhanced after targeted Pim1 localization to mitochondrial or nuclear compartments. Targeted Pim1 overexpression in hCPCs allows for selection of the desired phenotypic properties to overcome patient variability and improve specific stem cell characteristics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018926</affiliation-url><afid>60018926</afid><affilname>San Diego State University</affilname><name-variant>San Diego State University</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030612</affiliation-url><afid>60030612</afid><affilname>University of California, San Diego</affilname><name-variant>University of California San Diego</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025550</affiliation-url><afid>60025550</afid><affilname>Sharp Memorial Hospital</affilname><name-variant>Sharp Memorial Hospital</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55863021300</author-url><authid>55863021300</authid><authname>Samse K.</authname><surname>Samse</surname><given-name>Kaitlen</given-name><initials>K.</initials><afid>60018926</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56287408400</author-url><authid>56287408400</authid><authname>Emathinger J.</authname><surname>Emathinger</surname><given-name>Jacqueline</given-name><initials>J.</initials><afid>60018926</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:24281198400</author-url><authid>24281198400</authid><authname>Hariharan N.</authname><surname>Hariharan</surname><given-name>Nirmala</given-name><initials>N.</initials><afid>60018926</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24177095400</author-url><authid>24177095400</authid><authname>Quijada P.</authname><surname>Quijada</surname><given-name>Pearl</given-name><initials>P.</initials><afid>60018926</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56663022400</author-url><authid>56663022400</authid><authname>Ilves K.</authname><surname>Ilves</surname><given-name>Kelli</given-name><initials>K.</initials><afid>60018926</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:9735124000</author-url><authid>9735124000</authid><authname>Völkers M.</authname><surname>Völkers</surname><given-name>Mirko</given-name><initials>M.</initials><afid>60018926</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55682559300</author-url><authid>55682559300</authid><authname>Ormachea L.</authname><surname>Ormachea</surname><given-name>Lucia</given-name><initials>L.</initials><afid>60018926</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55694439400</author-url><authid>55694439400</authid><authname>De La Torre A.</authname><surname>De La Torre</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60018926</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55236523400</author-url><authid>55236523400</authid><authname>Orogo A.</authname><surname>Orogo</surname><given-name>Amabel M.</given-name><initials>A.M.</initials><afid>60030612</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36813254100</author-url><authid>36813254100</authid><authname>Alvarez R.</authname><surname>Alvarez</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60018926</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:25031447400</author-url><authid>25031447400</authid><authname>Din S.</authname><surname>Din</surname><given-name>Shabana</given-name><initials>S.</initials><afid>60018926</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:26427742400</author-url><authid>26427742400</authid><authname>Mohsin S.</authname><surname>Mohsin</surname><given-name>Sadia</given-name><initials>S.</initials><afid>60018926</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55445136900</author-url><authid>55445136900</authid><authname>Monsanto M.</authname><surname>Monsanto</surname><given-name>Megan</given-name><initials>M.</initials><afid>60018926</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7403154431</author-url><authid>7403154431</authid><authname>Fischer K.</authname><surname>Fischer</surname><given-name>Kimberlee M.</given-name><initials>K.M.</initials><afid>60018926</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7003927827</author-url><authid>7003927827</authid><authname>Dembitsky W.</authname><surname>Dembitsky</surname><given-name>Walter P.</given-name><initials>W.P.</initials><afid>60025550</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:8787569000</author-url><authid>8787569000</authid><authname>Gustafsson Å.</authname><surname>Gustafsson</surname><given-name>Åsa B.</given-name><initials>Å.B.</initials><afid>60030612</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7102731100</author-url><authid>7102731100</authid><authname>Sussman M.</authname><surname>Sussman</surname><given-name>Mark A.</given-name><initials>M.A.</initials><afid>60018926</afid></author><intid>36085813</intid><source-id>17592</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930216555"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930216555?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930216555&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930216555&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930216555</prism:url><dc:identifier>SCOPUS_ID:84930216555</dc:identifier><eid>2-s2.0-84930216555</eid><dc:title>Value of human brain natriuretic peptide in treatment of acute anterior myocardial infarction evaluated via three-dimensional speckle tracking imaging</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Genetics and Molecular Research</prism:publicationName><prism:eIssn>16765680</prism:eIssn><prism:volume>14</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>5699-5709</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.4238/2015.May.29.2</prism:doi><dc:description>© FUNPEC-RP. Three-dimensional ultrasound speckle tracking imaging was used to evaluate the effects of recombinant human brain natriuretic peptide (rhBNP) in acute anterior and extensive anterior myocardial infarction. Ninety patients with acute anterior or extensive myocardial infarction were randomly divided into 3 groups: Group A [emergency percutaneous coronary intervention (PCI)], Group B (emergency PCI + rhBNP early treatment), and Group C (emergency PCI + late rhBNP treatment). Within 6 h of admission and at 1 week and 3 and 6 months after PCI, patients underwent routine transthoracic echocardiography and real-time three-dimensional echocardiography. At 1 week, 1 month, 3 months, 6 months, and 12 months, ejection fraction values in groups B and C were significantly greater than those in group A (P &lt; 0.05), and left ventricular end-diastolic volume and left ventricular end-systolic volume values in groups B and C were less than those in group A (P &lt; 0.05). Within 6 h of admission in each group, long-axis, radial, circumferential, and area variables corresponding to anterior descending artery segments showed no significant difference (all P &gt; 0.05). However, at 1 week, 1 month, 3 months, 6 months, and 12 months, long-axis, radial, circumferential and area variables in groups B and C were significantly less than those in group A (P &lt; 0.05). Intervention with rhBNP can improve resilience of the local myocardium, left ventricular mechanical function, and cardiac remodeling. Within 6 h of admission or after PCI, rhBNP application showed no significant difference in heart function improvement or myocardial remodeling inhibition.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002593</affiliation-url><afid>60002593</afid><affilname>Southern Medical University</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>TongHe</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002593</affiliation-url><afid>60002593</afid><affilname>Southern Medical University</affilname><name-variant>Southern Medical University</name-variant><affiliation-city>TongHe</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005206</affiliation-url><afid>60005206</afid><affilname>Fujian Medical University</affilname><name-variant>Fujian Medical University</name-variant><affiliation-city>Fuzhou</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7601318514</author-url><authid>7601318514</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7601318514</author-url><authid>7601318514</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662635300</author-url><authid>56662635300</authid><authname>Gao F.</authname><surname>Gao</surname><given-name>F.</given-name><initials>F.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56662635300</author-url><authid>56662635300</authid><authname>Gao F.</authname><surname>Gao</surname><given-name>F.</given-name><initials>F.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55904695200</author-url><authid>55904695200</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>X. Y.</given-name><initials>X.Y.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55904695200</author-url><authid>55904695200</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>X. Y.</given-name><initials>X.Y.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662638200</author-url><authid>56662638200</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Y. M.</given-name><initials>Y.M.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662638200</author-url><authid>56662638200</authid><authname>Hou Y.</authname><surname>Hou</surname><given-name>Y. M.</given-name><initials>Y.M.</initials><afid>60002593</afid><afid>60002593</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56662590000</author-url><authid>56662590000</authid><authname>Tang Y.</authname><surname>Tang</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60005206</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7408522012</author-url><authid>7408522012</authid><authname>Yang S.</authname><surname>Yang</surname><given-name>S. L.</given-name><initials>S.L.</initials><afid>60005206</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662605300</author-url><authid>56662605300</authid><authname>Zhu S.</authname><surname>Zhu</surname><given-name>S. H.</given-name><initials>S.H.</initials><afid>60005206</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56662718100</author-url><authid>56662718100</authid><authname>Luo R.</authname><surname>Luo</surname><given-name>R. Y.</given-name><initials>R.Y.</initials><afid>60005206</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662553400</author-url><authid>56662553400</authid><authname>Lin S.</authname><surname>Lin</surname><given-name>S. F.</given-name><initials>S.F.</initials><afid>60005206</afid></author><authkeywords>Echocardiography | Myocardial infarction | Recombinant human brain natriuretic peptide | Three-dimensional speckle tracking imaging technology | Ventricular function</authkeywords><intid>2036081874</intid><source-id>22190</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930202252"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930202252?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930202252&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930202252&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930202252</prism:url><dc:identifier>SCOPUS_ID:84930202252</dc:identifier><eid>2-s2.0-84930202252</eid><dc:title>Perioperative heart failure - A special challenge for anaesthesiology | Perioperative Herzinsuffizienz - Eine besondere Herausforderung für die Anästhesie</dc:title><dc:creator>Bein B.</dc:creator><prism:publicationName>Anasthesiologie Intensivmedizin Notfallmedizin Schmerztherapie</prism:publicationName><prism:issn>09392661</prism:issn><prism:eIssn>14391074</prism:eIssn><prism:volume>50</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>328-329</prism:pageRange><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1055/s-0041-102211</prism:doi><citedby-count>0</citedby-count><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56572316400</author-url><authid>56572316400</authid><authname>Bein B.</authname><surname>Bein</surname><given-name>Berthold</given-name><initials>B.</initials></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55767479900</author-url><authid>55767479900</authid><authname>Scholz J.</authname><surname>Scholz</surname><given-name>Jens</given-name><initials>J.</initials></author><intid>1536087107</intid><source-id>21394</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930173725"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930173725?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930173725&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930173725&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930173725</prism:url><dc:identifier>SCOPUS_ID:84930173725</dc:identifier><eid>2-s2.0-84930173725</eid><dc:title>Secondly ECG recordings in the emergency room revealed Garenoxacin-induced abnormal QT interval prolongation in a patient with multiple syncopal attacks</dc:title><dc:creator>Tagawa M.</dc:creator><prism:publicationName>Heart and Vessels</prism:publicationName><prism:issn>09108327</prism:issn><prism:eIssn>16152573</prism:eIssn><prism:coverDate>2015-05-29</prism:coverDate><prism:coverDisplayDate>29 May 2015</prism:coverDisplayDate><prism:doi>10.1007/s00380-015-0693-x</prism:doi><dc:description>© 2015 Springer Japan A 73-year-old woman first visited our emergency room with multiple syncopal attacks. Before admission, she had received an antibiotic (Garenoxacin) for 3 days from a local clinic. First electrocardiogram (ECG) showed no ST-segment deviation but mild QT interval prolongation with a positive U wave. Second ECG recording 3 h later showed slightly slower heart rate and revealed marked QTU interval prolongation suggesting the cause of her syncopal attacks. After cessation of Garenoxacin, the QTU interval prolongation shortened. However, both epinephrine infusion and treadmill exercise test reproduced similar QTU interval prolongation and T wave deformities. Later, genetic analysis demonstrated that this patient had a mutation in KCNH2 gene, and she was diagnosed as a type-2 long-QT syndrome which was accentuated by use of garenoxacin. At the emergency out-patient clinic, repetitive ECG recordings can be useful and should be considered in order to identify the cause of syncopal attacks in patients who were prescribed antibiotics and had mild QT interval abnormalities.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113080698</affiliation-url><afid>113080698</afid><affilname>Nagaoka Chuo General Hospital</affilname><name-variant>Nagaoka Chuo General Hospital</name-variant><affiliation-city>Nagaoka</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027970</affiliation-url><afid>60027970</afid><affilname>Niigata University School of Medicine</affilname><name-variant>Niigata University</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027970</affiliation-url><afid>60027970</afid><affilname>Niigata University School of Medicine</affilname><name-variant>Niigata University</name-variant><affiliation-city>Niigata</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ip</subtype><subtypeDescription>Article in Press</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56661825100</author-url><authid>56661825100</authid><authname>Tagawa M.</authname><surname>Tagawa</surname><given-name>Minoru</given-name><initials>M.</initials><afid>113080698</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56661829800</author-url><authid>56661829800</authid><authname>Ochiai S.</authname><surname>Ochiai</surname><given-name>Sachie</given-name><initials>S.</initials><afid>113080698</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56661501200</author-url><authid>56661501200</authid><authname>Nakamura Y.</authname><surname>Nakamura</surname><given-name>Yuichi</given-name><initials>Y.</initials><afid>113080698</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643744800</author-url><authid>56643744800</authid><authname>Sato A.</authname><surname>Sato</surname><given-name>Akinori</given-name><initials>A.</initials><afid>60027970</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005587922</author-url><authid>7005587922</authid><authname>Chinushi M.</authname><surname>Chinushi</surname><given-name>Masaomi</given-name><initials>M.</initials><afid>60027970</afid></author><authkeywords>Garenoxacin | Long-QT syndrome | Syncope</authkeywords><intid>1536077074</intid><source-id>23221</source-id></entry></search-results>
